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3-hydroxyacyl-coA dehydratase (HACD) enzymes form part of a complex that elongates fatty 
acids with very long carbon chain length (VLCFA) (>20C). There are four paralogous HACD 
enzymes in mammals (encoded by HACD1-4), each with a distinct tissue distribution: HACD1 
is specifically expressed in striated muscles and mutations in HACD1 cause congenital 
myopathies in humans, dogs and mice. The canine autosomal recessive centronuclear 
myopathy, HACD1-CNM, is the most prevalent neuromuscular disorder in dogs with 15-20% 
of the Labrador retriever breed carrying the causative mutation. The pathogenesis of 
HACD1-associated myopathies and the roles of VLCFA in developing and mature muscle 
remain poorly understood. Membranous abnormalities, particularly affecting 
excitation-contraction coupling apparatus at the triad, are an important feature of CNMs due 
to other genetic causes and progressive t-tubule disorganisation has recently been documented 
in CNM affected dogs.  
We hypothesised that HACD1-deficiency reduces levels of specific VLCFA and impacts upon 
normal triad structure and function. We further hypothesised that hacd1-mutant zebrafish 
embryos can be used to model HACD1-associated myopathies. I aimed to: characterise 
expression of HACD enzymes in developing and adult zebrafish, and also a murine myoblast 
cell line during normal myogenesis and HACD1-deficiency; establish techniques for studying 
the impact of HACD1-deficiency on the lipidome and excitation-contraction coupling in these 
models; validate a novel model of HACD1-deficiency in zebrafish embryos generated using 
CRISPR/Cas9 genome editing.   
First I identified the zebrafish orthologues of mammalian HACD1-4 and evaluated their 
expression. The major findings confirmed hacd1 as the major HACD enzyme in developing 
and mature zebrafish muscle with hacd1-fl strongly upregulated during myogenesis as seen in 
mammals. A murine Hacd1-knockdown model in C2C12 was used to investigate the effect of 
Hacd1-deficiency upon membrane systems and lipid profiles - Hacd1 knockdown was 
significant in later stages of differentiation and no compensatory upregulation of Hacd2-4 
could be observed. Electrophysiological and NMR-lipidomic studies were established and 
optimised in this cell culture model and significant changes to the lipidome were detected in 
Hacd1-deficient myotubes in comparison with controls. NMR-lipidomics was then 
implemented on wildtype zebrafish embryos to establish their lipid phenotype. Finally, I 
characterised the phenotype and mutation spectrum in F0 hacd1-mutant embryos and 
documented functional motor impairment alongside gross and microscopic muscle 
abnormalities including disorganisation of RYR1 staining – a marker of junctional 
sarcoplasmic reticulum. These findings recapitulate those in dogs with HACD1-CNM and 
zebrafish embryo models of CNMs due to other genetic causes.  
In conclusion, embryonic zebrafish are a relevant model of HACD1-CNM due to their 
comparable HACD enzyme expression and myopathic phenotype in hacd1-mutant embryos. 
This will be a valuable asset and complement existing cell and mammalian models for future 
research to study the roles of HACD enzymes in muscle development and disease and the 
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 Overview of mammalian muscle development, anatomy and 
physiology   
Movement is a key feature of all animals, which vertebrates achieve through the contraction 
of skeletal muscle fibres. Over a quarter of adult human body mass is accounted for by skeletal 
muscle which must provide functional strength, movement and flexibility. The highly 
structured, repetitive nature of the muscle cells and their intracellular architecture has been 
specifically adapted to allow the muscles to function efficiently (Keynes et al., 2011). 
 Muscle development  
Skeletal muscle is a complex and highly specialised tissue which develops initially during 
embryogenesis via strict sequential expression of a number of transcription factors called 
myogenic regulatory factors (MRFs) during myogenesis (Figure 1.1) (Braun & Gautel, 2011; 
Buckingham, 1992). 
 
Figure 1.1: Schematic of mammalian (vertebrate) muscle differentiation.  
Muscle progenitor cells, termed satellite cells, are triggered by transcription factors Pax3 and Pax7. The 
upregulation of other muscle transcription factors, MyoD, Myf5, Myogenin and MRF4 further induce 
these cells into mature myotube differentiation (Adapted from Tidball et al., 2014). 
 
Myogenesis in mammals, and all vertebrates, can be divided into three parts – stages one and 
two occur during development (primary myotome formation and muscle growth respectively) 
and the third stage (adult myogenesis) is adapted for the repair of post-natal mature myofibres 
(Bryson-Richardson & Currie, 2008). The first stage begins in the mesoderm during gestation, 
more specifically the dermomyotome, from which the majority of the skeletal muscle forms 
through the alignment and fusion of early muscle cells, termed myoblasts. In phase two the 
myoblasts differentiate further on either side of the neural tube, which runs along the centre 
of the embryo during development in vertebrates (Bryson-Richardson & Currie, 2008). This 
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stage produces the mature musculature of the organism (Braun & Gautel, 2011). Transcription 
factors Pax3 and Pax7 are critical in this stage of early development to induce stem cell 
populations down a myogenic lineage (determination) (Kassar-Duchossoy et al., 2005). 
Subsequently other MRFs including MyoD, myogenin, Myf5, MRF4 are expressed – all of 
which are important for the differentiation and maturation of skeletal muscle (Bentzinger et 
al., 2012; Kassar-Duchossoy et al., 2005). During embryogenesis muscle mass originates from 
myoblast proliferation, and once developed, muscle is a terminally differentiated tissue. 
Postnatal growth occurs mostly through hypertrophy (increase of protein content), therefore 
increasing the size of fibres already present (Alnaqeeb & Goldspink, 1986). Muscle fibre 
number reaches its maximum shortly after birth and thereafter remains mostly unchanged. 
Increase in fibre size and increased myofibril number are the mechanisms by which the 
contractile force of a muscle is increased. (Alnaqeeb & Goldspink, 1986).  
The third stage of myogenesis is designed to repair damaged mature muscle by the muscle 
specific stem-cells; satellite cells (Bryson-Richardson & Currie, 2008). Satellite cells are 
found on the surface of muscle fibres and once activated work to generate new myoblasts that 
will differentiate into myotubes and produce new myonuclei for the fibres (Zammit, 2008). 
Pax7 is activated with the satellite cells and has been reported to be important in driving the 
differentiation of satellite cells (Zammit et al., 2006). The post mitotic nature of skeletal 
muscle fibres, means the capability of muscle to repair itself is limited; therefore, the satellite 
cells provide regenerative assistance through the fusing of newly differentiated myotubes into 
the myofibres to aid in muscle repair (Conceição et al., 2018; Shenkman et al., 2009; Zammit, 
2008). 
Vertebrate muscle can be divided into five sub-types: trunk, limb, branchial, oral (tongue and 
laryngeal) and extraocular. These sub-types require different combinations of MRF regulation 
for development but commonly all require MyoD and myogenin (Braun & Gautel, 2011). The 
differences in the network of regulatory genes within development provides a level of 
heterogeneity to muscles developed within an organism (Braun & Gautel, 2011). 
 Muscle anatomy   
Skeletal muscle is composed of many elongated intracellular, contractile myofibrils, together 
within a single muscle fibre (Figure 1.2). Myofibres are bound together by connective tissue 
into a muscle bundle and several of these together form a muscle. Mature muscle fibres can 
be as long as the muscle itself and are between 10-100µm in diameter (Braun & Gautel, 2011; 
Ehler & Gautel 2008; Keynes et al., 2011). Skeletal muscle myofibres are complete contractile 
systems that are under the control of motor neurons and carry out a variety of motor functions 
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within an organism from finer motions of facial expressions and the larynx during vocalisation 
to gross movements such as running or lifting weights (Fregosi & Ludlow, 2013; Keynes et 
al., 2011). 
 
Figure 1.2: Structure of skeletal muscle (Redrawn from Keynes et al., 2011).  
 
 Myofibre types 
Mammalian skeletal muscle is comprised of broadly two types of fibre: slow twitch (type I) 
and fast twitch (type II) (Blaauw et al., 2013; Schiaffino & Reggiani, 2011; Scott et al., 2001). 
The presence of different fibre types provides more heterogeneity, allowing one muscle to 
perform different tasks effectively according to varying functional demands (Schiaffino & 
Reggiani, 2011). Muscle fibre types are categorised by their metabolism and contractile 
response: type I fibres are commonly known as oxidative slow twitch fibres, and they are high 
in myoglobin giving them a red coloured appearance (Schiaffino & Reggiani, 2011). Type I 
fibres are adapted for endurance: they have a longer duration contraction and fatigue slowly. 
Conversely; type II fibres do not require oxygen for energy and so do not have the rich blood 
supply that type I fibres have. Type II fibres are specialised for quick and powerful contraction 
and fatigue quickly. (Essén et al., 1975; Schiaffino & Reggiani, 2011). Proportions of 
myofibre types varies between different muscles: those required for fast movement, such as 
those in the leg, are predominantly type II whereas other muscles such as those located around 
the spine for posture are predominantly type I myofibres (Schiaffino & Reggiani, 2011). 
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Proportional changes in the types of myofibres within a muscle have been documented as a 
secondary pathology in a number of congenital myopathies including nemaline myopathy, 
central core myopathy, congenital fibre-type disproportion and centronuclear myopathy 
(North & Clarke, 2003; Clarke, 2011; North et al., 2014). 
 Myonuclei 
Myofibres are unique in their nuclear architecture and a single muscle fibre can contain 
hundreds of nuclei due to a high number of myoblasts fusing to form the myofibre (Roman & 
Gomes, 2018). The myonuclei within mammals are uniquely located at the periphery of the 
myofibres, to provide maximum room for the contractile apparatus (Cadot et al., 2015). The 
nuclei are located evenly across the periphery, and the finite volume of cytoplasm they control 
through the transport of gene products and protein synthesis, is termed the myonuclear domain 
(MND) (Allen et al., 1999). Microtubules from nuclear envelopes act mechanically on 
neighbouring nuclei and cell boundaries to provide this even distribution of myonuclei along 
the myofibre (Manhart et al., 2018). This nuclear positioning is mediated by a number of 
proteins including Map7, nesprins and amphisphysin-2: of which the latter is also involved in 
triad organisation (Falcone et al., 2014). The elongated shape of myofibres provides reason 
for their requirement of multiple, precisely spaced nuclei - it is thought that clusters of 
myonuclei would leave areas of the myofibre without the appropriate transcription and 
translation to maintain a healthy myofibre (Pavlath et al., 1989; Ross et al., 2008).  
This peripheral positioning of nuclei is an important and well-established feature of 
mammalian muscle cells and their displacement to the centre of fibres correlates with muscle 
dysfunction and has been documented in a number of myopathies (Folker & Baylies, 2013). 
It is unknown whether nuclear centralisation is a primary or secondary factor of muscle disease 
and is likely to depend greatly upon disease aetiology. Centralised nuclei are also seen in 
regenerating fibres, suggesting that the centralised nuclei in certain diseased fibres may be due 
to attempted repair of damaged fibres and therefore secondary to the disease pathology (Folker 
& Baylies, 2013; Roman & Gomes, 2018; Shenkman et al., 2009). 
 Sarcomeres 
The contractile unit; the sarcomere, is approximately 2µm in length, and up to 250 sarcomeres 
may be found per mm of muscle fibre (Infantolino et al., 2010). Sarcomeres consist of two 
main proteins: the ‘thin’ actin and ‘thick’ myosin filaments of approximately 5nm and 11nm 
diameter respectively, which lie repetitively side by side against one another (Keynes et al., 
2011). Interaction between these two filaments allow skeletal muscle fibres to contract and 
generate force (Keynes et al., 2011). Myofibres have a distinct and recognisable striated 
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appearance derived from the highly organised layout of the actin and myosin within the 
sarcomeres (Figure 1.3) and these are one of the most consistent structures within animal cells 
(Ehler & Gautel, 2008).  
The repetitive patterning of the sarcomere is described by the bands and lines that the actin 
and myosin form together (Huxley & Hanson, 1954). The A band of the sarcomere appears 
darker using electron microscopy due to the presence of both thick myosin and thin actin 
filaments located there. In comparison, the I band of just actin filaments appears significantly 
lighter. The H band lies within the A band in an area of just the myosin filaments, and is 
bisected down the middle of the sarcomere by the M line which represents the cross links of 
myosin filaments. The actin filaments are attached by the Z line which is found in the middle 
of the I band (Huxley & Hanson, 1954). 
 
Figure 1.3: Diagram of the mammalian sarcomere.  
 
 Muscle contraction  
Muscle contracts according to Huxley’s sliding filament theory which explains shortening of 
the sarcomeres and hence the overall length of the muscle. Huxley & Hanson, (1954) and 
Huxley & Niedergerke, (1954) first observed that while one section of the sarcomere, the A 
band, remained consistent throughout contraction, the other notable section, the I band, 
changed in length (Huxley & Hanson, 1954; Huxley & Niedergerke, 1954). From this they 
concluded that the actin filaments were “sliding” past filaments of myosin. This mechanism 
occurs through the formation of cross bridges between the actin filament and myosin heads, 
pulling along and shortening the sarcomere and therefore causing muscle fibre contraction 
(Huxley & Hanson, 1954; Huxley & Niedergerke, 1954).  
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As well as myosin and actin there are a number of other important proteins involved in 
regulating muscle contraction including the protein complex troponin-tropomyosin that 
inhibits direct interaction between actin filaments and myosin heads at rest (Bailey, 1946). 
Tropomyosin is distributed along the myosin filaments and mediates the effect of calcium on 
actin-troponin binding (Bailey, 1948); troponin is bound to both tropomyosin and the actin 
filament and it is thought the binding of calcium ions (Ca2+) molecules causes a structural 
change in troponin which draws the tropomyosin away from the binding sites allowing 
myosin-actin cross bridges to form (Ebashi & Kodama, 1965; Keynes et al., 2011). 
ATP is essential for the contraction of skeletal muscle and adequate levels are maintained in 
muscle (Cooke, 1986; Widen & Barclay, 2006). The conversion of electrical stimulus into 
contractile response from the muscle is termed excitation-contraction coupling (ECC), and 
once this is initiated, Ca2+ is released from internal stores and binds troponin allowing actin 
and myosin to interact and utilise the ATP already present (Sandow, 1952). Conversely; with 
calcium present but ATP absent, actin and myosin can bind but there is no energy for 
movement, as seen in rigor mortis (Bate-Smith & Bendall, 1947). Hydrolysis of ATP provides 
the energy for cross-bridge cycling and contraction and occurs at the rate of one ATP per cycle 
- this repeats along the filaments during contraction. (Widen & Barclay, 2006). 
 Excitation-contraction coupling (ECC) 
Excitation-contraction coupling is the work of the entire motor unit: a single motor unit 
describes a motor neuron providing stimulation to a bundle of myofibres, of which hundreds 
can be found within a muscle (Celichowski, 2000), a schematic of ECC is shown in Figure 
1.4. The motor neuron provides an electrical signal that is received by the muscle at the 
neuromuscular junction (NMJ), a chemical synapse (Hall & Sanes, 1993). Depolarisation of 
the pre-synaptic nerve terminus results in Ca2+ influx, vesicle binding and release of 
acetylcholine which diffuses across the synaptic crest to post-synaptic receptors on the muscle 
endplate. This causes ligand-gated ion channels in the muscle cell membrane, the sarcolemma, 
to open and allow the influx of sodium ions (Na+) into the fibre (Hall & Sanes, 1993). The 
influx of positive ions into the cell depolarises the sarcolemma and triggers a muscle action 
potential. The action potential then propagates over the entire surface of the muscle fibre 
(Barnett & Larkman, 2007; Hall & Sanes, 1993) and into the fibre via sarcolemmal membrane 
invaginations known as transverse (t)-tubules. The positive increase in sarcolemmal charge 
(membrane potential) activates the voltage-sensitive calcium channel, the dihydropyridine 
receptor (DHPR), also known as Cav1.1, to open and allow Ca2+ influx (Corry, 2006; Hall & 
Sanes, 1993). The DHPR channels are in allosteric contact with another type of calcium 
channel found on the sarcoplasmic reticulum (SR) (muscle specific endoplasmic reticulum 
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and calcium store), the ryanodine receptor 1 (RYR1) and the physical interaction and 
conformational coupling between these two Ca2+ channels is crucial to the control of ECC 
(Paolini et al., 2004). DHPR and RYR1 bind via the DHPR cytoplasmic β1a subunit and the 
RYR1 α1s subunit (deletion of either of these subunits prevents ECC, DHPR subunit loss has 
been reported in β1a-null murine and zebrafish models) (Rebbeck, 2011; Karunasekara et al., 
2012) and the positioning of these channels permits bidirectional interactions (Lanner et al., 
2010). The final step of ECC is the Ca2+ release from the SR. Here the RYR1 channels are 
opened in response to a structural change in DHPR (Hernandez-Ochoa & Schneider, 2018). 
Local cytosolic calcium concentrations often increase by 100-fold during this process and 
result in muscle contraction by allowing myosin and actin to interact (Corry, 2006; Dulhunty, 
2006; Smith, 2007). 
The ECC machinery is similar between skeletal, smooth and cardiac muscle however the 
mechanism by which the cytosolic calcium is increased differs. In smooth and cardiac muscle 
calcium induced calcium release (CICR) via the influx of Ca2+ ions is the mechanism by which 
ECC is conducted. In skeletal muscle the RYR1 channel does not rely upon the influx of 
external calcium, due its large store of intracellular calcium within the SR (~1mM Ca2+ within 
the SR lumen at rest with cytosolic Ca2+ ~50nM) (Dulhunty, 2006; Rossi, 2008; Berchtold et 
al., 2000) and it is well established that RYR1 is activated during ECC by a structural change 
in DHPR (Dayal et al., 2017). This is corroborated by the speed of ECC, as it requires a rapid 





Figure 1.4: Schematic demonstrating the basis of excitation-contraction coupling (ECC) and its 
machinery.  




Excitation-contraction coupling in mammals is reliant upon communication between two 
highly specialised membrane domains and their aforementioned ion channels: invaginations 
of the sarcolemma called the t-tubules where the DHPR localise and the SR with their RYR1 
channels (Franzini-Armstrong & Jorgensen, 1994). Two SR termini and one t-tubule meet at 
the A-I band junction of the sarcomere in mammals, and this set of membranes is called the 
triad (Rossi, 2008). Development of the mammalian triad begins in a disorganised manner 
during gestation before becoming strict in organisation providing the most efficient layout of 
membrane systems for ECC. SR membranes appear early on in development and in a regular 
manner and t-tubules are for the most part formed postnatally. In mice this organisation 
happens early in life (3-4 weeks) (Franzini-Armstrong & Jorgensen, 1991; Flucher et al., 
1993; Takeshima et al., 1994).  
The t-tubule membrane system accounts for 80% of plasma membrane surface in skeletal 
muscle; and it functions to rapidly conduct the electrical signal from the sarcolemma to arrive 
close to the SR. Without the specialised t-tubule membrane system the surface action potential 
would be insufficient to activate contraction (Barrientos et al., 2017; Bers, 2014; Keynes et 
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al., 2011). The DHPR channels found along the t-tubules are L-type Ca2+ channels, which 
refers to its high-voltage activation and the length of which activation lasts a “L=long” time 
(Denniss et al., 2018; Hernandez-Ochoa & Schneider, 2018).  
The primary role of the SR is to store and regulate calcium homeostasis including the release 
of intracellular calcium into the cytosol during ECC via the RYR1 channel (Bers, 2014). RYRs 
are homotetrameric proteins weighing over two million Daltons, of which there are three 
isoforms that are found in numerous cell types including striated (skeletal and cardiac) and 
smooth muscle, testis, neurons and ovaries (Hamilton, 2005). RYR1 is specific to striated 
muscle with low levels found within cardiac and smooth muscle, RYR2 is expressed within 
cardiac muscle predominantly and RYR3 is expressed within the brain at high levels (Lanner 
et al., 2010). As part of its role in calcium homeostasis, the SR also communicates back to the 
DHPR via the release of Ca2+ in order to regulate the calcium influx through the DHPR 
(Paolini et al., 2004; Balog & Gallant, 1999). Calcium reuptake back into the SR is also 
imperative to regulate ECC and control the rate of muscle relaxation following contraction 
(Rossi & Dirksen, 2006). The sarcoplasmic reticulum Ca2+-ATPase (SERCA) pump is 
efficient at returning this calcium back into the SR (Rossi & Dirksen, 2006).  
Calcium homeostasis within the SR also depends upon a number of calcium binding proteins 
within the SR lumen, including calsequestrin (CSQ), which makes up ~27% of junctional SR 
protein (Beard, 2005). CSQ is important for calcium homeostasis within muscle fibres, it binds 
calcium within the SR,  keeps cytoplasmic levels of Ca2+ low when at rest and has a role in 
calcium sensing within the lumen of the SR (Beard, 2005; Berchtold et al., 2000). 
The formation of the triad requires a number of proteins that assist in coordinating this process. 
Junctophilins and triadins (transmembrane proteins expressed in excitable cells) are examples 
of the proteins critical for this, and therefore essential for ECC to function. By spanning both 
t-tubule and SR membranes junctophilins aid in triad formation, and indirectly assist with 
conversion of the cell membrane depolarisation into the intracellular Ca2+ signalling (Ito et 
al., 2001). Knock out of the junctophilin-1 gene (JP-1) in mice leads to the formation of diads 
instead of triads (Ito et al., 2001; Komazaki et al., 2001; Osseni et al., 2016). STAC3, another 
important protein for ECC, has been reported to be involved in linking the two calcium 
channels (Campiglio et al., 2018; Polster et al., 2018). It has been reported that STAC3 
knockout mice have defective ECC and that the activation of RYR1 relies on STAC3 being 




 Muscle membrane systems and disease 
The organisation of the highly specialised muscle membranes is imperative for muscle to 
function normally and in healthy muscle ECC is extremely robust, but many diseases are now 
known to result from mutations that lead to abnormalities in the ECC machinery (Jungbluth 
et al., 2018). This is an important pathogenic mechanism in congenital myopathies which 
leads to muscle dysfunction with little to no contractile force and often presents as progressive 
muscle weakness and therefore ultimately paresis (Allard, 2018). These ECC abnormalities 
can occur through a number of mechanisms: mutation of proteins within the Ca2+ release, 
alteration in triad structure, alterations in ion channels, abnormalities within calcium store 
(Marty & Fauré, 2016).  
 Congenital myopathies 
Congenital myopathies are a heterogeneous group of neuromuscular disorders that are 
grouped broadly based on their pathological features (North, 2008). Defining features of the 
congenital myopathies include: abnormal morphology of muscle tissues when examined 
histopathologically, abnormalities from within the myofibres (compared to dystrophies where 
pathology stems from the sarcolemma and extracellular matrices), and early onset clinical 
weakness and hypotonia that may be progressive (Cassandrini et al., 2017; North, 2008).  
 Histopathology of the congenital myopathies 
The congenital myopathies have been subcategorised into five major forms: nemaline 
myopathies, core myopathies, centronuclear myopathies, myosin storage myopathies and 
congenital fibre-type disproportions (North et al., 2014). Histopathology of these congenital 
myopathies is shown in Figure 1.5 and pathology of muscle biopsies has classically been used 
for diagnostics of the congenital myopathies (Goebel, 2003). 
Nemaline myopathy is characterised by rod-like inclusions within myofibres consisting of 
alpha-actinin (Wallgren-Petterron & Laing, 1999). Core myopathies are categorised due to the 
presence of circular structures, lacking both mitochondria and glycogen, seen within 
myofibres, “cores” and these can be present in multiples within one fibre (termed 
multi-minicores diseases) (Cassandrini et al., 2017; Engel et al., 1971). Centronuclear 
myopathy is characterised by the presence of mislocalised and internalised myonuclei within 
the centre of myofibres (Spiro et al., 1966). Myosin storage myopathies lead to an 
accumulation of myosin heavy chain inclusions within fibres (Tajsharghi et al., 2003). The 
final category of congenital myopathies, congenital fibre-type disproportion is described by 
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type I fibres which are consistently smaller than the type II fibres and predominate within the 
muscle (Clarke, 2011). 
 
Figure 1.5: Histology of the congenital myopathies.  
(a) (nemaline myopathy) Gomori trichrome stain of alpha-actinin rods within myofibres (purple) seen 
both at the periphery or centre. (b) (core myopathy) Cytochrome C oxidase stain highlighting the 
“cores” within fibres by lack of stain. (c and d) (Centronuclear myopathy (CNM)) H&E (haemotoxylin 
and eosin) stain showing nuclei in purple which a large proportion have migrated from the periphery of 
fibres into the centre. (c) CNM patient with a myotubularin mutation and (d) from a CNM patient with 
a dynamin2 mutation. (e) (multi-minicores myopathy) NADH-TR stain indicates areas with no 
oxidative stain, indicative of the cores. (f) (Congenital fibre-type disproportion) ATPase stain indicating 
the lighter stained type I fibres to be smaller in size and the predominating fibre within the muscle 
sample. (Figure taken from Cassandrini et al., 2017). 
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 Genetics of congenial myopathies 
The histopathology of muscle biopsies from myopathy patients provides initial insight for 
patient diagnosis, however the genetic and phenotypic heterogeneity of congenital myopathies 
means that it cannot be used alone in order to successfully diagnose patients (Bohm et al., 
2013). Table 1.1 displays a recent cataloguing of the congenital myopathies and their 
associated genes; the table highlights the heterogeneity within the myopathies (Jungbluth et 
al., 2018). Performing mutation analysis is crucial in the diagnosis of patients due to the vast 
number of genes associated with disorders which greatly overlap in phenotype: it can provide 



















Table 1.1: Genes associated with human congenital myopathies, adapted from Jungbluth et al., 
2018.  
(Bitoun et al., 2005; Coste et al., 2013; Jungbluth et al., 2018; McMillin et al., 2013; O’Grady et al., 
2016; Schnartner et al., 2017; Zhou et al., 2007). 
Gene symbol Protein Condition 
ECC, SR Ca2+ release or triad assembly 
RYR1 Ryanodine receptor 1 Central core disease, 
Multi-minicores disease, 
Centronuclear myopathy, 
Congenital fibre-type disproportion,  
King–Denborough syndrome 
STAC3 SH3 and cysteine-rich 
domain-containing protein 
3 
North American myopathy 
ORAI1 Ca2+-release-activated Ca2+ 
channel protein 1 
Tubular aggregate myopathy 
STIM1 Stromal interaction 
molecule 1 
Tubular aggregate myopathy, 
Stormorken syndrome 
MTM1 Myotubularin X-linked myotubular myopathy 
BIN1 Amphiphysin II Centronuclear myopathy 
DNM2 Dynamin 2 Centronuclear myopathy 
SPEG2 Striated muscle 
preferentially expressed 
protein kinase 
Centronuclear myopathy with central 
nuclei and cardiomyopathy 
CCDC78 Coiled-coil domain-
containing protein 78 
Centronuclear myopathy with cores and 
central nuclei 
CACNA1S/DHPR Voltage-dependent L-type 
Ca2+ channel subunit-α1S 
Centronuclear myopathy with 
extraocular muscle involvement 
SEPN1 Selenoprotein N Multi-minicores disease, 
Congenital fibre-type disproportion 
Thin-thick filament assembly and/or interaction, myofibrillar force generation and 
protein turnover 
NEB Nebulin Nemaline myopathy 
ACTA1 Actin, α-skeletal muscle Nemaline myopathy, 
Cap myopathy, 
Congenital fibre-type disproportion 
TNNT1 Troponin T, slow skeletal 
muscle 
Nemaline myopathy 




TPM3 Tropomyosin α3-chain Nemaline myopathy, 
Cap myopathy, 
Congenital fibre-type disproportion 
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MYH2 Myosin 2 Centronuclear myopathy with 
extraocular muscle involvement 
MYH3 Myosin 3 Distal arthrogryposis 
MYH7 Myosin 7 Congenital fibre-type disproportion, 
Multi-minicores disease, 
Myosin storage myopathy 
MYH8 Myosin 8 Trismus-pseudocamptodactyl 
syndrome, 
Carney complex 
KBTBD13 Kelch repeat and BTB 
domain-containing protein 
13 
Nemaline myopathy with cores 
KLHL40 Kelch-like protein 40 Nemaline myopathy 
KLHL41 Kelch-like protein 41 Nemaline myopathy 
LMOD3 Leiomodin 3 Nemaline myopathy 
MYBPC3 Myosin binding protein C, 
cardiac-type 
Congenital myopathy with 
cardiomyopathy 
MYPN Myopalladin Nemaline myopathy with 
cardiomyopathy 
TTN Titin Centronuclear myopathy, 
Multi-minicores disease 
Other cellular processes 
CFL Cofilin 2 Nemaline myopathy with cores 






channel component 2 
Distal arthrogryposis, 
Marden-Walker syndrome 
MEGF10 Multiple epidermal growth 
factor-like domains protein 
10 
Congenital myopathy with minicores, 
Congenital myopathy with areflexia, 




SCN4A Sodium channel, protein 
type 4 subunit-α 
Congenital myopathy 












The RYR1-associated congenital myopathies provide a strong example of the variability of 
disease phenotypes even within the dysfunction of one protein (Todd et al., 2018). RYR1 
mutations contribute to a number of congenital myopathies including CNM, central core 
disease, malignant hypothermia, multi-minicore disease (Avila et al., 2001; Bevilacqua et al., 
2011; Jungbluth et al., 2018; Zhang et al., 1993). Todd et al., (2018) reported six novel 
variants of RYR1, of which had previously been documented in numerous other cases of 
congenital myopathy (Jungbluth et al., 2018; Todd et al., 2018). 
Other important ECC proteins have been linked to musculoskeletal disorders including 
caveolin-3 (CAV3) and amphiphysin-2 (BIN1) which are both involved in t-tubule biogenesis 
(Nicot et al., 2007; Sotgia et al., 2003). Junctophilin-2 mutations have been linked to 
cardiomyopathies and Charcot-Marie-Tooth disorder due to perturbed calcium handling 
(Takeshima et al., 2000).  
Mutations in the CNM causing gene, HACD1, have shown to cause tubuloreticular membrane 
abnormalities in Labrador retrievers (Walmsley et al., 2017). HACD1-CNM is discussed in 
more detail in Section 1.3.1. 
 Centronuclear myopathies 
The centronuclear myopathies are a subset of congenital myopathy that are characterised by 
the mislocalisation of nuclei to the centre of >25% myofibres with no signs of regeneration, 
infiltration of fat into muscle tissue, a shift in fibre type proportions and inconsistency in 
myofibre size among other features (Spiro et al., 1966). The centralised nuclei in the CNMs 
are distinct to those found in dystrophies – in the latter, centralised nuclei are present within 
regenerating fibres (Dowling et al., 2009). Clinically, CNM patients have progressive 
weakness and hypotonia but may also present with breathing troubles or difficulty moving the 
eyes in severe cases (Jungbluth et al., 2008). 
Mutations in myotubularin, the lipid phosphatase, cause the severe X-linked form of CNM, 
termed myotubular myopathy (XLMTM) (Laporte et al., 1996). Biopsies of affected 
individuals show hypertrophy and a significant number of fibres with the characteristic 
centralised nuclei (Laporte et al., 1996; Pierson et al., 2005). Over half the XLMTM mutations 
inactivate the enzyme by missense mutations or protein truncation. XLMTM mice develop a 
progressive myopathy from around 4 weeks of age and their lifespan is severely reduced 
(Buj-Bello et al., 2002; Laporte et al., 1997). Mutations in a myotubularin related protein 
(MTMR14) also cause an autosomal recessive form of CNM (Tosch et al., 2006). Both MTM1 
and MTMR14 deficiencies result in defective ECC, decreased triad number and abnormally 
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formed t-tubules (Al-Qusairi et al., 2009; Buj-Bello et al., 2002; Dowling et al., 2009). 
Myotubularin expression increases postnatally, after the development of the t-tubules, hence 
it has been suggested that myotubularin is essential for the maintenance and maturation of 
t-tubules (Al-Qusairi & Laporte, 2011). 
An autosomal-dominant form of CNM is caused by mutations in the gene for dynamin 2 
(DNM2) which is involved in membrane trafficking (Bitoun et al., 2005). DNM2 localises to 
the I band of the sarcomere and perinuclear areas of the myofibre – areas of high levels of 
membrane trafficking (Durieux et al., 2010). Heterozygous DNM2 mutations have a large 
spectrum of severity and differ in their onset, from neonatal to childhood and DNM2-CNM 
presents with muscle weakness and delayed motor milestones (Bitoun et al., 2005; Bitoun et 
al., 2007; Jungbluth et al., 2010). Histologically, the nuclei mislocalise to the centre of fibres 
and slow type fibres predominate. Introducing a DNM2 mutation into mice resulted in altered 
mitochondrial staining as well as nuclear mislocalisation (Cowling et al., 2011; Durieux et al., 
2010; Jungbluth et al., 2008).  
Mutations in amphiphysin (BIN1), which is involved in membrane sensing and remodelling 
within cells causes an autosomal recessive CNM with triad disorganisation (Nicot et al., 2007; 
Toussaint et al., 2011). BIN1 is involved in the tubulation of membranes due to its membrane 
bending functions (Al-Qusairi & Laporte, 2011). The BIN1 gene is expressed highly within 
skeletal muscle and expression increases over the differentiation of the myogenic cell line, 
C2C12, in line with the development of internal membranes (Al-Qusairi & Laporte, 2011; Lee 
et al., 2002). The mechanism by which BIN1 deficiency causes CNM is likely to be the lack 
of proper t-tubule formation within the myofibres. This suggests that BIN1 is crucial to the 
development of the t-tubules at an earlier developmental stage than that of myotubularin. It 
has been hypothesised that both BIN1 and DNM2 proteins may need to functionally interact 
for normal nuclei positioning and muscle function therefore linking two of the CNM disease 
proteins (Cowling et al., 2017; Nicot et al., 2007).  
A dominant mutation in the calcium channel gene RYR1 causes CNM with a broad spectrum 
of phenotypes including disturbed DHPR function and significantly disrupting ECC 
(Jungbluth et al., 2007).  
The genes discussed above, in particular MTM1, DNM2 and BIN1 are those classically 
associated with CNM. Recently, other mutations have been associated with this phenotype 
(see Table 1.2). The large contractile protein, titin, has also been associated with CNM, as titin 
mutations were seen in five patients with CNM-like clinical pathology (Ceyhan-Birsoy et al., 
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2013). A mutation in CCDC78, a gene of unknown function, has also been found to be 
associated with CNM, and when modelled in zebrafish the characteristics mirror the human 
CNM pathology, (see Table 1.2) (Majczenko et al., 2012).  
Most if not all affected proteins fit into the membrane remodelling/ECC pathways, and in 
particular they are primarily involved with the formation and organisation of triads (Cowling 
et al., 2012). 
Table 1.2: Centronuclear myopathies including congenital myopathies with central nuclei.  
AR = autosomal recessive, AD = autosomal dominant. (Jungbluth et al., 2018; Schnartner et al., 2017). 
Gene symbol Protein Type Inheritance 
RYR1 Ryanodine receptor CNM AR 
MTM1 Myotubularin X-linked myotubular 
myopathy 
X-linked 
BIN1 Amphiphysin II CNM AR, AD 
DNM2 Dynamin 2 CNM AD 
TTN Titin CNM AR 
HACD1 3-hydroxyacyl-CoA 
dehydratase 1 
Canine CNM and poorly 
defined congenital 
myopathy in humans 
AR 
CCDC78 Coiled-coil domain-
containing protein 78 
Congenital myopathy with 
cores and central nuclei 
AD 
SPEG Striated muscle 
preferentially expressed 
protein kinase 
Congenital myopathy with 





Congenital myopathy with 
central nuclei  
AR, AD 
 
 HACD1 mutations and congenital myopathies 
Mutations in 3-hydroxyacyl-coA dehydratase 1 (HACD1) (previously PTPLA based on 
presence of a putative phosphatase-like domain (protein tyrosine phosphatase; proline instead 
of catalytic arginine) which lacks activity due to amino acid change in the active site) (Li et 
al., 2000; Uwanogho et al., 1999) also cause congenital myopathies in dogs, humans and mice 
(Blondelle et al., 2015; Maurer et al., 2012; Muhammed et al., 2013; Pelé et al., 2005; Toscano 
et al., 2017). HACD1, alongside other HACD and elongase enzymes functions in the 
biosynthesis of very long chain fatty acids (VLCFAs) (Ikeda et al., 2008). 
 Canine centronuclear myopathy and HACD1 
The clinical condition now known as canine CNM was first described by Kramer et al., (1976) 
- but its nature as a centronuclear myopathy was only described by Tiret et al., (2003). 
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Labrador retrievers with HACD1-CNM present with similar clinical and histopathology to 
that of other CNMs (Figure 1.7 shows the histopathology of HACD1-CNM). Clinically the 
dogs present with progressive symptoms, initially hypotonia, weakness and exercise 
intolerance (Blot et al., 2002). The dogs also present with decreased skeletal muscle mass, 
poor posture (shown in Figure 1.6) and a stiff gait leading to a ‘hopping’ style walk in the 
dogs (Blot et al., 2002; Tiret et al., 2003). Pathologically muscle fibres from CNM dogs have 
increased prevalence of centralised nuclei, fibre type proportional shift to type I 
predominance, fibrosis, fat infiltration and progressive tubuloreticular disorganisation (Blot et 
al., 2002; Kramer et al., 1976; McKerrell & Braund, 1987; Pelé et al., 2005; Tiret et al., 2003; 
Walmsley, 2013; Walmsley et al., 2017). 
 
Figure 1.6: Clinical features of centronuclear myopathy (CNM) within Labrador retrievers.  
(a) Clinically normal Labrador and a CNM-affected littermate (b) which present with generalised 













Figure 1.7: Canine muscle biopsy of both control (a) and HACD1-CNM (b) canines.  
(a) Control muscle biopsy cross section annotated with black arrows pointing to the peripherally located 
nuclei. Myofibres are consistent in size and uniformly organised (b) centronuclear myopathy affected 
muscle biopsy cross section with black arrows annotating the nuclei that have mislocalised to the centre 
of fibres. Samples also show great disorganisation with huge myofibre size disorganisation and fatty 
infiltrates (white spaces). 
 
The genetics underlying the disorder were unknown for some 30 years until its autosomal 
recessive inheritance pattern was discovered in 2002, followed shortly after by the discovery 
of a mutation within the HACD1 gene, (PTPLA) within the disorder in 2005 (Bley et al., 2002; 
Pelé et al., 2005). The HACD1 gene was mapped to a locus on chromosome 2 initially, which 
is orthologous to the human chromosome 10p (Tiret et al., 2003). Further work identified a 
tRNA-derived short interspersed repeat element (SINE) insertion within exon two of the gene 
(Figure 1.8) and this had a significant effect on the expression of HACD1 mRNA (Pelé et al., 
2005). This mutation lead to abnormal splicing and/or exon-skipping resulting in <1% of 
normal transcript being expressed in the canine muscles (Pelé et al., 2005). The function of 
HACD1 was unknown at the time of its association with CNM in 2005 and it was research by 
Ikeda et al., (2008) that identified this CNM causing gene to be involved in VLCFA 
biosynthesis (Ikeda et al., 2008). This SINE insertion was shown to be present in carrier dogs 
within 13 countries and HACD1-CNM is globally, the most common inherited neuromuscular 







Figure 1.8: Diagram of the canine HACD1 gene with the centronuclear myopathy (CNM) 
causative mutation annotated.  
Gene is mutated by the insertion of a short interspersed nuclear element (SINE) causing a frame shift 
in the transcript. Exons1-7 are labelled as ‘e1-7’. (Adapted from Pelé et al., 2005). 
 
 Human congenital myopathies and HACD1 
The discovery of mutations in HACD1 as a cause of congenital myopathies in humans has 
emerged in the past few years. A non-sense mediated decay in HACD1 reduced gene 
expression to approximately 30% within a Bedouin family with a congenital myopathy 
(Muhammed et al., 2013). The clinical findings in this family linked HACD1 to human 
myopathies for the first time (Muhammed et al., 2013). A second, Caucasian, family with 
myopathic phenotype has more recently been identified to have a mutation within the HACD1 
gene affecting the active site (Toscano et al., 2017). 
The human congenital myopathies have many features in common with CNM however 
centralised nuclei have not been established as a disease phenotype within these human 
patients (Muhammed et al., 2013; Toscano et al., 2017). Canines with CNM present with a 
clinical phenotype at six months of age, yet the dogs are two years of age when the centralised 
nuclei are a prominent feature within the fibres (Blot et al., 2002; Tiret et al., 2003). The 
detection of the centralised nuclei and recognition of the condition in dogs as a CNM (defined 
by the presence of centralised nuclei in >25% of myofibres (Ramero & Laporte, 2013) was 
the product of serial muscle biopsies of affected dogs in a colony; this would be difficult to 
achieve in human patients. It therefore possible that HACD1 mutations in humans cause a 
CNM rather than CFTD and that biopsies later in life are required from this diagnosis. 
Ultrastructural analyses and evaluation of ECC apparatus are also lacking in human patients 
(Blot et al., 2002; Muhammed et al., 2013; Tiret et al., 2003; Toscano et al., 2017). 
 HACD enzymes  
There are four paralogous HACD enzymes within mammalian species that are associated with 
the dehydration step of VLCFA biosynthesis: HACD1 (formerly known as: protein tyrosine 
phosphatase-like A; PTPLA), HACD2 (formerly: protein tyrosine phosphatase-like B; 
PTPLB), HACD3 (formerly: protein tyrosine phosphatase-like A domain-containing 1; 
PTPLAD1) and HACD4 (formerly: protein tyrosine phosphatase-like A domain-containing 2; 
PTPLAD2) (Ikeda et al., 2008). The HACD enzymes have been historically referred to as the 
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PTPLs due to the presence of a PTP like domain; though, they lack the important catalytic 
sequence that allows the PTPs to regulate the level of cellular tyrosine-phosphorylation (Li & 
Dixon, 2000). The need for four HACD isoforms in mammals is poorly understood (Yazawa 
et al., 2013).  
 HACD conservation 
The HACD enzymes sequences are highly conserved, both between isoforms and also 
between species. HACD orthologues have been studied in both plants and yeast. The study of 
the HACD orthologue (Phs1) in yeast, or S. cerevisiae has been crucial in the characterisation 
of the HACD enzymes (Ikeda et al., 2008). Phs1 was first understood to be involved in 
sphingolipid metabolism (Schuldiner et al., 2005) and it has been demonstrated that decreases 
in Phs1 lead to accumulation of fatty acids of C20 chain length due to the disruption of further 
elongation steps and VLCFA synthesis (Kihara et al., 2008). Its high conservation and 
homology, between isoforms and species, does not extend to that of other protein families 
(Denic & Weissman, 2017; Yazawa et al., 2013).  
 
Figure 1.9: Simplistic diagram of the transmembrane Phs1 enzyme in yeast.  
Essential amino acids for HACD activity are labelled with red boxes and found in the 5th transmembrane 
region (adapted from Kihara et al., 2008). 
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By mutating the 22 conserved residues in Phs1, Kihara et al., (2008) identified two essential 
amino acids for life, Tyr-149 and Glu-156, required for Phs1 function and these are conserved 
between species (essential amino acid residues highlighted by red boxes in Figure 1.9). There 
were another four mutations within residues that stopped growth in the yeast but these 
mutations were not fatal and so these were classed as important amino acids (Kihara et al., 
2008). A point mutation in the conserved glutamine residue in humans has since been found 
within CNM patients (Toscano et al., 2017). This suggests that these two amino acids are 
likely to be essential for HACD activity across species. This CNM causing mutation in a 
conserved amino acid, known to be essential is yeast, provides evidence that the HACD 
activity may be conserved within these amino acids (Toscano et al., 2017). 
Plants also require VLCFAs for cytokinesis and membrane fusion and the Arabidopsis 
orthologue of HACD/Phs1 is PASTICCINO2 (PAS2) is capable of rescuing the effects of 
Phs1 deficiency in yeast. A deficiency in PAS2 itself caused a reduction of VLCFAs in 
Arabidopsis seeds (Bach et al., 2008; Molino et al., 2014). 
 HACD1  
Expression patterns for HACD1 found it to be highly expressed in both skeletal and cardiac 
muscle, therefore suggesting perhaps a role in muscle development and maintenance (Li et 
al., 2000; Uwanogho et al., 1999). Work by Ikeda et al., (2008) as previously mentioned, 
demonstrated that HACD1 could sufficiently rescue Phs1-knockout yeast strains and 
interacted with the ELOVL enzymes, confirming the role as a dehydratase (Ikeda et al., 2008). 
 The gene was initially mapped in humans to a locus responsible for arrhythmic right 
ventricular dysplasia (ARVD) seemingly confirming its role within cardiac muscle (Li et al., 
2000). Conversely, a study by Konishi et al., (2010) discovered that the K46Q mutation in 
ARVD patients had no effect on the activity of the HACD enzyme and that the VLCFA 
synthesis cycle was unaffected.  
In Labrador retrievers it was discovered that the HACD1 gene expressed three differently 
spliced isoforms: including that of the full length HACD1 expressed in striated muscle, termed 
HACD1-fl; one transcript missing exon 5 that was translated into a truncated protein that was 
more ubiquitously expressed, termed HACD1-d5; and a transcript of only HACD exons 1, 6 
and 7, named HACD1-167 (Maurer et al., 2010; Pelé et al., 2005). The HACD1-d5 isoform 
has been reported to lack interaction with the trans-2,3-enoyl CoA reductase (TER) proteins 
of the elongase complex and the HACD1-167 isoform accumulates in the muscles of 
HACD1-CNM dogs (Blondelle et al., 2015; Pelé et al., 2005). HACD1 has also been 
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documented to have additional isoforms that do not encode the essential amino acids for 
HACD activity therefore function is unknown in other tissues, including haematopoietic cells 
and teeth (Tondeur et al., 2010; Valdés De Hoyos et al., 2012). 
A difficulty in understanding and characterising function of HACD1 in mammalian skeletal 
muscle and disease is the coding of four paralogues in mammals that express tissue specificity 
(HACD1-4). HACD2-4 have not been characterised in detail at a transcriptome level and little 
evidence exists for splice variants of these HACD enzymes (Ikeda et al., 2008; Maurer et al., 
2010; Pelé et al., 2005; Tondeur et al., 2010; Valdés De Hoyos et al., 2012).  
 Previous work on HACD1 in muscle 
HACD1 has been previously studied with respect to both human and canine CNM. 
Hacd1-knockout (ko) mice presented with reduced muscle mass, reduced and inconsistent 
myofibre size and maximal force, with phenotypes similar to CNM affected Labradors 
(Blondelle et al., 2015).  
To investigate the function of HACD1-fl in more detail, the gene was knocked down in vitro 
in the myogenic C2C12 cell line and it was found that myoblast fusion was significantly 
impaired and myotubes were unable to differentiate properly (Blondelle et al., 2015, Lin et 
al., 2012). With regards to the HACD1 function and VLCFA synthesis it was found that 
HACD1-fl in the cells increased the ratio of C18-26:C10-16 in the cells (Blondelle et al., 
2015). A different clone of HACD1-deficient C2C12 myotubes (and using optimised cell 
culture conditions to allow for cell fusion) has been used to research HACD1 and these Hacd1-
knockdown (kd) cells were found to have disruption in their internal membrane systems 
(Walmsley, 2013; Walmsley et al., 2017). Hacd1-kd myotubes differentiated unlike the 
previous knockdown used by Blondelle et al., (2015) and the myotubes formed with an 
increased number of intracellular vacuoles and increased number of abnormally clustered 
nuclei (Walmsley et al., 2017). A recent study using Hacd1-null mice, which presented with 
reduced body and muscle weight, only a ~40% HACD activity reduction was seen and there 
was no change in lipid membrane composition; therefore, suggesting compensation may have 
occurred by another HACD enzyme within this Hacd1-null mouse model (Sawai et al., 2017).  
 HACD2 
HACD2 (previously PTPLB) is localised to the endoplasmic reticulum (ER) whereby it 
undergoes a fast turnover via the ERs proteasome system through significant interaction with 
the chaperone protein, BAP31 (Wang et al., 2004). The role of HACD2 in VLCFA synthesis 
was reported by Ikeda et al., (2008) due to its sequence homology with Phs1 - and it was 
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shown to interact with the elongase complex (Ikeda et al., 2008). HACD2 has high redundancy 
with HACD1 and they have been reported to elongate the same forms of VLCFA; as well as 
both HACD1 and HACD2 having functional redundancy with the yeast paralogue, Phs1 
(Ikeda et al., 2008; Sawai et al., 2017). Sawai et al., (2017) disrupted HACD2 in a human cell 
line which prevented the elongation of both saturated and unsaturated FAs and when 
disrupting HACD1 activity this also led to further reductions in the same VLCFAs. HACD2 
may therefore have the potential to compenstate for HACD1-deficieny. 
 HACD3 
HACD3 was shown to compartmentalise to golgi/endosome fractions in response to insulin, 
leading to the initial hypothesis that HACD3 might play a role in insulin signalling and 
diabetes (Boutchueng-Djidjou et al., 2015; Boutchueng-Djidjou et al., 2018). HACD3 
(referred to as BIND1 and PTPLAD1 previously) was shown to have strong expression in 
mouse testis, kidney, brain and liver, with weaker signals in skeletal muscle, spleen and heart 
(Courilleau et al., 2000). HACD3 also shares sequence homology with Phs1, although it was 
unable to rescue Phs1 defiency in yeast (Ikeda et al., 2008) and  the overexpression of HACD3 
in the HACD2-disrupted cell line exhibited a weak activity in elongating saturated and 
monounsaturated VLCFAs suggesting it has less redundancy with HACD1 and HACD2 than 
they have with each other (Sawai et al., 2017).   
 HACD4 
HACD4 (previously PTPLAD2) was mapped in humans to locus 9p21.3 (Zhu et al., 2014), 
which harbours a number of tumour suppressor genes; the loss of the HACD4 loci has been 
associated with oesophageal squamous cell carcinoma and frameshift mutations in HACD4 
have been associated with colon cancers (Yeon et al., 2017; Zhu et al., 2014). The HACD4 
haplotype has also been linked to accelerated atherosclerosis and myocardial infarction in a 
Serbian, male population (Zivotic et al., 2018a; Zivotic et al., 2018b). HACD4 was also shown 
to be involved in VLCFA synthesis through its sequence homology, however both HACD3 
and HACD4 are less homologous to Phs1 than HACD1 and HACD2 (Ikeda et al., 2008). As 
with HACD3, HACD4 also could not rescue Phs1 deficiency in yeast (Ikeda et al., 2008). The 
study by Sawai et al., (2017) found no HACD activity in the HACD2-disrupted human cell 
line even once HACD4 had been overexpressed. 
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 Lipids in skeletal muscle membranes 
Due to the involvement of HACD1 in the synthesis of VLCFA (Ikeda et al., 2008), this section 
will discuss fatty acids and lipids, and their roles within mammals; specifically within muscle 
and plasma membranes. 
Lipids are an abundant class of molecules within all living organisms and they are diverse in 
both structure and function, with cells using ~5% of genes to synthesise lipids (Cox & Nelson, 
2012; van Meer et al., 2008). Complex, polar lipids such as phospholipids and sterols provide 
structure within plasma membranes whereas simpler fats and oils provide energy and may 
have important roles in processes such as signalling or membrane trafficking (Cox & Nelson, 
2012). The lipid bilayer is the key component of skeletal muscle membranes, providing both 
structural support and fluidity as well as forming a barrier, contributing to the biophysical 
properties of the cell and aiding membrane fusion (van Meer et al., 2008).  
 Fatty acids 
Fatty acids (FAs) are the simplest form of lipids structurally and are composed of a 
hydrocarbon chain, ranging in length from 4-36 carbons (C4-C36) with a carboxylic group 
(COOH) positioned at one end of the chain (Cox & Nelson, 2012). FAs predominantly have 
even numbers of carbons in their chain. These may be single chains or may branch out into 
numerous chains: this structure forms the fundamental basis of most biological lipids from 
which the synthesis of more complex lipids is built (Cox & Nelson, 2012). The hydrocarbon 
chain backbone may: a) be entirely saturated with only single bonds present between atoms 
(the carbon atoms available bonds are saturated with carbon or hydrogen atoms) (SFA); b) 
include only one double bond in their chain (MUFAs, mono-unsaturated fatty acid); or c) have 
more than one double bond along the hydrocarbon chain (PUFA) (Figure 1.10) (Jakobsson et 




Figure 1.10: Example lipid saturation in a C10 fatty acid (carbon chain length = 10).  
The right end of hydrocarbon chain represents the carboxyl group (COOH) and unsaturated bonds are 
represented by an extra line along the hydrocarbon chain. Figure created using LIPID MAPS 
(https://lipidmaps.org). 
 
Fatty acids can either be taken up into the body through the diet, or synthesised by the fatty 
acid synthase (FAS) enzyme, up to 16 carbons in chain length (Jakobsson et al., 2006). It has 
been reported that 90% of fatty acids in mammals are synthesised de novo, indicating the 
importance of efficient fatty acid synthesis as well as diet (Moon & Horton, 2003). 
 Fatty acid classes and function 
Fatty acids can be classified according to their carbon chain length and are required for normal 
physiology; deficiency of FAs can lead to infertility, dermatitis and stunted growth (Lauritzen 
et al., 2001). Shorter fatty acids (C4-10) are absorbed for use as an energy source very readily 
and have also been shown to activate leukocytes through signalling pathways (Kinsella, 1990; 
Le Poul et al., 2003). Long chained fatty acids (LCFAs) range from 10-20 carbon chain length 
and are the most abundant FA species in mammalian cells (Leonard et al., 2004). LCFAs often 
act as precursors and can be modified into more complex structural molecules that are also 
highly valuable to the cell (Abedi & Sahari, 2014; Leonard et al., 2004). LCFAs, when not 
synthesised further, can be used for energy during exercise, whereby there is a large increase 
in the metabolism of LCFA in muscle (Kiens, 2006). 
Very long chain fatty acids are classified as FAs with a carbon chain length of over 20 and are 
far less abundant than shorter length FAs, and relative to their own expression, are highly 
abundant in the skin, retina, testis and brain (Monroig et al., 2010). VLCFAs have important 
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functions that LCFAs cannot compensate for, such as functions in inflammation resolution, 
sphingolipid biogenesis and vesicular transport (Kihara et al., 2012; Obara et al., 2013).  
 Very long chain fatty acids (VLCFAs) 
 VLCFA function 
The VLCFAs play important roles in the eye, skin, testis and CNS that have been well 
documented: their functions include barrier formation, inflammation, retinal function, 
spermatogenesis and maintenance of the nuclear envelope (Monroig et al., 2010; Schneiter et 
al., 1996). Their length is thought to aid in the lipids ability to match up with increasingly 
thick areas of the lipid bilayer (Gaigg et al., 2005). 
 Docosahexanoic acid (DHA, C22) is important in the nervous system and decreased levels 
affect learning, cognition and emotions. DHA makes up 50-60% of the FA composition of the 
retina, it activates retinal signalling and decreased levels of DHA reduce vision (Tanaka et al., 
2015). DHA is also present within testis and brain and one of its main functions is to generate 
lipid mediators that turn off inflammation response (Sassa & Kihara, 2014). Cognitive 
function correlated positively with mothers taking VLC-PUFA supplements during pregnancy 
and lactation: this has been observed in a number of studies including one correlating DHA 
levels in pregnancy with infant cognition (Braarud et al., 2018; Helland et al., 2003). Ceramide 
is critical in spermatazao and cells have been reported to apoptose in its absence and VLC 
sphingolipids are required for cell proliferation (Rabionet et al., 2015; Tvrdik et al., 2000). In 
mammals, VLCFAs with carbon chain lengths above 30 form permeability barriers (including 
the water permeability barrier of the epidermis) that are required for formation of the skin 
(Denic & Weissman, 2007). 
Although no clear overall function for VLCFAs has been established they seem to be critical 
for functioning of membranes, either by formation of membranes themselves and the 
maintenance of said membranes, or trafficking and signalling via membranes (Monroig et al., 
2010; Schneiter et al., 1996). 
 VLCFA in muscle 
The localisation of a muscle specific enzyme, HACD1, now known to be involved in the 
elongation of VLCFA has highlighted their importance within muscle, despite this VLCFA 
functions are still poorly understood (Ikeda et al., 2008; Kihara et al., 2012).  
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 VLCFA synthesis 
The elongation of VLCFAs requires a set of endoplasmic reticulum (ER) bound enzymes 
(Kihara et al., 2012). The elongation is a cyclical process of four sequential steps (displayed 
in Figure 1.11): condensation of long chain fatty acids, reduction, dehydration and a further 
reduction step, resulting in the addition of two carbons per cycle to the carboxylic acid side of 
the FA (Kihara et al., 2012).  
 
 
Figure 1.11: Cyclic process of very long chain fatty acid (VLCFA) synthesis (Adapted from 
Kihara et al., 2012). 
 
The initial condensation step in this cycle was found to be a rate limiting step, in which the 
carbon donor of malonyl-CoA is introduced to the fatty acid, resulting in β-ketoacyl-CoA 
(Nugteren, 1965). The ELONGASE protein family is responsible for catalysing this step and 
there are 7 mammalian isoforms (ELOVL1-7) which favour the elongation of different fatty 
acid chain lengths/saturations, and have been extensively researched (Kihara et al., 2012; 
Sassa & Kihara, 2014).  
ELOVL1 is highly involved with the synthesis of C24 sphingolipids, and Elovl1-ko mice have 
severe and lethal epidermal defects (Ohno et al., 2010, Sassa et al., 2013). Knockout in Elovl2 
leads to the absence of C26 VLCFAs in the testis of mice which lead to infertility (Zadravec 
et al., 2011). ELOVL4 favours the elongation of VLC-PUFAs and is critical for both retinal 
function and the formation of the water permeable barrier (Harkewicz et al., 2012). Mutations 
in Elovl4 result in loss of formation of the skin barrier in mice, the depletion of ceramide and 
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of retinal glycerophospholipids containing VLC-PUFAs (Harkewicz et al., 2012; Li et al., 
2007; Vasireddy et al., 2007). ELOVL5 was reported to elongate long chain C18 FAs for the 
liver and Elovl5-ko has been reported to cause hepatic stress in mice (Moon et al., 2009). 
ELOVL6 also elongates shorter chain lengths, with no apparent role in elongating VLCFAs: 
it is reported to elongate fatty acids of C12-C16 chain length (Moon et al., 2001). ELOVL3 
and 7 elongate C16-C22 FAs with particular affinity towards C18 chain lengths and so 
elongate both LCFA and VLCFA (Ohno et al., 2010; Zadravec et al., 2010). The ELOVL 
proteins have been documented to show a degree of tissue specificity within mammals: 
ELOVLs 1, 2, 3, 5 and 6 have been reported in the liver (Brolinson et al., 2008; Wang et al., 
2005) and ELOVLs 1, 5 and 6 in the heart (Igarashi et al., 2008). 
The first reduction step, and second in the cycle, requires nicotinamide adenine dinucleotide 
phosphate (NADPH) as a cofactor. The 3-ketoacyl-CoA is converted to 3-hydroxyacyl-CoA 
by the 3-ketoacyl-CoA reductase (KAR) enzyme (Moon and Horton, 2003.) In the third step 
the fatty acid chain is dehydrated to become an enoyl-CoA, and this is catalysed by the 
3-hydroxyacyl-coA enzymes dehydratase (HACD) enzyme (Ikeda et al., 2008; Kihara et al., 
2012). This step has also shown to be rate-limiting due to the accumulation of these 
3-hydroxyacyl-CoA molecules during in vitro FA elongation assays (Kihara et al., 2012). The 
TER enzyme catalyses the final reduction step to generate the extended acyl chain, also using 
NADPH as a cofactor (Moon & Horton, 2003). The TER enzymes are also involved in the 
degradation of sphingosine (Wakashima et al., 2014). 
 Membrane lipids 
The composition of lipids within membranes is extremely varied both between organisms and 
within them, including variation between organelle membranes, as the lipid composition is 
highly important for each specific membrane’s functions (Harayama & Riezman, 2018; 





Figure 1.12: Diversity of fatty acids found in membranes (Adapted from Harayama & Riezman, 
2018). 
 
Membrane lipids self-assemble in accordance to the cellular environment and the main 
membrane lipids are sphingolipids, glycerophospholipids and sterols, particularly cholesterol 
(Blanco, 2017; van Meer et al., 2008). Poly-unsaturated fatty acids (PUFAs) and 
glycerophospholipids (GPLs) are important for providing membrane fluidity and selective 
permeability. In contrast saturated fatty acids (SFAs) provide the cell membrane with more 
rigidity and organisation (Harayama & Riezman, 2018; Leonard et al., 2004.). Lipids 
modulate membrane properties and can affect the activity of membrane proteins – for example 
ion channel activity (Rosenhouse-Dantsker et al., 2012). Cholesterol, phosphoinitols and 
sphingolipids are known to regulate ion channel function through lipid-protein interaction and 
through physically altering membranes. (Ciardo & Ferrer-Montiel, 2017; 
Rosenhouse-Dantsker et al., 2012). Lipids within the membrane undergo constant 
maintenance and their homeostasis is crucial as evidenced by the vast number of genetic 
diseases associated with lipids (Harayama & Riezman, 2018). Lipid accumulation in a number 
of disorders has been linked with muscle weakness; such as the lipid storage myopathies and 
dysferlin deficient myopathies (Grounds et al., 2014; Laforêt & Vianey-Saban, 2010).  
 Sarcolemmal membrane lipids 
In skeletal muscle, lipid composition of the sarcolemmal membranes is important for structure 
and for the fusion of myoblasts (Mukai et al., 2009). Cholesterol is important for preventing 
ionic leak through ion channels, modifying lipid organisation and playing a role in membrane 
fluidity (Barrientos et al., 2017; Briolay et al., 2013; Mukai et al., 2009). Membrane 
cholesterol has been documented to modulate DHPR activity, potentially through interactions 
with Caveolin-3 (Barrientos et al., 2017). GPLs, the other highly abundant class of lipids 
within skeletal muscle membranes, are associated with providing structure for the membranes 
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and GPLs were reported to contribute for up to 50% of membrane lipids in the L6 muscle cell 
line (Briolay et al., 2013).  
 Internal skeletal muscle membrane lipids 
T-tubule membranes are composed largely of sphingolipids and cholesterol which creates a 
highly ordered lipid membrane; t-tubules are reported to be less fluid than other mammalian 
plasma membranes (Al-Qusairi & Laporte, 2011; Barrientos et al., 2017). Lipid composition 
within internal membranes varies between fibre types: type II SR membrane contains more 
phosphatidylcholine (PC) (64%) and less sphingomyelin (SM) (5%) than SR from type I fibres 
(37% and 15% respectively (Borchman et al., 1999). The PC: SM ratio is hypothesised to be 
related to membrane fluidity, suggesting type II fibres have more fluid SR membranes 
(Borchman et al., 1999). 
 Lipidomic techniques 
Studying the lipidome within HACD1-deficient muscle will be instrumental in understanding 
which lipids are affected, due to HACD1’s role in elongating VLCFA (Ikeda et al., 2008). 
Developments in techniques such as mass spectrometry (MS) and nuclear magnetic resonance 
(NMR) have allowed lipidomics as a field of research to advance greatly, however as it is a 
developing field there are limitations yet to be overcome (van Meer et al., 2009). For example: 
low concentrations of lipids within samples, halting enzymatic and oxidative processes of 
samples and a lack of lipid standards making the identification of lipids in samples difficult 
(Li et al., 2017; Vuckovic, 2018). Table 1.3 compares a number of methods currently in use 
for lipidomic studies including MS and NMR methods. MS as a technique is highly sensitive 
however, the level of ionisation of lipids is variable and therefore loses reproducibility (Li et 
al., 2017). MS is destructive to samples and therefore complementary analyses cannot be 
performed, unlike with NMR in which samples stay intact and available for further study: 
therefore making NMR desirable as an initial experimental choice (Li et al., 2017).
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Table 1.3: Brief overview of lipidomic analyses techniques (Adapted from Yang et al., 2016). 









Reproducible, high resolving 
power, high sensitivity for 
focused analysis 
Low throughput, complex 
data processing, 
destruction of sample 
Pitt 2009; Yang 






Samples mixed with matrix 
material and applied to 
metal plate 
Samples then pulsed with 
laser and desorbed before 
molecules are ionised 
Tolerant to contaminations, 
extraction is not required and 
off-line sample preparation 
allows for focused analyses 
Low throughput, 
destruction of sample, low 
sensitivity for low 
abundance molecules 
Cramer 2009, 




Gas phase separation of ions 
by size, shape and charge 
Increased signal: noise ratio 
and ion separation  
Loss of sensitivity, 
destruction of sample 
Paglia et al., 
2015; Wang et 
al., 2015; Yang 
et al., 2016 
Shotgun MS Tandem MS Internal standards added for 
lipids of interest, focused 
technique 
Simple, fast and quantitative, a 
focused technique 
Selection of standards 
difficult due to 
availability, destruction of 
sample 






Highest possible mass 
resolution 




destruction of sample 
Marshall et al., 






Nuclear magnetic fields are 
perturbed by magnetic field 
and produce spectral 
characteristics dependent 
upon their environment 
1H-NMR, 13C-NMR and 
31P-NMR combinations can 
provide increasingly more 
informative spectra  
Used often as an exploratory 
method 
Time efficient, reproducible, 
samples preserved, instruments 
are robust 
Crowded spectra due to 
lack of separation, low 
resolution for lipids of the 




Li et al., 2013; 
Li et al., 2017 
Ramen 
spectroscopy 
Uses scattering of light 
source to provide 
information about 
vibrations within sample 
Used for a targeted 
approach 
Quantitative, samples 
preserved, fast and reliable, 
single-cell applications, can be 
used as a focused technique 
Requires highly sensitive 
and optimised equipment 
Buzgar et al., 
2009; Wu et al., 




 Current HACD1-CNM models  
Animal and cellular muscle models in research have greatly enhanced our understanding of 
CNM, as well as a number of other musculoskeletal disorders including muscular dystrophies 
(Blondelle et al., 2015; Buj-Bello et al., 2002; Cowling et al., 2017; Dowling et al., 2009; 
Dowling et al., 2010; Durieux et al., 2010; Nance et al., 2012; Sabha et al., 2016; Sawai et 
al., 2017; Smith et al., 2014; Walmsley, 2013; Walmsley et al., 2017; Ytterberg, 1991).  
 HACD1-CNM Labrador retrievers  
In 1992, a colony of HACD1-CNM dogs was established in Alfort Veterinary School, France, 
and using these dogs the genetics and pathology of canine CNM was characterised using these 
dogs (Blot et al., 2002; Maurer et al., 2012; Pelé et al., 2005; Tiret et al., 2003). However, the 
use of dogs for further research is less practical due to size, cost and ethics (Collins & Morgan, 
2003).  
 Hacd1-null mice 
Mice have been used as a longstanding model for neuromuscular diseases, including CNM 
(Nance et al., 2012; Vainzof et al., 2008). The mdx mouse is a widely used model of Duchenne 
muscular dystrophy (DMD) and has provided great insight into the disease, but their 
phenotype is very mild and this is not representative of DMD in both humans and canines 
(Cox et al., 1993) and so are not necessarily the most appropriate model of muscle disease. 
Mice models have also been used in the study of HACD1-CNM providing a greater 
understanding of the mechanisms in which HACD1 might be involved in (Blondelle et al., 
2015; Sawai et al., 2017). Hacd1-null mice (Hacd1-/-) presented with reduced body weight 
gain after birth and into adulthood due to a 29% reduction in muscle mass; these mice had a 
27.5% reduction in absolute maximal force, although specific force (force per unit mass) was 
unchanged (Blondelle et al., 2015). These phenotypes are comparable to the phenotype of 
HACD1-CNM dogs (Maurer et al., 2012; Tiret et al., 2003). Blondelle et al., (2015) 
hypothesised that a defect in myoblast fusion was present as a result of HACD1-deficiency as 
they exhibited smaller fibres with fewer nuclei within their Hacd1-/- mice (Blondelle et al., 
2015). Sawai et al., (2017) also used a Hacd1-/- mouse model in their research and found 
corroborating results in terms of reduced body and muscle mass. It was also documented that 
the reduction in HACD activity was only ~60% of the control which was less severe than 
expected - they proposed HACD2 was responsible for this remaining HACD activity within 
the muscles (Sawai et al., 2017). 
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 Hacd1-deficient C2C2 cell line  
Skeletal muscle cell lines allow the study of muscle without the need for live animal models 
and so complies with the NC3Rs guidelines by reducing the number of animals required within 
research. The mouse muscle cell line, C2C12, and the rat muscle cell line, L6 are used within 
research and promoted to differentiate into multinucleated myotubes through the removal of 
serum high in growth factors (Yaffe, 1968; Yaffe & Saxel, 1977). 
C2C12 cells have been widely documented within muscle research and shown to have a 
number of characteristics making them a suitable resource. These characteristics include: the 
measurement of force and contraction and the measurement of ECC and its apparatus 
including RYR1, DHPR and SERCA channels (Manabe et al., 2012; McMahon et al., 1994). 
Blondelle et al., (2015) used a Hacd1-knockdown (Hacd1-kd) C2C12 cell line alongside their 
Hacd1-/- mouse model and found a reduction in myotube fusion in these cells. They also found 
defects in membrane properties such as fluidity and abnormal cell lipid profiles (Blondelle et 
al., 2015). A different clone of HACD1-deficient C2C12 myotubes (using optimised cell 
culture conditions to allow for cell fusion) has been used to study ECC defects and these 
Hacd1-kd cells were found to have disruption in their internal membrane systems including 
abnormal nuclei clustering (often developed in ring formations) and development of internal 
vacuoles (Walmsley, 2013; Walmsley et al., 2017). 
 Zebrafish as a potential HACD1-CNM model 
Zebrafish are an established model organism for studying mammalian disease and have been 
used in biomedical research for approximately 40 years, when they were first used in an 
experiment to study mutations affecting their nervous system (Streisinger et al., 1981). They 
are now used widely for drug and genetic screening as well as for modelling mammalian 
diseases (Den Hertog, 2005; Dooley & Zon, 2000). DMD has been studied in zebrafish 
extensively since the generation of the sapje DMD zebrafish model (Bassett & Currie, 2004). 
The model has an extremely close phenotype to DMD phenotype and the translatability of 
using zebrafish as a myopathy model has arisen from the high similarity in their muscular 
characteristics to that of mammals (Guyon et al., 2007). 
As a model organism the zebrafish has a number of advantages over other models. Invertebrate 
organisms such as Drosophila and C.elegans are powerful models and can be used in large 
numbers, but as invertebrates, they lack basic homology of anatomy with mammals, for 
example, the absence of kidneys (Dooley & Zon, 2000; Wilson-Sanders, 2011). For this 
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reason, they are limited in the issues they can address in mammalian physiology. Mice are 
also widely used and as mammals they offer a clear advantage in terms of translatable results: 
however studying mice also comes with disadvantages to which zebrafish offer a valid 
solution. Mice are expensive to house and maintain and often lack key phenotypes in their 
disease models compared to zebrafish models which are often good representative for 
mammalian disease (Dooley & Zon, 2000; Guyon et al., 2007; Kasher et al., 2015). Zebrafish 
provide a bridging of this gap between the invertebrate and mammalian models (Dooley & 
Zon, 2000; Kabashi et al., 2011; Phelps & Neely, 2005).  
Zebrafish have high fecundity and females may spawn up to 300 eggs per week which undergo 
rapid development: the cardiovascular and nervous systems among other organs are fully 
developed by 1-week post fertilisation (Kimmel et al., 1995). Thus, making them a valuable 
resource for studying neurological and musculoskeletal disorders within development (Crilly 
et al., 2018; Sarasamma et al., 2017), Figure 1.13 presents embryos from 1-3 days post 
fertilisation (dpf). Zebrafish models allow for the study of early development as the embryos 
develop separately from the mother and so are highly accessible and non-invasive to attain 
(Phelps & Neely, 2005). This external development also allows for easier genetic 
manipulation through the injection of RNA/DNA at a single cell stage (Liu et al., 2017). 
A potential limitation of using zebrafish to study genetics is the genome duplication that the 
ancestral zebrafish lineage underwent, over 500 million years ago (Meyer & Schartl, 1999). 
While this is a potential set back with zebrafish genetic studies, comparative mapping against 
the human genome has been completed to identify segments that may have arisen due to this 
(Howe et al., 2013). These duplicated genes may have lost function over time, and it has been 
documented that larger families of genes with more paralogues are present within zebrafish 
compared to the mammalian orthologues (Postlethwrait et al., 1999). Despite this potential 
limitation, zebrafish share over 75% of human disease genes making them a suitable model 
for the diversity of human and mammalian disease (Howe et al., 2013; Sarasamma et al., 
2017). Zebrafish embryos are also valuable in biomedical research as they have high optical 
clarity due to their transparency - allowing developing cells and organs to be observed 





Figure 1.13: Images of developing zebrafish from 1dpf – 3dpf (days post fertilisation).  
Anatomy including heart sac, yolk sac, tail and chorion are labelled, scale bar indicates 0.5cm. 
 
 Muscle in developing zebrafish embryos 
Neurogenesis begins at around 10 hours post fertilisation (hpf) and within the first 24 hours 
key components of the CNS are present within the embryos (Kabashi et al., 2011). Zebrafish 
embryos develop somites from approximately 10-24hpf and shortly after somite formation the 
first muscle cells are present within the embryos (Devoto et al., 1996; Kimmel et al., 1995). 
Devoto et al., (1996) reported that by using cell fate mapping, the type of myofibre (type I or 
type II) could be recognised before the formation of the somites. At approximately 17hpf 
embryo tails begin to twitch, confirming the connection between nerve and muscle 
(Saint-Amant & Drapeua, 1998). Muscle function is commonly evaluated within zebrafish 
muscle due to the rapid development of the musculoskeletal and nervous systems 
(Saint-Amant & Drapeua, 1998). This optical clarity of the embryos has allowed zebrafish 
embryos to be utilised in the study of calcium signalling within muscle through the use of 
fluorescence imaging. Calcium homeostasis and signalling are highly regulated throughout 
development; including the expression of RYR1 from early stages of development (Ashworth 
et al., 2005; Brennan et al., 2005; Wu et al., 2011). The developed myofibres within 2dpf 





Figure 1.14: Images of 3dpf (days post fertilisation) zebrafish embryo tails stained with both 
haemotoxylin & eosin (H&E) and RYR1 immunofluorescence showing the developed myofibres. 
White scale bar represents 100µm.  
 
 Comparisons between mammalian and zebrafish muscle 
Although zebrafish are a non-mammalian model there a number of important similarities 
between two sets of musculoskeletal systems. Zebrafish have the presence of both type I and 
type II myofibres, and these are topologically separate, unlike mammals (Devoto et al., 1996; 
Sparrow et al., 2008). As mammalian myopathies often only effects one fibre type the 
separation of fibre types may be seen as advantageous (Devoto et al., 1996; Sparrow et al., 
2008). Their muscle also develops from the dermomyotome in three stages, as seen in 
mammalian muscle development, and zebrafish muscle development utilises satellite cells 
comparable to the satellite cells of mammals (Bryson-Richardson & Currie, 2008; Devoto et 
al., 2006; Sparrow et al., 2008). The zebrafish satellite cells express orthologues of Pax7 and 
Pax3 which are required in mammalian muscle development and present within mammalian 
satellite cells. The development of a pax7-mutant zebrafish confirmed its role in adult muscle 
repair (Berberoglu et al., 2017). Zebrafish provide incredibly useful tools for studying 
mammalian muscle, and this is supported by the sapje zebrafish DMD model (Bassett & 
Currie, 2004). The sapje zebrafish phenotype is representative of the human disease phenotype 
whereas the mouse DMD model, the mdx mouse, has a much milder phenotype than is seen 
in DMD (Bassett & Currie, 2004). 
 Methods of zebrafish genome editing 
There are a number of ways to genetically alter the hacd1 gene within zebrafish embryos to 
create a hacd1-mutant model and investigate the role of HACD1: the method favoured and 
used in this thesis will be CRISPR/Cas9 genome editing. 
39 
 
Morpholinos are another common genome editing tool within zebrafish and have been used 
widely within zebrafish in the past due to their ability to phenotypically mimic characterised 
mutants (Stainer et al., 2017). Morpholinos are composed of synthetic nucleic acid 
oligonucelotides that bind to RNA and block further binding or interactions from molecules 
therefore blocking translation (Heasman, 2002). However; morpholinos often degrade, have 
many uncertain off-target effects and exhibit low sequence specificity (Summerton, 1999). 
When comparing morpholino zebrafish to the Sanger Zebrafish Mutation Project Kok et al., 
(2015) found that approximately 80% of known morphant phenotypes were not seen in the 
morpholino zebrafish suggesting a lack of efficiency in the genome editing (Kok et al., 2015). 
Where morpholino genome editing was shown to be inefficient, CRISPR/Cas9 efficiency in 
zebrafish has reported to reach up to 86% and be hereditable (Hruscha et al., 2013). 
Other methods include zinc finger nucleases (ZFN), transcription activator-like effector 
nucleases (TALENS) and morpholinos. ZFN works by cleaving targeted DNA and inducing 
DSB (Carroll, 2011). TALENS also works via DNA cleaving, using nucleases that target 
single nucleotides to provide high levels of specificity (Joung & Sander, 2013). CRISPR/Cas9 
has a comparable rate of mutagenesis compared to ZFNs or TALENs and is better adapted 
than that of TALENs or ZFNs (Gagnon et al., 2014).  
CRISPR DNA sequences are found naturally within prokaryotic organisms and originate from 
their adaptive immune response to degrade DNA from invading viruses, and these sequences 
have been found in approximately 50% of bacteria genomes (Hille et al., 2018). The Cas9 
(CRISPR-associated 9) enzyme utilises the CRISPR sequences as a guide to introduce double 
strand breaks (DSB) into the sequence specific DNA, which therefore destroys the virus. 
These DSB occur adjacent to a specific 3-5bp (base pairs) sequence within the genome known 
as a protospacer adjacent motif (PAM), and are now utilised in order to mutate gene sequences 
of choice (Sander et al., 2014). CRISPR/Cas9 is a rapidly developing method of editing 
genomes and due to the frequency of the PAM sequences within the genome a primary 
advantage of CRISPR/Cas9 is the allowance to direct mutagenesis to almost anywhere within 
the genome simply by editing the sequence of the single-guide RNA (sgRNA); this provides 
great flexibility in the technique.  
 Current zebrafish CNM congenital myopathy models 
Due to the benefits of using zebrafish embryos; several zebrafish models of CNMs have been 
developed to study different genetic causes, more specifically mutations in: MTM1, MTMR14, 
BIN1 and DNM2 (Dowling et al., 2009; Dowling et al., 2010; Gibbs et al., 2013a; Sabha et 
al., 2016; Smith et al., 2014). Dowling et al., (2009) demonstrated that mtm1-morphant 
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zebrafish presented with early muscle phenotype including: mislocalised, rounded nuclei and 
a disorganised t-tubule network. This model was suggested to be more translatable to the 
disease than the mouse model of MTM1-deficiency in which the mouse phenotype appeared 
after a period of normal muscle growth and function (Dowling et al., 2009).  
Dowling et al., (2010) then investigated the other myotubularin-related gene (mtmr14) 
knockdown in zebrafish which resulted in, similar to mtm1-knockdown, an abnormal motor 
phenotype including diminished spontaneous contractions and impaired ECC function 
(Dowling et al., 2010). Gibbs et al., (2013a) characterised two isoforms of dynamin 2 in 
zebrafish embryos of which they hypothesised to be due to the genome duplication. When 
knocking expression of these isoforms down they found morphological defects in embryos, 
including shortened somites and body axis, by 1-day post fertilisation (dpf) comparable to 
mammalian centronuclear myopathy (Gibbs et al., 2013a). The BIN1-CNM zebrafish model 
generated by Smith et al., (2014) displayed structural defects in the muscle comparable to 
those seen in human biopsies and they reported abnormal calcium homeostasis (Gibbs et al., 
2013a).  
The current zebrafish CNM models have furthered the understanding of CNM pathogenesis 
and the function of some of the genes within the disease (Dowling et al., 2009; Dowling et 
al., 2010; Gibbs et al., 2013a; Smith et al., 2014). Zebrafish embryos bridge the gap between 
the ease of using invertebrate models and the translatability of mammalian models (Dooley & 
Zon, 2000; Kabashi et al., 2011; Phelps & Neely, 2005). For this reason, zebrafish should 
make a relevant model for HACD1-CNM and once generated will have great potential for the 









 Aims and hypotheses 
Mutations in HACD1 cause spontaneous congenital myopathies in dogs and humans, and 
Hacd1-deficient mouse and myogenic cell culture models demonstrate similar characteristics. 
Muscle membrane abnormalities are a key feature of CNMs, including canine HACD1-CNM, 
however the role of HACD1 and VLCFA in the development and maintenance of skeletal 
muscle membrane systems is poorly understood. The overall aim of this project was to validate 
and characterise a zebrafish embryo model with hacd1 mutations and develop techniques 
(initially using a mammalian cell culture model) to study the effects of HACD1-deficiency on 
muscle membrane development, structure and function. Our specific aims were as follows:  
 
1) Determine the zebrafish homologue of HACD1 and investigate the hypothesis that HACD 
enzyme genes are evolutionarily conserved with comparable expression patterns in zebrafish 
to those documented in mammals; 
2) Utilise a murine myoblast cell culture model to evaluate the effect of Hacd1-knockdown 
on differentiation and function via an electrophysiological study of the cell membranes;  
3) Explore the effects of HACD1 expression (by examining samples in early development 
prior to HACD1 upregulation and after) and deficiency on the lipidome of cell and embryonic 
zebrafish models using 1H-NMR;  
4) Investigate the hypothesis that zebrafish embryos with mutations in hacd1, introduced by 










2  Spatial and temporal evaluation of HACD enzyme 
expression in zebrafish 
 Introduction 
Expression of HACD1 in developing and mature skeletal and cardiac muscle was first reported 
several decades ago (Uwanogho et al., 1999). Linkage analysis in a pedigree of Labrador 
retrievers with CNM documented a hypomorphic mutation and confirmed the protein’s 
importance for normal muscle function (Maurer et al., 2012; Pelé et al., 2005). However, the 
role of HACD enzymes in VLCFA biosynthesis was only discovered more recently after 
elucidation of fatty acid elongation pathways in yeast allowed identification of the elongase 
complex enzymes and their mammalian orthologues (Denic & Weissman, 2007; Riezman, 
2007).  Yeast Phs1 and the four mammalian HACD enzymes (HACD1-4) share sequence 
similarities, in particular two conserved amino acids are thought to be essential for the 
enzymes active site and dehydratase activity in the elongation cycle of VLCFAs (Ikeda et al., 
2008; Kihara et al., 2008).  
A bottleneck in understanding the precise function of individual HACD enzymes in mammals 
has been the presence of paralogues which are differentially expressed between tissues. 
HACD1 is predominantly expressed in skeletal and cardiac muscle (Ikeda et al., 2008; Li et 
al., 2000), HACD4 in leukocytes (Ikeda et al., 2008) and both HACD2 and 3 are expressed 
ubiquitously (Courilleau et al., 2000; Ikeda et al., 2008; Wang et al., 2004). This suggests 
tissue-specific requirements for HACD enzymes and VLCFA. Hence, to evaluate the specific 
roles of HACD1 in skeletal muscle we cannot consider it in isolation: a recent report found 
HACD1 and HACD2 to have functional redundancy therefore suggesting compensatory 
mechanisms might be possible (Sawai et al., 2017).  
Two main transcripts of HACD1 are recognised: specifically, in striated muscles HACD1-fl 
(full length isoform) is expressed and ubiquitously expressed HACD1-d5 (excluding exon 5) 
has a different reading frame in the 3’ sequence therefore this does not code for the essential 
amino acids and does not have HACD activity (Blondelle et al., 2015; Kihara et al., 2008; 
Maurer et al., 2010; Pelé et al., 2005). Other splice variants include ‘HACD1-CAP’ encoding 
140 of the full length 288 amino acids, which was reported to be expressed in teeth cementum, 
heart and liver (Valdés de Hoyos et al., 2011), and a transcript encoding only exon 1 of the 
transcript in haematopoietic stem cells (Tondeur et al., 2010). In CNM affected dogs the SINE 
insertion results in multiple splice variants (Maurer et al., 2010; Pelé et al., 2005), only one of 
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these HACD1-167 expresses exon 6 in frame with the potential for HACD activity (Pelé et al., 
2005).   It is unknown if the other three HACD enzymes are also prone to multiple splicing.  
To determine whether zebrafish embryos could be a relevant model for HACD1-deficient 
myopathies and used to evaluate the role of HACD enzymes in muscle development and 
disease, normal expression pattern of these enzymes in zebrafish were evaluated to determine 
whether their functions are likely to be evolutionarily conserved. 
Previous work on hacd1 in zebrafish embryos (Walmsley, 2013) identified the two major 
hacd1 transcripts, (hacd1-fl and hacd1-d5) already characterised in mammals (Maurer et al., 
2010; Pelé et al., 2005; Walmsley, 2013). Zebrafish embryos were seen to have a number of 
different isoforms in early embryogenesis including hacd1-fl following the onset of muscle 
development in somites (Walmsley, 2013). Preliminary evaluation by whole-mount in situ 
hybridisation (ISH) found expression of hacd1 within somites from 24hpf and myotome and 
heart from 72hpf (Walmsley, 2013). We aimed to provide more detail regarding the expression 
of hacd1-4 within zebrafish embryos. 
 Chapter aims 
The work of this chapter aimed to characterise the HACD enzymes within developing 
zebrafish embryos and adult tissues, more specifically to: 
1) Identify the zebrafish orthologues to mammalian HACD1-4; 
2) Design conventional RT-PCR assays to clone each of these genes to evaluate for 
alternatively spliced transcripts and as templates to synthesise probes for ISH; 
3) Investigate the localisation of hacd enzyme transcripts in developing zebrafish 
embryos by ISH; 
4) Develop quantitative RT-PCR assays, including validation of reliable housekeeping 











ENSEMBL and NCBI databases were utilised to identify zebrafish (Danio rerio) HACD 
genes and previously documented transcripts. Coding sequence and amino acid sequence, 
transcript length, exon arrangement and structure were compared between putative zebrafish 
HACD enzyme and those from humans, mice and dogs as genome databases for these 
mammalian species have more in-depth annotation. BLAST search of HACD1 coding 
sequence was performed to evaluate for other common sequences that might be additional 
paralogues. Synteny of surrounding areas on chromosomes was also evaluated to obtain 
evidence for homology which was particularly important considering the ancestral zebrafish 
genome duplication (Meyer & Schartl, 1999). 
 Alignments 
CLC Workbench (Qiagen) was used to align the hacd cDNA transcripts and amino acid 
sequences with human and murine counterparts. All four zebrafish hacd cDNA transcripts and 
Hacd amino acid sequences were also aligned to evaluate similarity between the four genes 
and proteins, as any area of high sequence homology would need to be considered later when 
designing primers and probes. CLC Workbench was also used to annotate and store this data 
(CLC Bio). 
 Zebrafish husbandry 
Adult AB wild type zebrafish were housed in a licensed facility under a 12 hour light – 12 
hour dark cycle and at 28oC. Embryos were staged in accordance to Kimmel et al., (1995). 
Fish were fed a diet of basic grade 230 artemia (ZM systems), tetramin flake (Tetra) and hikari 
pellets (Hikari) to provide optimised diet for zebrafish breeding. Facility management and 
handling of fish and embryos was in accordance with local rules and UK Home Office 
regulations. 
 Zebrafish rearing 
As the optimal age for embryo production in zebrafish is between 6-18 months a stock was 
bred and reared to breeding age for the purposes of experiments (Nasiadaka & Clark, 2012). 
Embryos were housed in 5L tanks with constant water flow, and fed on a diet of both live 
brine shrimp and fish feed tailored to the size of the growing fry (ZM systems). 
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 RNA extraction from zebrafish embryos 
Embryo pools of 20 at set embryonic stages were collected in microcentrifuge tubes, system 
water was removed and then replaced with 1ml TRIzol (Life Technologies). Embryos were 
then homogenised using a 25g syringe and passed through this 10 times before storage at -80oC 
until extraction was carried out. 
Once thawed, samples in TRIzol were first incubated at room temperature for five minutes. 
200μl chloroform (Sigma Aldrich) was added to each sample and agitated for 15 seconds 
before a two-minute incubation again at room temperature. Samples were then centrifuged at 
12,000g for 15 minutes at 4oC. This separated the embryo homogenate into several layers: an 
upper aqueous phase (containing RNA), an interphase containing DNA and a lower organic 
protein containing phase. The aqueous phase from each sample was then transferred to new, 
clean tubes and 500μl isopropanol (Sigma Aldrich) was added to precipitate RNA. These 
samples were left to incubate for 10 minutes at room temperature (~22oC) before 
centrifugation at 12,000g for 10 minutes at 4oC. Supernatant was removed and the pellet 
washed with 1ml of 75% molecular grade ethanol (Sigma Aldrich) and mixed gently. Samples 
were then centrifuged at 7,500g for five minutes at 4oC. Ethanol supernatant was removed and 
RNA pellets allowed to air dry for 10 minutes before re-suspension in 20μl RNase-free water. 
RNA samples were analysed on the Nanodrop to ascertain concentration (ng/μl) and purity of 
extracted RNA as measured by the 260/280 and 260/230 absorbance ratios. These provide 
information on contamination by protein or phenol (260/280 and 260/230 ratios), phenol 
contamination may arise from TRIzol used during extraction (260/230). A proportion of RNA 
samples were also sent to the Centre for Genomic Research within the University of Liverpool 
for samples to be analysed on the Qubit (Thermo Fisher) and Bioanalzyer (Agilent) for further 
information on RNA quality. 
 RNA extraction from adult zebrafish tissues 
Adult tissues obtained from zebrafish over 12 months of age. Zebrafish were culled via the 
“concuss and pith” method (Valentim et al., 2016). Samples were either snap frozen in liquid 
nitrogen or stored in RNA Later (Life Technologies). 
 Muscle 
Due to the fibrous nature of mature muscle, a fibrous tissue specific RNA extraction kit 
(Qiagen, catalogue number 74104) was used. The muscle was first ground in liquid nitrogen 
to a powder before addition of 350μl buffer RLT (containing β-mecaptoethanol to denature 
RNases). This was then transferred to the QIAShredder column and centrifuged at 13,000rpm 
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for two minutes at 4oC. Proteinase K (Qiagen) diluted in RNase-free water (600μl total) was 
then added to debris and incubated for 10 minutes at 55oC. Following steps were all carried 
out at room temperature. Incubated samples were then centrifuged at 10,000rpm for three 
minutes before supernatant was collected and combined with 500μl of 96-100% ethanol. 
Solution was then transferred to the Qiagen RNeasy columns and centrifuged at 8,000g for 15 
seconds and flow through discarded: this was done twice to ensure flow through was 
eliminated from column. 350μl buffer RWI was added and columns centrifuged at 8,000g for 
15 seconds and again flow through discarded. 80μl of buffer RDD and Dnase solution was 
added to column and incubated at room temperature for 15 minutes. Columns were then 
centrifuged again at 8,000g for 15 seconds and 500μl buffer RPE added before another 
centrifuge step at 8,000g for 15 seconds and flow through discarded, this was repeated again 
as well as an extra centrifuge step with no addition of buffer RPE to completely remove 
leftover buffer. 30μl RNase free water was then added and columns were spun at 8,000g for 
one minute to elute through RNA. Samples were also assessed for purity on the Nanodrop as 
described in Section 2.2.6. 
 Other (non-fibrous) tissues 
All other adult tissues were ground in liquid nitrogen as in Section 2.2.6 and RNA was then 
extracted using the TRIzol method described in Section 2.2.5.  
 cDNA synthesis from zebrafish embryo and adult RNA for RT-PCR 
cDNA was synthesised by reverse transcription (RT) (SuperScript III, Invitrogen) using 8μl 
of approximately 1μg RNA (isolated by protocols in sections 2.2.6.1 and 2.2.6.2) and was 
combined with 1μl random primers (50ng/μl) and 1μl of 0.5mM dNTPs. The reaction was run 
for five mins at 65oC followed by one minute at 4oC before the addition of 10mM DTT, 1x 
RT buffer, 2.5mM MgCl2, 40U/μl RNase out and 200U/μl SuperScript III reverse 
transcriptase. Reaction was then run for a further 10 minutes at 25oC, 50 mins at 50oC and 
85oC for five minutes before the addition of RNase (2U/μl) and run at 37oC for 20 minutes to 
remove any residual RNA. 2μl of cDNA was then used for further RT-PCR reactions. 
 RT-PCR 
Primers were designed using the open source website Primer3 (http://primer3.ut.ee/) to 
amplify a 600-800 base pair fragment of cDNA for in situ hybridisation probe generation 
(Table 2.1). Primers were designed to cover the coding sequence and include the start codon 
and essential amino acids so they could be cloned for use in expression vectors and would 
allow us to evaluate for the presence of alternative transcripts. HACD1, HACD2 and HACD4 
coding sequences are 729, 735 and 669bp respectively therefore the same primer pair was 
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suitable for both these applications. The coding sequence of HACD3 is 1080bp, therefore 
separate primers were designed for probe generation and cloning. Due to the sequence 
similarity between HACD1 and HACD2 an additional set of primers was designed to generate 
a probe in the 3’ UTR of HACD2 for evaluation. 
RT-PCR was performed using Amplitaq Gold DNA polymerase (Applied Biosciences). Each 
50μl reaction contained: 4% cDNA, 0.25μM forward and reverse primers, 0.25mM dNTPs 
(Fisher Scientific), 1 x PCR buffer II, 2.5mM MgCl2 and 0.025U/μl Taq DNA polymerase 
(Applied Biosciences). Reactions were run for 35 cycles of: 95oC for five minutes (initial 
denaturing) followed by 40 cycles of 94oC for 30s (denaturing), 55oC for 30s annealing (unless 
otherwise stated as this is primer dependent and reactions were optimised via temperature 
gradients to determine annealing temperature) and 72oC for 50s extension (unless otherwise 
stated) and a final extension step of 72oC for seven minutes. PCR products were visualised 
after gel agarose electrophoresis on a 1.5-2% gel with GelRed nucleic stain (Cambridge 
Biosciences). Products were run against either a 100bp or 1kbp ladder (Invitrogen) and all 
samples were mixed with BlueJuice loading dye to aid visualisation and loading (Invitrogen). 
PCR products were then purified prior to cloning or sequencing using a QIAquick PCR 
purification kit (Qiagen, catalogue number 28104) or, where multiple bands were detected, 
bands were cut out of the agarose gel under UV light and extracted using a gel extraction kit 
(Qiagen, catalogue number 28704). Sequencing was carried out by commercial company 












Table 2.1: List of RT-PCR primers used to amplify up cDNA for RNA probe synthesis and 
cloning, annotated with red arrows in Figure 2.5. 
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Several primer pairs were initially designed and tested for each assay. Reaction conditions 
were optimised including the annealing temperature was determined by applying a gradient to 
different reactions in the thermocycler; a range of magnesium concentrations was also trialled 
for certain reactions to improve product yield or reduce any non-specific binding that might 
have occurred. 
 Cloning of hacd transcripts  
Purified products from RT-PCR assays were cloned for sequencing, to allow for future 




Transcripts were ligated into the pGEM-T plasmid vector (Promega) (Figure 2.1) (50ng) 
containing both the T7 and SP6 promoter sites using the T4 ligase enzyme (Promega) 
overnight at 4oC. Reaction contained 3µl transcript, 5µl 1X reaction buffer, 1µl vector (50ng) 
and 1µl T4 ligase (3 Units/μl). 
 
 
Figure 2.1: pGEM-T plasmid with hacd1 transcript inserted as an example.  
Universal M13 primer binding sites and polymerase sites Sp6 and T7 (used for probe synthesis) are 
annotated. 
 
Plasmids were used to transform chemically competent E.coli (TOP10, Invitrogen) using heat 
shock. The entire ligation mixture was added to 50μl of competent cells and incubated on ice 
for 30 minutes. This mixture was heat shocked at 42oC for 30 seconds before placing on ice 
again for two minutes. 250μl SOC medium (Super Optimal broth with Catabolite repression, 
Sigma Aldrich) (preheated to 37oC) was added and shook for one hour at 225rpm. This was 
then plated and colonies were allowed to grow overnight at 37oC on LB agar plates containing 
100μg/mL ampicillin (Sigma Aldrich).  
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Individual colonies were selected and seeded into LB broth containing 100μg/mL ampicillin 
(Sigma Aldrich) and grown overnight again at 37oC in in an orbital shaker. To confirm 
successful transformation with ligated vector, RT-PCR reactions were performed either 
directly on selected colonies or from the broth after overnight incubation. To simplify probe 
synthesis, we required ligation of hacd1-4 in the correct orientation for antisense probe 
synthesis from SP6 promoter and sense (control) probe synthesis from the T7 promoter. To 
select for this, the M13 reverse primer found within the plasmid sequence was used alongside 
the forward primer for the transcript to produce the desired product if cloning was successful 
(Figure 2.2). Plasmid DNA was then extracted by Miniprep spin columns (Qiagen, catalogue 
number 27104) and sent for sequencing using the universal primer binding site (M13R) and a 
primer from inside the hacd insert (GATC). Purified plasmid from several colonies for each 
of hacd1-4 were sent for sequencing to evaluate the sequence of cloned transcripts. Plasmids 
confirmed by sequencing to contain full length hacd transcript in the desired alignment and 








Figure 2.2: RT-PCR evaluation of cloning for full length hacd transcripts.  
Selective RT-PCR for (a) hacd1, (b) hacd2, (c) hacd3 and (d) for hacd4 ligated into pGEM-T performed 
on transformed bacterial colonies, green asterisk indicates colonies subsequently confirmed by 
sequencing to have the correct sequence for the full length transcript inserted in the desired orientation. 
The red aterisk indicates a novel isoform of hacd2 encoding exons 1, 2 and 7. All gels were run against 
the 100bp ladder, black arrow indicating the 600bp reference band. 
 
 In situ hybridisation  
 RNA probe synthesis 
pGEM-T plasmids containing the hacd sequences were purified by Midiprep (Qiagen, 
catalogue number 12125) and approximately 1μg/μl plasmid was linearised using either AatII 
or SacI in 50μl reactions at 37oC overnight (16 hours) before a 20-minute heat inactivation 
step (80oC for AatII and 65oC for SacI). Efficiency of restriction enzyme activity was assessed 
by performing single and double digests of each plasmid to check for complete digestion. 
Figure 2.3 shows the restriction digests performed on the pGEM-t plasmids containing a hacd 
transcript after digest via either AatII, SacI, cut with both and the uncut plasmid. When cut by 
either AatII or SacI the linearised plasmid was ~3000bp in length, and when plasmid was 
digested successfully with both enzymes this produced a larger fragment of DNA at ~2500bp 
and a smaller fragment of ~500bp. The uncut plasmid ran at several levels due to the nature 
of circular DNA running through agarose: bands were produced from the circular structure, 
supercoiled and with single strand nicks in its structure. This verified that other plasmids were 
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completely linearised before moving onto the probe synthesis, as without completely linear 
plasmid DNA the reaction efficiency is impaired.   
 
Figure 2.3: Restriction digest of pGEM-T plasmid containing hacd1-4 inserts (panels a-d 
respectively).  
Plasmids were cut with either AatII, SacI or a double digest was performed with both enzymes. Samples 
were run against uncut plasmids as a control and a 1kb plus ladder, black arrow indicates 1kb reference 
band. For all single digests the results show single bands of the linearised plasmid which was 
approximately 3.5-4kb in size. The double digests all produced two bands of the expected length of 
approximately 3kb and a smaller band containing the hacd transcript at 600-800bp (white arrows). 
 
Linearised plasmids were cleaned using sodium acetate and ice-cold ethanol and concentration 
assessed on the Nanodrop. Then 1μg of purified DNA template was used to synthesise 
digoxigenin-labelled (Roche) RNA probes using the SP6 (antisense probes) and T7 (sense 
probes) polymerases within the pGEM-T sequence. Alongside the DNA the reaction included 
1X NTP labelling mixture (containing 10mM ATP, 10mM CTP, 10mM GTP, 6.5mM UTP 
and 3.5mM DIG-11-UTP), 1X transcription buffer, RNase inhibitor (20U/μl) and either the 
SP6 or T7 RNA polymerases (20U/μl). The reaction was run for two hours at 37oC before 
RNase free DNase was added (10U/μl) to the reaction and run for a further 15 minutes to 
remove any leftover DNA template. RNA probes were also subject to a cleaning protocol, this 
time using 1X TE buffer (Sigma Aldrich), LiCl (Sigma Aldrich) and ice-cold ethanol. Probes 
were frozen in 5μl aliquots and stored at -80oC to prevent degradation. Probes were visualised 
and checked via agarose gel electrophoresis at various stages after DNase treatment and 
purification steps. Figure 2.4 shows successful clean-up of all probes (lanes 2 and 4 display a 
few clear bands, indicative of running RNA on an agarose gel). One lane 1 is missing bands, 
due to the sample not being saved to run on the gel, however the cleaned probe in lane 2 




Figure 2.4: DIG-labelled RNA probe clean up for in situ hybridisation, run on 1% agarose gel. 
Figures a-d represent RNA probes for hacd1-4 respectively. Lanes numbered 1 represent the unclean 
antisense RNA probe and lane 2 the cleaned probe. Lanes 3 indicate the unclean sense probe with 4 
representing the final cleaned product. All cleaned up products show a number of clearly defined bands 
indicative of RNA gels. 
 
 In situ hybridisation protocol 
Embryos from different developmental stages were collected and fixed in 4% 
paraformaldehyde (PFA) before dehydration through graded concentrations of methanol and 
storage at -20oC. They were then rehydrated with PBS (Sigma Aldrich) and 0.1% Tween-20 
(Sigma Aldrich) before the experiment and prepared for experiment dependent upon age 
(Table 2.2). Embryos over 48hpf were first de-pigmented via a bleaching solution (0.5x SSC 
(Sigma Aldrich), 1% H2O2 (Sigma Aldrich), 5% formamide (Sigma Aldrich) and 0.1% 
Tween-20 in PBS) and then permeabilised with proteinase K (Table 2.2), any embryos under 






Table 2.2: Proteinase K (10µg/ml) digestion times of zebrafish embryos prior to in situ 
hybridisation.  
Embryos were digested in various concentrations for differing lengths of time according to their age as 
hours post fertilisation (hpf). 
Age of Embryo (hpf) Permeabilisation in Proteinase K 
10-12 2.5 mins in 1X 
16-22 3 mins in 1X 
24 10 mins in 1X 
36-48 10 mins in 1X 
48 10 mins in 1X 
72 20 mins in 2X 
96 20 mins in 3X 
 
Embryos were then incubated in a prehybridisation solution (50% formamide, 5x SSC and 
0.1% Tween-20, pH 6) for two hours at 68oC before changing the solution to a hybridisation 
solution (50% formamide, 5x SSC, 0.1% Tween-20, 5mg/ml torula RNA (Sigma Aldrich), 
50μg/ml heparin (Sigma Aldrich), pH 6 and preheated to 70oC) and incubated for one hour at 
68oC. Solution was then changed to fresh hybridisation solution (again preheated to 70oC) and 
digoxigenin-labelled RNA probes (antisense or sense) added before incubating overnight. 
After overnight incubation embryos were put through a series of wash steps (with solutions 
all preheated to 70oC and washes carried out at 68oC. The first wash was five minutes in 
prehybridisation solution before five minutes with 25% prehybridisation solution and 75% 2x 
SSC. Embryos were then washed in 2x SSC for 10 minutes, twice, before three washes of 0.2x 
SSC for 30 minutes. MABT buffer (150mM NaCl (Sigma Aldrich), 100mM malic acid (Sigma 
Aldrich) and 0.1% Tween-20) was then used to wash embryos twice for five minutes before 
embryos were blocked with 2% Blocking Agent (Roche) in MAB buffer (MABT without 
Tween-20) for 2.5 hours at room temperature on a rocker to aid prevention of non-specific 
staining before incubating in the 2% blocking solution with a 1:6000 dilution of anti-DIG 
(conjugated with an alkaline phosphatase) overnight at 4oC. Colour was then developed with 
Nitro Blue Tetrazolium (NBT) and 5-bromo-4-chloro-3-indolyl phosphate (BCIP) (Sigma 
Aldrich) through detection of the alkaline phosphatase conjugated to the antibody. BCIP is a 
substrate to the alkaline phosphatase which was oxidised by the NBT to form the blue dye 
5,5′-dibromo-4,4′-dichloro-indigo. 
Bright field images were taken with an Olympus SZX12 camera and embryos then fixed in 
4% PFA and stored at 4oC prior to processing and sectioning. 
55 
 
 Whole embryo processing & sectioning 
Embryos were processed by hand as, having been previously permeabilised and bleached, 
auto-processing proved too harsh and embryos fragmented. Embryos were first washed twice 
in Diethyl pyrocarbonate (DEPC, Sigma Aldrich) treated water for 10 minutes to remove any 
PFA. Embryos were then dehydrated with increasing ethanol washes (10 minutes in 30%, 
50%, 70%, 95% and two x 100% ethanol) before the infiltration stage using increasing 
concentrations of xylene (Sigma Aldrich) in ethanol to aid the paraffin later infiltrate the tissue 
(10 minutes in 50% xylene, 75% xylene and 100% xylene). Embryos were then immersed in 
melted paraffin for two x 20 minutes to allow time for complete infiltration. 
Embryos were then embedded in fresh paraffin to allow for either transverse or longitudinal 
sectioning. Sectioning was performed using a Leica Microtome and sections were cut at a 
thickness of 4 microns. Sections were left overnight at 37oC to dry on the coverslips and then 
dewaxed with two x 100% xylene washes for five minutes before cover slipping with DPX 
mountant (Sigma Aldrich) to protect samples and ensure their longevity. Sections were then 
imaged with the Zeiss BX60 microscope using bright field microscopy. 
 cDNA synthesis for qRT-PCR 
From RNA isolated as described in section 2.2.5, 1μg was converted to cDNA by reverse 
transcriptase (iScript, BioRad). RNA was combined with nuclease free water to give a volume 
of 13μl then added to 1x Reaction Mix (4μl) and iScript reverse transcriptase (1μl). Reaction 
was run at 25oC for five minutes, 46oC for 20 minutes and 95oC for one minute. cDNA was 
then stored at -20oC until use. 
 qRT-PCR geNorm 
As this study involved zebrafish embryos developing from a single cell to an organism capable 
of self-feeding at 5dpf (days post fertilisation) many genes will be up and down regulated 
within this time frame. Housekeeping genes for embryonic zebrafish have been previously 
published (Cooper et al., 2006; McCurley et al., 2008), however these did not work or were 
highly inefficient when tested. Thus, a housekeeping test was conducted with a 14-primer 
assay to determine the most stable genes between 12-96hpf. This qRT-PCR reaction was set 
up as described in Section 2.2.13 and analysis was done via the qBase+ software (Biogazelle). 
Genes tested for stability were: gapdh, actb2, 18s, actb1, sdha, top2a, usp5, ef1a, eif1b, ywhaz, 
slc25a5, rlp13, nadh and atpsynth. 
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 qRT-PCR primer and assay optimisation 
Primers were self-designed initially but found to have poor efficiencies and so the final 
primers used in this thesis were designed by Primer Design based on information provided 
about different transcripts in zebrafish embryos. Cloned hacd1-4 transcripts were provided as 
positive control for initial validation by Primer Design. All primers crossed one exon-exon 
boundary, except the primer set for hacd3 (Figure 2.5). Primers for both hacd1 and hacd2 
were designed to have two sets: one to amplify up total amount and one set designed to amplify 
just the full-length isoforms that contain the essential amino acids for HACD activity (Kihara 
et al., 2008). Table 2.3 displays the sequences for primer sets (Primer Design) used in this 
study and Figure 2.5 shows annotation of these primers qRT-PCR in purple, as well as those 
used in RT-PCR experiments (for ISH probe synthesis, red annotations) in Section 2.2.8. 
Appendix figures A1.2, A1.3, A1.4 and A1.5 represent the hacd1-4 cDNA sequences with 
primers annotated. 
Table 2.3: List of final zebrafish qPCR primers.  
Sequences of the house keeper genes from Primer Design were not provided. 
Gene Product Length 
(bp) 
Primers (5’-3’) 
hacd1-total 85 F:GTGTCCTTTGACTATTACTACTTCTTGA 
R:GTAGCATGTGGAAGTAGAGCTGA 
hacd1-fl 112 F:AGCATCAGACAGATTCAGAACGAG 
R:GCAGATGGTTGAGCAGGTTGAA 
hacd2 - total 95 F: GACCATTGGATGATCCAGTCTTTC 
R: GCACAGTGAGTCCGGTCAC 
hacd2-fl  114 F:ACCCGATGGGAGTGATGGG 
R:AGTCGAATGAGAAGTTGTACTTGTTAG 
hacd3 75 F:GTTGGCCTGCATTGACACTG 
R:AGAGGGTACAGCGGCATCC 
hacd4 120 F:CACCGATGTACATGTATTCTCCATA 
R:TCCAGCTCTCCAGATTCTCTTT 
rlp13 N/A Sequence not provided  
nadh N/A Sequence not provided 





Figure 2.5: Annotation of both RT-PCR primers used for the synthesis of in situ hybridisation 
(ISH) probes and qRT-PCR primers.  
Exons are numbered and in blue, with the exon containing the essential amino acids in orange. Red 
arrows indicate ISH primers and purple indicate qRT-PCR primers. Where two sets of qRT-PCR 
primers were used these have been labelled. 
 
To confirm there was no contamination by genomic DNA, qRT-PCR assays included a well 
where the template was prepared without addition of reverse transcriptase for cDNA synthesis 
(no RT control) and to confirm no contamination of reagents of false positive results a well 
was run with molecular grade water instead of cDNA (no template control). Primers from 
Primer Design were independently validated once received and standard curve reactions were 
performed to evaluate assay efficiencies as a secondary validation. Standard curves were run 
with a pooled set of zebrafish embryo cDNA from various time points throughout 
development as template and the cDNA was serially diluted 1:10, 1:100, 1:1,000 and 1:10,000. 
A reaction efficiency of 90-110% indicates that the amount of product is being doubled every 
cycle (Figure 2.6a).  
The standard curve (Figure 2.6c) allows calculation of the efficiency of the reaction and also 
a correlation coefficient (R2) value. Efficiency is calculated using the slope of the graph 






𝐬𝐥𝐨𝐩𝐞 − 𝟏) ∗ 𝟏𝟎𝟎 
Equation 2.1 
  
Melt curves and peaks were assessed to ensure they only produced one clear peak, indicating 
only one target was being amplified (Figure 2.6a&b) (Wienken et al., 2011).  
All the hacd genes passed this validation with efficiencies of 90-110% (Table 2.4) with the 
exception of hacd4 which was slightly below this. It was concluded this was likely due to the 
low abundance of hacd4 due to higher Ct values within these assays.  
Table 2.4: qRT-PCR primer validation results for hacd genes in zebrafish.  
Primer Efficiency (%) R2 Slope 
hacd1-total 112.8 0.997 -3.049 
hacd1-fl 95.5 0.995 -3.435 
hacd2-total 97.1 0.989 -3.394 
hacd2-fl  91.5 0.993 -3.545 
hacd3 94.4 0.997 -3.464 





Figure 2.6: Validation of all pRT-PCR assays for hacd1-4 expression in embryonic zebrafish. 
Outputs from BioRad CFX Manager software: (a) melt curves, (b) melt peaks both indicating only 
single products being amplified and therefore primers sufficiently specific and (c) standard curves 




 Quantitative RT-PCR assay 
20μl reactions were run with 8μl cDNA diluted 1:100 using molecular grade water, 2μl 
(0.15μM) primer and 10μl (1x) SYBR green mastermix (Roche). Each reaction was run at 
95oC for 10 minutes to initially denature the cDNA before 40 cycles of: 95oC for 15 seconds 
followed by a combined annealing and extension step at 58oC or 60oC (primer dependent) for 
one minute. Reactions were run on the BioRad CFX Connect Real Time PCR System 
(BioRad). 
Zebrafish embryo cDNA was tested at 12, 24, 48 and 72hpf in triplicate to assess levels of 
each gene over development including both full length isoforms of hacd1 and hacd2. 
Expression levels were calculated via the ΔΔCt method (Livak & Schmittgen, 2001) and 
normalised against three housekeeping genes: rlp13, nadh and atp-synthase, selected after 
stability analysis. 
 Statistical analysis 
Analysis of variance (ANOVAs) were conducted for qRT-PCR data in GraphPad Prism 
(GraphPad Software Inc.) and represented as mean values with error bars indicating standard 
error of the mean (SEM). Significance annotated on graphs as follows: * indicates p≤0.05, ** 











 Using bioinformatics to identify the zebrafish orthologues of the HACD 
enzymes 
To identify HACD enzymes in zebrafish the ENSEMBL database was consulted to identify 
genes most likely to be orthologues of mammalian HACD1-4 and evaluate for other potential 
paralogues (particularly important in zebrafish due to their genome duplication). Transcript 
data was also evaluated and compared, particularly those likely to have functional HACD 
activity and the potential to compensate for HACD1-deficiency (Kihara et al., 2008; Sawai et 
al., 2017). Exon arrangements and synteny were compared with human and murine databases 
as transcriptomic annotation of zebrafish genes was comparatively poor. 
 HACD1 
The ENSEMBL genome database reported one orthologue for human HACD1 in zebrafish 
(Danio rerio) ENSDARG00000103744. This gene was previously suggested as the zebrafish 
homologue of HACD1 (Walmsley, 2013) based on sequence similarity, exon arrangements 
and transcript expression in muscle, and this sequence was annotated as hacd1 in the 
ENSEMBL database. Some synteny was apparent on comparison of the region surrounding 
hacd1 with corresponding area in humans and mice (Figure 2.7). Only one transcript was listed 
on ENSEMBL for hacd1 (NCBI Reference Sequence NM_014241.3, 
ENSDART00000157873, which is the full 7 exon length isoform hacd1-fl) in zebrafish, 
however two main transcripts have been listed previously (HACD1-fl and HACD1-d5) in 
canine (Pelé et al., 2005) mouse tissues (Blondelle et al., 2015) and were also found in 
zebrafish embryos (Walmsley, 2013).  
On the ENSEMBL database, the human HACD1 had the full length transcript listed 
(ENST00000361271.8) and two other listed transcripts that were said to be protein coding 
(ENST00000326961.6 and ENST00000466335.1) though neither encoded exon 6 with the 
essential amino acids, therefore suggesting no HACD activity. The canine HACD1 had four 
listed transcripts that were protein coding on ENSEMBL: the full length HACD1-fl 
(ENSCAFT00000049354.2), a second transcript with an extra exon, a third with 10 exons that 
were mostly a few base pairs long, suggesting this transcript required further characterising 
(ENSCAFT00000045812.1) and finally the Hacd1-d5 transcript (ENSCAFT00000037117.3). 
The mouse HACD1 gene had three protein coding transcripts, the full length Hacd1 
(ENSMUST00000114753.7), one transcript with eight exons (ENSMUST00000074854.8) 
and the Hacd1-d5 transcript (ENSMUST00000091429.11). 
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The zebrafish hacd1 gene had three paralogues listed in the genome browser: hacd2 
(ENSDARG00000014806), hacd3 (ENSDARG00000016038) and hacd4 
(ENSDARG00000102221) as expected and had conserved amino acid sequences among the 
paralogues (Appendix Figure A1.1). Sequence identity between human HACD1-fl and 
zebrafish hacd1-fl was 74%.  BLAST search of Hacd1 amino acid sequence in ENSEMBL 






Figure 2.7: Synteny of the HACD1 gene over human, mouse and zebrafish species over a 1MB region.  
Genes found in all three species are annotated in green, genes found in human and mice annotated as red, those only in mouse annotated as blue and genes only in the zebrafish 






ENSEMBL identified one zebrafish orthologue for HACD2 gene (ENSDARG00000014806). 
Analysis of synteny reported the gene to be in a syntenic block of four other genes across 
human and mouse genomes (Figure 2.8). ENSEMBL genome browser identified three 
transcripts for hacd2 for zebrafish gene, five for the human and one for the mouse gene. One 
transcript (ENSDART00000133998), likely to be the orthologue of the protein encoding 
human HACD2 (due to comparison of exon arrangement) had a 78% sequence identity with 
the human HACD2. A BLAST search of Hacd2 amino acid sequence in ENSEMBL against 
the zebrafish protein database returned only Hacd1-4. The zebrafish hacd2 gene had a target 




Figure 2.8: Synteny of the HACD2 gene over human, mouse and zebrafish species over a 1MB region.  
Genes found in all three species are annotated in green, genes found in human and mice annotated as red, those only in mouse annotated as blue and genes only in the zebrafish 





ENSEMBL identifies one zebrafish orthologue for HACD3 and this zebrafish hacd3 gene 
(ENSDARG00000016038) and this was found in a block of six genes that had conserved 
synteny across human and murine genomes (Figure 2.9). There was one transcript 
(ENSDART00000006300) listed for the zebrafish hacd3 gene, 12 transcripts for human and 
one transcript listed for the murine genome. The zebrafish transcript 
(ENSDART00000006300.7) and what was likely to be the full length HACD3 human 
transcript (ENST00000261875.10), due to its high annotation and exon arrangement shared a 
70% sequence identity. BLAST search of Hacd3 amino acid sequence in ENSEMBL against 
the zebrafish protein database identified Hacd1-4 as the top hits with a family of prostaglandin 
synthase proteins also returned; however, these had shorter alignments of lower identity which 
did not match with the conserved region and essential amino acids in exon 9. The zebrafish 




Figure 2.9: Synteny of the HACD3 gene over human, mouse and zebrafish species over a 1MB region.  
Genes found in all three species are annotated in green, genes found in human and mice annotated as red, those only in mouse annotated as blue and genes only in the zebrafish 





ENSEMBL identified one zebrafish orthologue for HACD4 and this zebrafish hacd4 gene 
(ENSDARG00000102221) and was found in a block of six genes with synteny across human 
and murine genome sequences (Figure 2.10). There was only one transcript listed for hacd4 
(ENSDART00000157618) for zebrafish, two for human (with only one annotated as protein 
coding) and three for mouse. This zebrafish transcript had a 76% sequence identity with the 
protein coding human HACD4 transcript (ENST00000495827.3). BLAST search of Hacd4 
amino acid sequence in ENSEMBL against the zebrafish protein database returned only 





Figure 2.10: Synteny of the HACD4 gene over human, mouse and zebrafish species over a 1MB region.  
Genes found in all three species are annotated in green, genes found in human and mice annotated as red, those only in mouse annotated as blue and genes only in the zebrafish 




Bioinformatics analysis identified four genes, likely to be the only orthologues for HACD1-4 
in zebrafish. This was based on sequence similarity with mammalian counterparts, exon 
structure, full length transcripts producing proteins and the synteny of the genes on 
surrounding chromosome regions. 
 hacd1 is expressed in developing and mature muscle in embryonic and adult 
zebrafish  
Expression of hacd1 in embryonic zebrafish was evaluated by conventional RT-PCR using 
primers designed to amplify the full-length coding sequence (Figure 2.11). Products at each 
time point were of a size consistent with both the hacd1-fl and hacd1-d5 isoforms (expected 
product lengths of 730 and 608bp respectively). Relative expression of hacd1-fl in comparison 
with hacd1-d5 appeared to increase in later embryonic developmental stages (48 and 72hpf). 
Sequencing subsequently confirmed the hacd1-fl within the embryos. 
The same RT-PCR evaluation for hacd1 was performed on a variety of adult zebrafish tissues 
and the same the products were identified (Figure 2.12). The larger of the products thought to 
be hacd1-fl was detected exclusively in striated muscles (skeletal muscle and heart samples), 
whereas the smaller band, thought to be hacd1-d5 was detected in heart, spleen & kidney and 




Figure 2.11: Expression of hacd transcripts in developing zebrafish embryos.  
Agarose gel analysis of RT-PCR products from embryonic ages 12-72 hours post fertilisation (hpf) 
including a no template control (molecular grade water) run in the far-right lane (labelled as “-ve”). 
Products were run against a 100bp ladder, black arrow indicates the 600bp band for reference. (a) 
RT-PCR for hacd1 detected two products of approximately 800 and 700bp lengths consistent with the 
hacd1-fl (expected at 730bp) and hacd1-d5 (expected at 608bp) transcripts label them: the full-length 
transcript was subsequently confirmed via sequencing. (b) RT-PCR for hacd2 revealed products of 
approximately 750 (full length product expected at 777bp), 550, 400 and 300bp length 12hpf with only 
bands at 750, 550 and 300bp in later time points. (c) RT-PCR for hacd3 RT-PCR detected a single 
product from embryos at all time points of approximately 700bp (expected product was 706bp). (d) 
RT-PCR for hacd4 on mRNA from embryos at all time points detected no transcripts by agarose gel 




Figure 2.12: Expression of hacd transcripts in adult zebrafish tissues by RT-PCR on cDNA from 
tissue RNA extraction.  
Samples analysed by agarose gel electrophoresis and run against 100bp ladder with a black arrow 
indicating 600bp reference band and a negative control in the far-right lane (molecular grade water in 
the place of cDNA template, labelled “-ve”). (a) RT-PCR for hacd1 displaying products that 
corresponded to the hacd1-fl and hacd1-d5 transcripts; with the corresponding product for hacd1-fl 
present in muscle and heart samples and products corresponding to hacd1-d5 in heart spleen and swim 
bladder samples (hacd1-fl product expected at 730bp and hacd1-d5 at 608bp). (b) RT-PCR for hacd2 
with products identified at approximately 750, 550 and 300bp with the largest product (expected to be 
777bp) seen in all tissues and the smaller products in heart, spleen & kidney, swim bladder and intestine. 
(c) RT-PCR for hacd3 showing a single product at approximately 700bp (expected product was 706bp) 
in all tissues but only very faint bands in muscle and heart cDNA samples. (d) RT-PCR gel for hacd4 
products with a very faint band seen at approximately 800bp (expected product was 777bp) in the heart 
tissue sample and another in the spleen & kidney cDNA sample. 
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 hacd2-fl is ubiquitously expressed in zebrafish embryos from 12 to 72hpf and 
adult zebrafish tissues  
Embryonic RT-PCR reactions amplified four products at 12hpf (approximately 750, 550, 400 
and 300bp) and three products at 24, 48 and 72hpf (approximately 750, 550 and 300bp) 
(Figure 2.11). The largest and most intense product of approximately 750bp (expected product 
was 777bp) corresponded to the full length hacd2 transcript (hacd2-fl) which was the only 
listed transcript and was subsequently confirmed by sequencing. The other products were 
approximately 550, 400 and 300bp: the largest and smallest of these were subsequently cloned 
and sequenced (Section 2.3.3.1). 
In adult zebrafish tissues; the largest product corresponding to the listed transcript of hacd2 
(referred to as hacd2-fl in this thesis) was present in all tissues. This was the only product 
identified in eye and brain tissues, these samples were extracted and analysed separately 
therefore relative intensity cannot be compared. The product of ~550bp was amplified in all 
tissues expect eye and brain and also lower intensity in muscle samples compared to other 
tissues (heart, spleen & kidney, swim bladder and intestine). A 400bp produce was not 
detected in adult tissues. The smallest product of 300bp had only faint bands seen in heart, 
spleen & kidney, swim bladder and intestine tissues. 
 Two novel hacd2 isoforms were identified 
RT-PCR for hacd2 performed on both adult tissues and embryos detected additional smaller 
products of low relative abundance to hacd2-fl. To determine if these were previously unlisted 
transcripts, products were isolated and extracted from the gel, cloned and sequenced. The 
largest product was confirmed to be the full length hacd2 transcript (expected product was 
777bp). The product of around 550bp was identified as an alternative transcript without exon 
6 (598bp). The shortest product of around 300bp was identified as a transcript containing only 
exons 1, 2 and 7 (368bp) (depicted in Figure 2.13). These isoforms, like hacd1-d5, do not 




Figure 2.13: Novel isoforms of hacd2.  
(a) RT-PCR for hacd2 run against 100bp ladder, black arrow indicates reference 600bp. Four bands are 
present and annotated by the red arrows. (b) Three out of four isoforms were then successfully isolated 
and sequenced and these have displayed here as blocks of exons, with the active site containing exon 
highlighted in pink.
 
 RT-PCR expression data for hacd3 in embryonic and adult zebrafish tissues 
found it to be ubiquitously expressed  
RT-PCR for hacd3 in embryonic zebrafish detected one product at approximately 700bp 
which was present at all time points across development (Figure 2.11), this was subsequently 
cloned and sequenced to be the full length hacd3 transcript previously listed (expected product 
was 706bp). The same product of approximately 700bp was found in all adult tissues except 
the skeletal muscle samples (Figure 2.12). A primer set designed from exons 1-11 was 
designed also to amplify any other possible isoforms, but the RT-PCR reactions with this 
primer set were unsuccessful. 
 RT-PCR expression data for hacd4 was inconclusive 
Standard 35-cycle RT-PCR for hacd4 in embryonic zebrafish samples detected no products at 
any time point, even once assays were optimised, expected product length would have been 
expected at 776bp. A 40-cycle RT-PCR reaction was run including cDNA from both 96 and 
120hpf embryos (Figure 2.14). When reaction products were run on a gel it displayed two 
products at all time points of approximately 1kb and 800bp and fainter bands under 600bp, 
seen from 24hpf onwards (expected product from primers was 776bp). It was unclear from 
the RT-PCR gel if these products are hacd4, or if they are due to artefacts from running a 
longer than conventional reaction. 




Figure 2.14: Products from a 40 cycle RT-PCR reaction for hacd4 over embryogenesis, 12-120 
hours post fertilisation (hpf) with a negative control run on the far right.  
PCR was run against a 100bp ladder with a black arrow indicating the 600bp position. Products 
appeared at approximately 1kb and 800bp with fainter bands at approximately 600 and 400bp and 
expected full length product was expected to be 776bp. 
 
When adult tissue samples were run through RT-PCR with primers to amplify hacd4, there 
were faint bands of approximately 800bp seen for hacd4 in muscle, heart, spleen and kidney 
(Figure 2.12).  
 Localisation of hacd enzymes throughout embryogenesis 
The presence of the hacd enzymes throughout embryogenesis and the tissue specificity in 
adult fish was initially assessed via RT-PCR. To determine what tissues and stages of 
developing embryos expressed the various HACD enzymes whole mount ISH was performed 
on the embryos at a variety of ages. 
 hacd1 is localised in the striated muscle of zebrafish embryos 
As HACD1 is expressed throughout myogenesis in mammals (Blondelle et al., 2015; Lin et 
al., 2012; Walmsley, 2013) and preliminary work (Walmsley, 2013) had detected hacd1-fl 
expression in somites of embryos by the Prim-5 stage/24hpf, time points were selected for 
before, during and after the onset of myogenesis (Figure 2.15). hacd1 expression (shown by 
dark purple staining) could not be detected in early embryos of the early segmentation period 
(around 5 somites)/12hpf but the colour began to develop with the development of somites by 
the segmentation period of 20-somites (18hpf). Functional muscle is present in the embryo at 
17hpf (Saint-Amant & Drapeua, 1998) and by 21hpf a clear line along the developing tail had 
developed colour demonstrating hacd1 expression (Kimmel et al., 1995). By 72hpf 
(protruding-mouth stage) the expression of hacd1 was seen unmistakably in the myotomes of 
the tail where myoblasts had developed into mature myofibres.  
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Embryos imaged from the dorsal plane showed the two separate myotomes on either side of 
the developing notochord. For all stages control experiments were run with sense probes and 
representative control samples are shown: these control experiments exhibit trapping of the 
probes which tends to occur in both the head and the yolk sac due to presence of unbound 
probe. Importantly the controls show no staining within the muscle of the embryos. 
 
Figure 2.15: Localisation of hacd1 throughout zebrafish embryogenesis.  
Experimental embryos with anti-sense probe are shown in a-f and control (sense probe) embryos in g-
i. Stages are as follows: 12 hours post fertilisation (hpf) (a), 14hpf (g) 18hpf (b), 21hpf (c, h), 24hpf (d) 
and 72hpf (e, f, i). In the experimental embryos from 18hpf onwards the dark purple stain indicating 
hacd1 expression can be seen along the tail of the embryos where the mature muscle develops. In the 
control embryos there was varying levels of non-specific binding seen in both the head area and yolk 
sac. 
 
 hacd2 is ubiquitously expressed in developing zebrafish embryos 
Previous conventional RT-PCR experiments had shown hacd2 to be ubiquitously expressed 
in all adult zebrafish tissues tested (Figure 2.12). Whole-mount ISH of embryos detected 
hacd2 predominantly in the head and eye areas of developing embryos. The hacd2 transcript 
could be detected as early as the segmentation period/12hpf predominantly located around the 
developing head of the embryo. A similar pattern was observed at the Prim-5 stage/24 hpf 
with well circumscribed areas of intense staining associated with brain and eye regions. At the 
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protruding-mouth stage/72hpf brain and ocular structures are again strongly stained and there 
was also staining in the body cavity and potential staining along the notochord (this was 
subsequently discounted on sectioning, see Figure 2.21). There was no staining for hacd2 
observed within the developing or mature striated muscles of the embryos at any stage. The 
control embryos all showed some degree of trapping in and around the yolk sac but 
importantly no staining where the hacd2 expression was detected in the head. 
 
Figure 2.16: Localisation of hacd2 throughout zebrafish embryogenesis.  
Top row (a-d) displays the experimental embryos (anti-sense probe) and bottom row (e-g) displays the 
control experiments (sense probe). Developmental stages are as follows: 12 hours post fertilisation (hpf) 
(a, e), 24hpf (b, c, f) and 72hpf (d, g). Experimental embryos had staining in the brain and eye areas 
and none in the muscle and this staining of head and eye regions was not present in the control embryos, 
which display some level of non-specific binding in and around the yolk sac. 
 
One set of hacd2 ISH was conducted using a probe designed to bind to the 3’UTR of the hacd2 
gene. These probes were designed for this area as the main hacd2 sequence shared a high 
homology with hacd1 and therefore a second probe was designed in case the hacd2 probe 
bound to hacd1 mRNA also. Figure 2.16 and Figure 2.17 both show comparable expression 
patterns within the experimental embryos indicating the main hacd2 probe from Figure 2.16 
was specific only to hacd2 and was therefore used for experiments. The control for the 3’ UTR 




Figure 2.17: In situ hybridisation (ISH) of hacd2 in zebrafish embryos using a probe against the 
3’ UTR of hacd2.  
(a) 24hpf (hours post fertilisation) embryo incubated with the antisense 3’UTR hacd2 probe. (b) Control 
embryo incubated with sense probe. Staining was comparable to the staining seen when using the main 
hacd2 probe: within the head and eye areas of the embryo. Control probe shows stain also within the 
head. 
 
 hacd3 localisation is centred in the eyes of zebrafish embryos 
Results from RT-PCR found hacd3 to be ubiquitously expressed in all adult organs (Figure 
2.12). ISH found staining for hacd3 expression in the eyes and brain, and also perhaps the 
notochord at 72hpf. Importantly, as with hacd2, there was no staining for hacd3 expression 




Figure 2.18: Localisation of hacd3 through zebrafish embryogenesis.  
Embryos a&b represent experimental embryos with anti-sense probe hybridised and c&d represent the 
control embryos hybridised with the sense probe. Ages of embryos are as follows: 30 hours post 
fertilisation (hpf) (a&c) and 72hpf (b&d). Experimental embryos showed staining at both 
developmental stages, within the developing brain and eyes and no staining within the muscle. Control 
embryos displayed some trapping of unbound probe within the yolk sacs. 
 
 hacd4 could not be detected by in situ hybridisation 
In situ hybridisation was performed in embryos of 48 and 72hpf and no staining for hacd4 
expression could be detected. Sense control embryos also had no staining apart from some 




Figure 2.19: Localisation of hacd4 throughout zebrafish embryogenesis.  
Embryos a&b represent experimental embryos with anti-sense probe hybridised and c&d represent the 
control embryos incubated with the sense probe. Ages of embryos are as follows: 48 hours post 
fertilisation (hpf) (a&c) and 72hpf (b&d). There was no visible staining in the experimental embryos 
and a small amount of trapping in the heads of control embryos.  
 
 Hacd1 is the major hacd enzyme expressed in zebrafish embryo muscle 
Whole-mount stained embryos were sectioned for more precise localisation of expression.  
Consistent expression of hacd1 was detected within the muscle at 24 and 72hpf symmetrically 
within the four developing myotomes (Figure 2.20). Importantly no staining for transcripts 





Figure 2.20: Expression of hacd1 in the developing muscle of embryonic zebrafish.  
Expression of hacd1 can be detected in both 24hpf (hours post fertilisation) (left) and at 72hpf (right) 
within the myotomes of the tail muscle. There was no hacd1 expression in others sections of the tail 
cross sections including the notochord (NC) (Zebrafish Bio-Atlas, Penn State University). 
 
Figure 2.21 shows 72hpf muscle cross sections for all four hacd genes to allow for comparison 
between them. There was no staining for hacd2 in the myotomes, and specific staining in 
developing abdominal organs between the muscle and yolk sac could be detected. There was 
no staining for hacd3 expression within the muscles but there was staining within the 
notochord. As seen in the whole mount images there was no hacd4 staining within the muscle 





Figure 2.21: Localisation of hacd genes within 72 hours post fertilisation (hpf) zebrafish embryo tail muscle.  
Figure shows both the antisense and sense (control) transverse sections for all four hacd genes, two embryos per sample set were sectioned. Expression of hacd1 could be seen 
uniquely in the muscle of the embryos, specifically in the myotomes and was absent from the notochord (NC) and neural tube (NT) labelled on the hacd1 sense embryo: whilst 
hacd2-4 are all absent from the muscle. Staining for hacd2 was present between the muscle and yolk sac, in the area which the majority of organs, including the abdominal 
organs, grow that will form the main body cavity of the fish. Staining for hacd3 was strong in the notochord (NC) of the embryos. Hacd4 showed no staining in the tail of the 
embryo (Zebrafish Bio-Atlas, Penn State University). 
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Sections through the head (Figure 2.22) found hacd1 staining was not present in the majority 
of the anatomy. There was one line of staining in line with where the developing oesophagus 
would be. As reported for whole-mount stained embryos, hacd2 and hacd3 expression was 
found within the head and eyes of protruding-mouth stage/72hpf embryos: hacd2 had a more 
intense staining within the photoreceptors of the eye and less intense staining across the most 
parts of the eye and brain and hacd3 had an even spread of staining including the developing 
fore, mid and hindbrain (telencephalon, diencephalon and myelencephalon respectively). 
Unexpectedly, hacd4 stained embryos had small areas of focal and symmetrical staining 
within the brain (labelled with red asterisks) indicating hacd4 expression within the 




       
Figure 2.22: Localisation of hacd genes within 72 hours post fertilisation (hpf) embryo heads.  
Figure shows both the antisense and sense (control) transverse sections for all four enzymes and two embryos per sample set were sectioned. Figure shows that hacd1 staining 
was not present in the majority of the head apart from a line of staining which corresponded to the positioning of oesophagus. Staining for hacd2 was seen in the eye with 
intense staining in the photoreceptors and also the diencephalon area of the brain. As with hacd2, hacd3 was also seen within the eyes and brain, but in all areas of the 
myelencephalon, diencephalon and telencephalon areas which develop into the fore, mid and hindbrain. Staining of hacd4 had two bilaterally symmetrical spots of staining 
(annotated by black arrows) just ventromedial to the eyes (within the myelencephalon area of the brain) (Zebrafish Bio-Atlas, Penn State University). 
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 Identification of appropriate housekeeping genes for RT-PCR assays 
Before qRT-PCR assays could be performed and analysed accurately, housekeeping genes 
that were stably expressed over embryonic development had to be identified and validated. 
 
Figure 2.23: Identification of appropriate house keeper genes for embryonic zebrafish qRT-PCR 
assays.  
Figure shows the outputs from qbase+ software (Biogazelle). (a) Stability of each housekeeping gene 
with most stable toward the right-hand side of X axis. (b) Displays the V value indicating the number 
of housekeeping genes to use as references. 
 
Using the qbase+ algorithm the most stable housekeeping genes were found to be nadh, 
atpsynth and rlp13 and the optimal number of reference targets was 3 due to the V,0.15 
number generated (Figure 2.23). Figure 2.24 shows the raw Ct values for all three selected 
house-keeping genes, these values were stable across development, with deviations of 
approximately four Ct values. These three genes were then taken forward to use in all future 





Figure 2.24: Stability of chosen housekeeping genes over zebrafish development, from 12 hours 
post fertilisation (hpf) till 96hpf.  
Graphs display the Ct values for the three selected housekeeping genes for zebrafish embryo qRT-PCR: 
nadh, atpsynth and rlp13. 
 
 Expression of hacd genes throughout embryogenesis 
Quantitative (q) RT-PCR analysis found that only the full-length isoforms of hacd1 and hacd2 
significantly increased over embryonic development (p=0.0063 and p=0.0015 respectively). 
Whereas hacd2-fl exhibited a gradual 2-fold increase over development, hacd1-fl underwent 
a 6-fold increase between 12 and 48hpf and 7-fold between 12 and 72hpf. Expression of both 





Figure 2.25: Expression of hacd1-4 genes throughout zebrafish embryogenesis by qRT-PCR 
assays, including full length transcripts of hacd1 and hacd2.  
One-way ANOVA tests reported that total hacd1, total hacd2, hacd3 and hacd4 expression levels were 
not significantly altered over embryonic development (p=0.4316, p=0.2913, p=0.9099 and p=0.0682 
respectively). Expression levels of hacd1-fl and hacd2-fl were significantly increased over development 
(p=0.0063 and p=0.0015 respectively). Tukey’s multiple comparisons were performed and annotated 





Mutations in HACD1 have been implicated in both canine and human myopathies, with the 
mutation in canines contributing to the most commonly inherited neuromuscular disorder in 
Labrador retrievers; CNM (Maurer et al., 2012; Muhammed et al., 2013; Pelé et al., 2005; 
Toscano et al., 2017). Mammalian HACD1 has been documented to encode a VLCFA 
dehydratase alongside three other VLCFA dehydratase genes, HACD2-4, all of which are 
localised to specific mammalian tissues to carry out this function (Ikeda et al., 2008; Kihara 
et al., 2008). As well as a requirement for tissue specific genes, HACD1 is prone to a high 
level of splicing creating a number of different isoforms, some of which exclude the essential 
amino acids for HACD activity when translated to protein (Valdés de Hoyos et al., 2011; 
Tondeur et al., 2010; Walmsley, 2013).  
The work documented in this chapter has characterised these four enzymes and their isoforms 
both within developing zebrafish embryos and adult zebrafish tissues. Different techniques 
were utilised to gain a global picture of the four enzymes and demonstrate that the zebrafish 
is a very suitable model for studying both HACD1 and CNM. We were able to easily detect 
three of the four hacd genes from zebrafish embryos, reporting a number of novel isoforms 
for zebrafish hacd2 and corroborating previous work on the isoforms for hacd1. We have 
successfully shown that zebrafish embryos, as well as adult fish, have a comparable hacd 
expression pattern to that of mammals with hacd1 specific only to striated and cardiac muscle, 
hacd2 and hacd3 were both found in most tissues and hacd4 was found at very low levels and 
so data on this gene was inconclusive. Work undertaken in this thesis was also able to validate 
a number of appropriate housekeeping genes for expression work in zebrafish embryos. 
 Zebrafish hacd1 is the true orthologue of mammalian HACD1 
Analysis of zebrafish hacd1 expression identified products corresponding to both the full 
length, hacd1-fl and the hacd1-d5 isoform (the latter does not code for essential amino acids 
for HACD activity) (Kihara et al., 2008; Maurer et al., 2010). Both of these isoforms were 
present during 12-72hpf with the larger hacd1-fl product increasing in intensity from 48hpf 
onwards, corroborating previous expression data by Walmsley, (2013). In adult tissue the 
product corresponding to hacd1-fl was present at high intensity in both muscles tissue samples 
and the heart sample, with products corresponding to hacd1-d5 found in the heart, spleen & 
kidney and swim bladder tissues. This corresponds to this isoform having more ubiquitous 
expression (Maurer et al., 2010). Embryonic ISH verified results seen in the conventional RT-
PCR. The expression of hacd1 supported results seen previously by Walmsley, (2013), which 
was then explored in greater detail in this study with a more extensive set of embryonic stages: 
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to determine exactly when expression of hacd1 was visible through ISH. At ~18hpf (around 
the developmental stage of 20-somites present) somites with staining could be seen and by 
24hpf (Prim-5 stage) a large amount of staining was seen down the tail of the embryos. No 
other hacd gene expression was seen in the muscles through ISH, and sectioned embryos also 
confirmed this. The tail staining of hacd1 was seen in a clear chevron pattern with the stain 
absent in between myotome boundaries – where extracellular proteins are found (Henry et al., 
2005). These ISH results correspond to those seen in embryonic mice where Hacd1 expression 
was seen to be within the skeletal muscle through X-Gal staining (Blondelle et al., 2015; 
Uwanogho et al., 1999). 
qRT-PCR data from this study reported significant hacd1-fl upregulation between both 
12-48hpf (6-fold) and 12-72hpf (7-fold) but this was not reflected in expression levels of total 
hacd1 transcripts. Walmsley, (2013) discovered a number of isoforms for hacd1 in early 
embryos of 9-22hpf: one missing exons 5 & 6 and another containing intron 4, both of which 
would not produce the functional Hacd1 protein in the embryos, like that of the previously 
characterised hacd1-d5 isoform. As these are expressed in early embryos and not specific to 
striated muscle (Walmsley, 2013) we speculate that the presence of these early on in 
development dampens the increase that was seen from hacd1-fl in the later embryos and 
therefore overall hacd1 transcripts are not unregulated. This thus suggests that expression 
levels of the other three isoforms may be down regulated over development (Walmsley, 2013). 
Unfortunately, the 12hpf time point for hacd1-fl had large error bars, which we suggest is 
because this time point is highly dynamic with respect to gene expression. Pooled embryos 
were used collected from embryo batches collected from marbles placed in tanks over several 
hours from morning (lights on). Therefore, there would have been some variability in embryo 
development in the pools incorporated. This error could have been reduced by collecting 
embryos from single male female pairs with a more precisely known time of lay and 
fertilisation and collecting embryos at further time points over the first 36 hours to more 
precisely characterise the upregulation of hacd1. 
Expression and localisation data of hacd1 in zebrafish supports previous findings from 
Walmsley, (2013) as well as allowing me to conclude that hacd1 is also muscle specific like 
its mammalian orthologue (Ikeda et al., 2008). During the time of this study a detailed 
transcriptomic time course evaluating mRNA expression by RNA sequencing (RNA-seq) over 
zerbrafish development was published by the Vertebrate Genetics and Genomics Group at the 
Wellcome Trust Sanger Institute and displayed in an online expression atlas 
[https://www.ebi.ac.uk/gxa/experiments/E-ERAD-475/Results] (White et al., 2017). This 
database published RNA-seq data on all four hacd genes: reporting hacd1 to first be expressed 
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from the 1-4 somite stage, ~10hpf (White et al., 2017) (Figure 2.26). This is earlier than 
evaluated in this study but is in line with assumption that hacd1 upregulating with the 
development of somites. 
 
Figure 2.26: Expression levels of the hacd genes from RNA-seq data within developing zebrafish 
embryos from fertilised eggs: 0 hours post fertilisation (hpf) through to 72hpf. 
Expression level is represented by transcripts per million (TPM) (Adapted from White et al., 2017). 
 
 Zebrafish hacd2 expression is comparable to HACD2 in mammals and is prone 
to multiple splicing in a similar manner to that of hacd1 
RT-PCR expression data for hacd2 in embryonic zebrafish and adult tissues showed it to also 
be ubiquitously expressed like its mammalian orthologue. Products for hacd2 were found at 
all ages of development and in all tissues of adult zebrafish including the muscle samples 
which were likely to contain intramuscular bone, therefore the presence of hacd2 within the 
muscle could not be concluded at this point (Danos & Ward, 2012). The most likely candidate 
for a compensatory mechanism resulting from HACD1-deficiency was hacd2, due to its high 
conservation with hacd1, and so the time was taken to characterise this gene in particular. We 
evaluated for the presence of alternative isoforms particularly those encoding essential amino 
acids which might have HACD activity. Two novel hacd2 transcripts were characterised 
through cloning and sequencing of RT-PCR products from zebrafish embryo cDNA. There 
was a fourth product detected in early embryos unfortunately cloning was unsuccessful so a 
fourth novel transcript was not confirmed. To understand if this band was a PCR product 
amplified from another novel transcript, RT-PCR with shorter extension times could be used 
in order to favour amplification of shorter products in order to produce proportionally more 
of the product of interest compared to the highly abundant hacd2-fl band: this would allow for 
easier isolation of the PCR product. Additional isoforms present in early development are 
present for other genes (Tonduer et al., 2010) and described previously in C2C12 cells and 
zebrafish for HACD1. Walmsley, (2013) documented a number of isoforms for hacd1 in early 
embryogenesis which were then not present again at later time points. 
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The hacd2 ISH staining was seen in the head and developing organs of the embryos at all time 
points studied. When sectioned these reported some intense staining in the photoreceptors of 
the eye as well as less intense staining in other areas of the eye and brain. 
Previous ISH has been undertaken for hacd2 in developing embryos and it was documented 
to have no spatial restriction, which might have been due to a lack of specificity for their probe 
as this study has reported no muscle staining from ISH experiments with minimal levels found 
in RT-PCR as discussed for the hacd2 in adult muscle (Thisse & Thisse, 2004, 
[http://zfin.org/ZDB-GENE-030131-6053]). Expression levels of hacd2 have also been 
reported in mice in which hacd2 found to be in the cardiac tissue; this is in line with our 
findings from adult tissue RT-PCR in which hacd2 produced bright visible bands for the heart 
tissue samples (Tiret, personal communications). 
Quantitative RT-PCR expression data for hacd2-total was reported to increase slightly over 
development (though this was not found to be significant) and the full length hacd2 transcript, 
hacd2-fl, did increase significantly over embryonic development (2-fold). This was in line 
with results from the ISH, where hacd2 was present from the earliest embryos of the 5-9 
somite stage/12hpf right through to protruding-mouth stage/72hpf and we therefore hypothesis 
that hacd2 is a ubiquitous gene present throughout embryogenesis. The RNA-seq data 
published during this study found hacd2 to be expressed from the 128 cell stage/~2hpf (Figure 
2.26) which corroborates hacd2 as a ubiquitous gene expressed over embryogenesis (White et 
al., 2017).  
 Zebrafish hacd3 is expressed comparable to mammalian expression 
RT-PCR products corresponding to the hacd3 zebrafish gene were detected at all embryonic 
time points and in all adult tissues tested. These primers bound exon 5 and exon 11 and those 
designed to amplify the whole coding sequence were unsuccessful and so even though no 
isoforms were detected, it cannot be concluded that there are no other hacd3 isoforms. Results 
for hacd3 ISH displayed similar expression localisation to hacd2 with the majority of staining 
in head and eyes. Upon sectioning only hacd3 could be seen within the notochord of the 
embryos, suggesting possible, novel spatial expression for hacd3 within zebrafish. Published 
ISH on hacd3 in zebrafish embryos is in line with our findings with the expression seen mostly 
in the head of embryos (Thisse & Thisse, 2004). Quantitative RT-PCR expression data for 
hacd3 reported a slight increase over development (although this was insignificant) which 
corresponds to the results from the ISH, where hacd3 was present from 48-72hpf. As hacd3 
levels did not increase over expression this suggests it may be present at all embryonic stages. 
RNA-seq data by White et al., (2017) found hacd3 expression from the 2-cell stage/<1hpf 
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(Figure 2.26) which is in line with the hypothesis that hacd3 is present all throughout 
embryogenesis (White et al., 2017). 
 Zebrafish hacd4 results were inconclusive 
No products for hacd4 were amplified in the initial RT-PCR reactions, although a 40-cycle 
RT-PCR for hacd4 did present with numerous bands which might have been novel transcripts 
of the gene but due to these only being present in the high cycle RT-PCR reactions these 
products may not have been amplified from the gene and may be artefacts. The presence of 
hacd4 RT-PCR products in all tissues of the adult tissue RT-PCR could be explained as 
mammalian hacd4 is present in leukocytes which could be present in all tissues due to the 
presence of blood vessels/capillaries running through all tissues (Ikeda et al., 2008). ISH of 
adult tissues would verify this localisation. ISH of hacd4 within embryonic zebrafish was 
unsuccessful as no staining could be seen, this provided me with inconclusive results for the 
expression of hacd4 in embryonic zebrafish as it is possible embryos were not left for long 
enough for the development of pigment in leukocytes, if hacd4 is indeed localised to the 
leukocytes. Another possibility was that the wrong transcript published on ENSEMBL was an 
error due to the genome duplication in ancestral zebrafish species. Upon sectioning these 
embryos, one embryo had unexpected staining indicating hacd4 expression in the brain, this 
staining was bilaterally symmetrical indicating that it was not an artefact yet it was only seen 
in one embryo section therefore inconclusive and may well corroborate the idea that the hacd4 
transcript on ENSEMBL may be an error. There was no change seen in hacd4 expression 
levels which corresponds to the ISH where no hacd4 expression was detected as well as the 
RNA-seq data in which very small levels (1-9/78 TPM (transcripts per million) comparatively 
to 78 TPM for hacd1 expression) to of hacd4 were found from 128-cell stage/2hpf onwards 
(Figure 2.26) (White et al., 2017). 
 Limitations and future work 
A potential limitation of this study was the focus on gene expression without assessing protein 
expression. This is not a linear relationship and therefore important to not only look at RNA 
expression but synthesised proteins. Both hacd1 and hacd2 have been reported to have 
multiple splice variants however it is unknown if all of these variants are synthesised into 
proteins and if so, what their functions are as none of their isoforms apart from the full-length 
isoforms contain the essential amino acids thought to be required for HACD activity. We were 
unable to study protein expression easily due to the novelty of HACD: there are no available 




To completely characterise novel transcripts for all four of the hacd genes; a technique such 
as 3’ RACE could be performed, on all four hacd genes for completeness, to conclusively 
state the isoforms of hacd present in zebrafish (Chen et al., 2000). This was not done for this 
study as two novel transcripts were discovered for hacd2, neither of which contained the 
essential amino acids for HACD activity and were therefore unlikely to compensate for Hacd1 
function: and hacd3 and hacd4 share so little homology that it was decided any transcripts for 
these were unlikely to compensate for Hacd1 function. 
For completeness, ISH could be performed on sections of adult tissues, specifically muscle to 
verify the localisation of the genes in adult zebrafish; particularly for hacd4 in which results 
from this study were inconclusive. 
 Chapter conclusions 
In conclusion the work in this chapter has characterised the fundamentals of hacd expression 
within developing zebrafish embryos, as well as touching on expression within adult zebrafish. 
It has been found that hacd1 is the major hacd gene within embryonic and adult zebrafish 
muscle and that the other hacd genes are localised elsewhere, in a comparable manner to 
mammalian hacd expression. The expression of hacd1 was shown to be in time with the 
development of somites within the embryo and increase as myoblasts differentiated into 
mature myofibers found within zebrafish embryos at 3dpf. 
Zebrafish embryos have been previously used to study other genes implicated in the 
centronuclear myopathies, including DNM2, MTM and BIN1. These genes have high synteny 
and similar expression patterns to the mammalian orthologues. (Dowling et al., 2009; Dowling 
et al., 2010; Gibbs et al., 2013; Sabha et al., 2016; Smith et al., 2014). As zebrafish are 
emerging as a good model to study CNM; characterising the expression of the hacd genes 
within wildtype zebrafish adults and embryos was an essential first step in the generation of a 
HACD1-CNM zebrafish model. This model was generated alongside the work done for later 
chapters in this thesis via CRISPR/Cas9 genome editing and was available for the work in 
Chapter 5. Having reported that hacd1 is the major hacd gene within the muscle of developing 
zebrafish embryos strengthen the foundations for work in mutating the gene and assessing the 
effects of these mutations upon the embryos and their muscle structure. The hacd expression 
data in this thesis provides a model for comparing hacd expression in mutant embryos: as we 
suspect hacd1 expression should significantly decrease in successful hacd1-mutant embryos. 
The conservation between hacd1 and hacd2 will be important as there could be a 
compensatory mechanism that is activated upon hacd1 mutation with zebrafish. 
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3 Evaluating the effect of Hacd1 deficiency on the membrane 
properties of a myogenic cell line 
 Introduction 
Tubuloreticular membrane abnormalities are a central feature of centronuclear myopathies 
(CNMs) which result from a number of different genetic mutations (Al-Qusairi & Laporte, 
2011; Nance et al., 2012). Disruption of excitation contraction coupling (ECC), more 
specifically abnormal triad formation and calcium homeostasis, leads to functional 
abnormalities and profound neuromuscular weakness (Al-Qusairi & Laporte, 2011). Defects 
in ECC and/or the membranes involved have been reported in myotubular myopathy 
(Al-Qusairi et al., 2009; Dowling et al., 2009; Laporte et al., 1996), BIN1-CNM (Nicot et al., 
2007; Smith et al., 2014), DNM2-CNM (Bitoun et al., 2005; Gibbs et al., 2013a; Jungbluth et 
al., 2010) and RYR1-CNM (Jungbluth et al., 2007). Altered calcium homeostasis has been 
hypothesised to result from the morphological membrane abnormalities seen within the triads 
in CNM and high cytosolic Ca2+ concentration as a secondary pathology has been historically 
correlated with muscle weakness (Al-Qusairi & Laporte, 2011; Fraysse et al., 2016; Jungbluth 
& Gautel, 2014; Nance et al., 2012). The interaction between both the voltage-gated 
dihydropyridine (DHPR) and the ryanodine receptor 1 (RYR1) calcium release channel may 
be involved in the pathologies seen within CNM pathology (Jungbluth & Gautel, 2014). 
Mutations in the DHPR gene have been reported to cause congenital myopathies with 
internalised myonuclei (Schartner et al., 2017) further corroborating its importance within 
ECC and myopathies.  
Due to the implication that, alongside tubuloreticular membrane disorganisation seen in CNM 
(Al-Qusairi & Laporte, 2011), ECC and the function of DHPR and RYR1 calcium channels 
may be highly involved in CNM pathogenesis: this chapter aimed to further evaluate the 
impact of Hacd1-deficiency on cell membranes and calcium responses of the C2C12 murine 
muscle cell line. The murine muscle cell line, C2C12 has been well studied and found to 
develop basic and functioning forms of SR and t-tubules (Carozzi et al., 2000; Lee et al., 2002; 
Parton et al., 1997; Nori et al., 2006; Wang et al., 2009). Functionally, C2C12 myotubes 
exhibit calcium transport from internal and external environments via a number of calcium 
channels including DHPR and RYR1 (Gutierrez-Martin et al., 2005) and express ion channel 
activity that imitates activity seen in skeletal muscle fibres (Kurth et al., 2015). They have 
also been used extensively to study altered calcium homeostasis and disruptions within the 
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ECC apparatus (Araya et al., 2003; Wang et al., 2006; Wang et al., 2009; Vega et al., 2011). 
Here a transfected clonal C2C12 cell lines were used with short hairpin RNA (shRNA)-
mediated Hacd1 knockdown and a control with an empty vector that were originally a gift 
from Prof L. Tiret (Blondelle et al., 2015) and previously validated in our laboratory 
(Walmsley, 2013; Walmsley e  al., 2017). shRNA knockdown is a method of post translational 
gene silencing using RNA interference, in this case directed against exon 4 of the Hacd1 
transcript (Blondelle et al., 2015; Walmsley, 2013; Walmsley et al., 2017). 
Previous work on this Hacd1-kd cell line conducted by Blondelle et al., (2015) reported 
impaired differentiation within the clones investigated. They reported that upregulation of 
Hacd1-fl during early myogenesis was associated with a reduction in membrane fluidity in 
myotubes at 3dpd (days post differentiation). They concluded that Hacd1-deficiency lead to 
impaired myoblast fusion, which was then successfully restored by re-expression of Hacd1-fl, 
and therefore further concluded HACD1 activity was responsible for the increase in membrane 
fluidity myoblasts prior to fusion (Blondelle et al., 2015). Lin et al., (2012) also conducted 
research on the C2C12 line transfected with an shRNA targeting Hacd1. Their results were in 
line with Blondelle et al., (2015) and reported Hacd1 to be important for myoblast growth and 
differentiation (Lin et al., 2012). Recent cell work was done in a human haploid cell line which 
confirmed the redundancy of HACD1 and HACD2 (Sawai et al., 2017), but this was not a 
muscle cell line and membrane properties affected by either HACD1 or HACD2 were not 
evaluated. 
Walmsley, (2013) and Walmsley et al., (2017) tested several of the clones used by Blondelle 
et al., (2015) and used a clone which differentiated under certain conditions (hydrophilic 
polymer coated dishes and a particular batch of horse serum in the differentiation media). This 
allowed the cells to differentiate into myotubes and therefore develop the internal membrane 
structures for excitation evoked calcium response (Walmsley, 2013). Work was also 
undertaken to investigate into the localisation of RYR1 in these cells; unusual clusters of 
nuclei within the Hacd1-kd cells at 12dpd were reported that often formed complete or partial 
rings of nuclei and these correlated with focal areas of intense RYR1 and BIN1 
immunostaining (Walmsley, 2013; Walmsley et al., 2017). Walmsley, (2013) found RYR1 
function, through the stimulation of SR calcium release via caffeine, to be impaired as they 
reported slower responses in Hacd1-kd cells that tended to oscillate: which is an uncommon 
response for mature myotubes and seen more frequently in early differentiation (Lorenzon et 
al., 1997). This suggested numerous calcium releases via the RYR1 channel from just one 
stimulation: an abnormal response. Excitation-evoked calcium release was similar between 
control and knockdown cells and this was thought to be due to limitations of the techniques 
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used including the lack of a perfusion system to apply different reagents onto the cells and the 
low temporal resolution of the confocal imaging technique – quick responses would not have 
been recorded. Therefore patch-clamp techniques would be an appropriate way in which to 
study calcium release through the assessment of calcium-activated channels, providing fast 
kinetic information on calcium homeostasis and ECC within the cells (Leech & Holz, 1994).  
This approach allows analysis with the “cell-attached” mode of patch clamp (Hamill et al., 
1981).  This approach has a number of strengths such as the applicability to both small and 
large cells (there is no limit to the size of the target cell) and the fact that cells are “intact” 
there is no need to rupture the membrane, or introduce chemical dyes or expose to high power 
light sources (Hamill et al., 1981).  A limitation of the cell-attached mode of recording is that 
analysis generally requires knowledge of the underlying resting membrane potential (see 
Chapter  3 methods). 
Electrophysiology has long been used to study calcium responses (Sperelakis, 1987) and the 
patch-clamp technique, studying the ionic currents through cells, is a common way to do so 
(Leech & Holz, 1994). Numerous patch-clamp based techniques have been developed 
including: using classical patch-clamp methods to hold membranes at different voltages and 
measuring the calcium responses via fluorescence in a technique that combines both 
patch-clamp and calcium imaging protocols (Jacquemond, 1997). Previous 
electrophysiological work on CNM includes Al-Qusairi et al., (2009) findings: in 
Mtm1-deficient myofibres RYR1 protein expression was decreased 3-fold and a dampened 
calcium release in response to voltage-clamp depolarisations was reported. Bin1-deficient 
myofibres presented with swollen t-tubules, and Tjondrokoesoemo et al., (2011) reported this 
phenotype to be linked with a reduced voltage-induced intracellular calcium release 
suggesting disruption in the coupling between the voltage sensitive DHPR and the SR Ca2+ 
channel RYR1.  
Work in this chapter was undertaken to investigate the effect of HACD1-deficiency on 
calcium homeostasis and electrophysiology properties of a myogenic cell line including 
characterising any distinct channel phenotypes observed between the control and Hacd1-kd 
cells. Several ion channels are activated by intracellular calcium and could potentially be 
useful surrogates for intracellular calcium release. One of the most well-established families 
are calcium activated potassium channels (Vergara et al., 1998). Calcium-activated potassium 
channels are essential regulators of cell excitability (Vergara et al., 1998) and therefore will 
be assessed between the control and Hacd1-kd cells among all other channels recorded. The 
calcium-activated potassium channels may be of small (SK channels), intermediate (IK 
channels) or large conductance (BK channels) (Kim et al., 2014; Vergara et al., 1998). It is 
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plausible that sarcolemmal ion channels are affected as a secondary pathology seen in CNM 
after membranes are disrupted (Jungbluth & Gautel, 2014). Congenital myopathies have been 
associated with loss-of-function mutations in SCN4A that presented with neonatal-onset 
hypotonia (Zaharieva et al., 2016). Thus, using cell-attached patch clamp to both assess ion 
channels profiles within cells and characterising the ion channels present on the cells 
sarcolemma will provide insight into the membrane systems of these cells.  
 Chapter aims and hypotheses  
The work conducted in this chapter aimed to further characterise the phenotype and function 
of Hacd1-deficient C2C12 myoblasts and myotubes. We hypothesised that a change in 
calcium handling will result in measurable differences in electrophysiological properties of 
Hacd1-kd myotubes in comparison with control myotubes. Aims were specifically to: 
1) Assess the comparative differentiation of control and Hacd1-kd myotubes; 
2) Quantify the expression of Hacd genes over differentiaionm including the effect of 
Hacd1 knockdown upon this expression 
3) Measure the resting membrane potential in control and Hacd1-kd cells both at 
myoblast and myotube stages; 
4) Investigate the differential functional expression of ion channels in control and 
Hacd1-kd cells, in both single cell myoblasts and also multinucleated myotubes at 














 C2C12 cell culture 
The Hacd1-kd C2C12 cell line used in this chapter, selected because it retained myogenic 
capacity under the conditions described here, is a clonal cell line stably transfected with the 
pGIPZ shRNA construct (Figure 3.1) (V2LHS_5923 (GCTCATTACTCACAGTATA) 
against exon 4 of Hacd1 (Thermo Scientific) (Walmsley et al., 2017). An additional clone, 
developed in the same fashion, expressed an empty vector for use as a control (RHS4349). 
The C2C12 murine cell line has been well characterised previously and cells were cultured 
under standard conditions (37oC and 5% CO2) and aseptic technique (Yaffe & Saxel, 1977). 
C2C12 myoblasts were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma 
Aldrich) containing: 10% foetal calf serum (FCS) (Gibco), 2mM L-Glutamine (Sigma 
Aldrich), 0.1mg/ml penicillin and streptomycin (Sigma Aldrich) and 2μg/ml of puromycin 
(Invitrogen) within the media to select for only the cells containing the pGIPZ plasmid and 
therefore the shRNA to knockdown Hacd1 expression. Wildtype C2C12 were grown under 
the same conditions, but without the puromycin added to media.  
To stimulate differentiation and the fusion of myoblasts into myotubes, cell media was 
swapped to media containing 2% horse serum (HS) (Gibco) in the place of 10% FCS for up 
to 12 days and differentiation of cells was visually inspected over this time by phase contrast 
microscopy using a Nikon Diaphot microscope (Nikon) and ToupView software (ToupTek). 
Hacd1-kd and control cells were grown and differentiated in the selective media containing 
puromycin and expression of turboGFP (tGFP) (which was linked to shRNA expression via 
the IRES) was confirmed periodically using a Nikon Eclipse TiE live cell fluorescent 
microscope (Nikon) and the NIS-elements software (Nikon). 
Cell culture was carried out in T75 tissue culture flasks (Costar) and passaged once confluency 
reached 70-80% using 1x trypsin (Sigma Aldrich) to remove cells from flasks and spinning at 
1000rpm for five minutes at room temperate to pellet and cells resuspended in fresh DMEM 
media before plating at a seeding density of 5000 cells per cm2, cells were counted using an 




Figure 3.1: The pGIPZ plasmid within C2C12 Hacd1-kd cells.  
Control cells included plasmid with empty vector. cPPT = central polypurine tract, Zeo = zeocin 
bacterial selection marker, CMV = cytomegalovirus promoter, tGFP = turbo green fluorescent protein, 
IRES = internal ribosome entry site, PuroR = puromycin resistance, shRNA = short hairpin RNA, WRE 
= woodchuck hepatitis virus posttransciptional regulatory element, sin LTR = self-inactivating long 
terminal repeat, sv40 Ori = origin of replication, pUC ori = origin of replication, AmpR = ampicillin 
resistance. 
 
Myoblasts were seeded into 6-well tissue culture plates (Costar) for molecular studies and for 
immunocytochemistry cells were seeded onto hydrophilic polymer coated, optical-bottomed 
Ibidi dishes or slides (35mm dishes or 8-welled slides) (Thistle Scientific). For 
electrophysiological experiments undertaken on myoblasts cells, cells were resuspended in 
serum free DMEM media while passaging and pipetted into a chamber within the 
electrophysiology rig. Cells were then allowed to settle for an hour to lightly adhere to the 
bottom. When using myotubes for patch-clamping: the cells were seeded onto broken sections 
of treated polymer coverslips (Ibidi, Thistle Scientific) and differentiated into myotubes on a 
surface that would then fit into the rig for experiments. 
Cells were seeded at time zero and, to stimulate differentiation, media was changed to 
differentiation media 8 hours later. Day 0 was defined to be 24 hours post seeding and day 1 
defined as 24 hours after the change to differentiation media.  This was done for both 
consistency and to eliminate the different media as a variable that could show up in 1H-NMR 
lipidomic analysis (Chapter 4). 
 RNA extraction and cDNA synthesis from C2C12 cell lines 
C2C12 myoblasts and myotubes were cultured as described in Section 3.2.1, and were 
harvested using a cell scraper (Corning) into 1ml of TRIzol reagent (Life Technologies) before 
storing at -80oC until RNA extraction. Scraping of cells was visually checked to ensure cells 
were not left behind on the tissue culture plastic. 
Once thawed, samples were incubated at room temperature for five minutes. 200μl chloroform 
(Sigma Aldrich) was added to sample, agitated for 15 seconds and allowed to stand at room 
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temperature for a further 15 minutes. Samples were then centrifuged at 12,000g for 15 minutes 
at 4oC. This separated the cell lysates into several layers: an upper aqueous phase (containing 
RNA), an interphase containing DNA and a lower organic protein containing phase. The upper 
phase was transferred into a new tube and combined with 500μl isopropanol (Sigma Aldrich), 
vortexed briefly and incubated at room temperature for 10 minutes before a 10 minute 
centrifugation at 12,000g and 4oC. Supernatants were discarded and RNA pellets washed with 
75% ethanol (Sigma Aldrich) and centrifuged again at 12,000g and 4oC for five minutes. 
Supernatants again discarded and pellet allowed to air dry for 10 minutes. 
RNA pellets were then re-suspended into 30μl RNase and DNase free water. Re-suspension 
was aided by a heating step of 55oC for 15 minutes. Samples were then analysed on a 
Nanodrop (Nanodrop 2000, Thermo Scientific) to test concentration (ng/μl) and purity, with 
respect to protein or phenol (260/280) and phenol contaminants (260/230). 1μg of RNA was 
then reverse transcribed into cDNA by a reverse transcriptase (iScript, BioRad). RNA was 
combined with nuclease free water to give a volume of 13µl RNA and combined with a 1x 
Reaction Mix and iScript reverse transcriptase. The reaction was run at 25oC for five minutes, 
46oC for 20 minutes and 95oC for 1 minute. The cDNA was stored at -20oC until use. 
 Quantitative RT-PCR assay 
Both control and Hacd1-kd C2C12 cells were grown in triplicate in 6 well plates and 
differentiated to 10 days. Cells were collected at 0, 1, 2, 4, 8 & 10 dpd (days post 
differentiation) and RNA was isolated and cDNA synthesised as described in sections 3.2.2. 
qRT-PCR assays were used to quantify levels of all four Hacd genes and the full-length 
isoform of Hacd1 across these time points. Three technical replicates were performed for each 
of the three biological replicates cultured. 20μl reactions were run with 8μl cDNA diluted 
1:100 using molecular grade water, 2μl (0.15μM) primer and 10μl (1x) SYBR green 
mastermix (Roche). The reaction was run at 95oC for 10 minutes to initially denature the 
cDNA before 40 cycles of: 95oC for 15 seconds followed by a combined annealing and 
extension step at 60oC for one minute. Relative gene expression was calculated against the 
house keeping gene Gapdh (Walmsley, 2013) by the ΔΔCt method (Livak & Schmittgen, 
2001). 
Primer sequences were obtained from Walmsley, (2013) (Hacd1 and Gapdh primers) and 
Blondelle et al., (2015) (Hacd2-4 primers) and standard curves were performed using 1:10 
serial dilutions of a pooled set of C2C12 control cDNA. Plotting a standard curve allowed the 
efficiency (E) of the reaction to be calculated using the slope, which should be between 
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Table 3.1: List of primers used in C2C12 qRT-PCR assays 
Gene Product Length 
(bp) 
Primers (5’-3’) 
Hacd1-total 212 F: ATATCCCGTTGGAGTTGCTG 
R: CGTGGAGCACCTTTCTTCTC 
Hacd1-fl 184 F: ATGAAGAGAGCGTGGTGCTT 
R: AAGGCGGCGTATATTGTGAG 
Hacd2  160 F: TGCTATAGGGATTGTGCCATC 
R: ACGGATAATTTCCGTGATTGTCC 
Hacd3 174 F: GACGTGCAGAACCCTGCTATC 
R: CTTCTGGACTGTGATGTTCACC 
Hacd4 186 F: CAGCTCACAGAGAGAGTGATC 
R: GAGTGTTTGACTGAGCCATGTC 
Gapdh 283 F: TTGTGATGGGTGTGAACCAC 
R: TTCAGCTCTGGGATGACCTT 
 
 qRT-PCR primer validation  
Primer sequences (Table 3.1) were used from Blondelle et al., (2015) and Walmsley, (2013) 
and were validated by assessing melt curves and peaks, and standard curves to evaluate 
efficiencies. Hacd1-4 sequences with primers annotated can be seen in Appendix Figures 




Figure 3.2: Validation of Hacd and Gapdh primers for C2C12 qRT-PCR assays.  
Outputs from BioRad CFX Manager software: (a) melt curves, (b) melt peaks both indicating only 
single products being amplified and therefore primers sufficiently specific and (c) standard curves 





Table 3.2: Efficiency of primers used in C2C12 qRT-PCR reactions in this chapter. 
Primer Efficiency (%) R2 Slope 
Hacd1-total 90.2 1.00 -3.583 
Hacd1-fl 91.5 0.998 -3.544 
Hacd2 96.3 0.994 -3.415 
Hacd3 105.4 0.998 -3.198 
Hacd4 88.2 0.989 -3.643 
Gapdh 87.4 0.998 -3.665 
 
 Immunocytochemistry 
Cells were seeded onto coated hydrophilic polymer coated, optical-bottomed Ibidi dishes or 
slides (35mm dishes or 8-welled slides) and fixed at day 0 as myoblasts or myotubes at 8dpd. 
Cells were fixed and permeabilised using ice cold methanol: acetone (Fisher Scientific) at a 
ratio of 1:1 before air drying and storing at -20oC till use. On day of experiment cells were 
brought back up to room temperature and blocked in 1% goat serum (Sigma Aldrich) in 
phosphate buffered solution (PBS, Sigma Aldrich) before incubating with the primary 
antibody overnight on a rocker at 4oC. After primary incubation cells were washed with PBS 
before incubating for an hour at room temperature on a rocker with the secondary antibody, 
from this stage onwards cells were protected from light due to the fluorescent nature of 
secondary antibodies used. Cells were then washed again and incubated with Hoechst at a 
concentration of 1mg/ml (Sigma Aldrich) for 10 minutes at room temperature to stain the 
nuclei of the cells. Cells were then covered with a coverslip using Hydromount (National 
Diagnostics) for imaging.  
Samples were imaged using a Hamamatsu camera (Hamamatsu), a Nikon TE2000 microscope 
(Nikon) and IP Lab software (BD Biosciences). Exposure times were decided upon using 
control cells and the auto-exposure tool. Once an appropriate exposure time was decided upon 
for each antibody, this was kept consistent across all experiments. Images were taken at the 









Table 3.3: Table of antibodies used in this chapter. 
Primary 
Antibody 
Type Concentration Secondary 
Antibody 
Source 
RYR1 Mouse monoclonal 
IgG1 




DHPR Rabbit polyclonal 
IgG 




MF20 Mouse monoclonal 
IgG2b (Supernatent) 





 Assessment of myotube differentiation 
To assess the differentiation of myoblasts into multinucleated myotubes both the control and 
Hacd1-kd cells were stained at 8 days post differentiation (dpd) with an antibody against 
sarcomeric myosin (MF20) which is used as a marker for differentiation (Wallace et al., 2016) 
as described in Section 3.2.5. Into the 8-well Ibidi dis hes, control and Hacd1-kd cells were 
seeded into four/eight wells each - three were incubated with the primary antibodies and one 
well for each cell type used for negative controls with no MF20 primary antibody incubation 
step. This was repeated twice creating an n=6 for analyses. Three images were taken from 
each well creating a total of 18 images which were analysed and averaged per well to create 
the n=6. 
Differentiation index was obtained by manually counting nuclei and calculated as the 
percentage of all DAPI stained nuclei counted within the MF20 positive myotubes (containing 
at least two nuclei) (Blondelle et al., 2015) and fusion index as the average number of nuclei 
per myotubes using the same criteria (Blondelle et al., 2015; Wallace et al., 2016). Myotube 
density was calculated using Image J (National Institute of Health) to analyse the percentage 
of image area that was positive for MF20; images were converted into binary images where 
the fluorescence of the image was converted to black pixels. These black pixels then 
represented MF20 stain and therefore myotube differentiation (Velica et al., 2011). Clusters 
of abnormal myonuclei were classified as four or more myonuclei in contact with another or 
those forming ring-like shapes. 
 Electrophysiology 
Patch pipettes were prepared using 1.5mm thick walled borosilicate glass capillary tubes 
(Intracel) using a Narishige two-step pipette puller (Narishige). When filled, whole-cell 
pipettes had a 3-8MΩ/Ohm resistance and pipettes for cell-attached patch configuration had 
8-12MΩ/Ohm resistance. Solutions used in these experiments are detailed in Table 3.4. 
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For all experiments patch pipettes were filled with the appropriate solution and lowered down 
the cell chamber via a micromanipulator to reach a single myoblast or myotube. Once the 
pipette was just touching the top of the cell negative pressure was applied to form a giga-seal 
with the cell. Cell-attached patch requires this seal and whole-cell requires high pressure being 
applied in order to perforate the membrane (Hamill et al., 1981). The establishment of a 
giga-seal ensures that any current activity recorded is from channel gating on the cell 
membrane (Hamill et al., 1981). Recordings were collected into the WinEDR software (John 
Dempster) using an Axopatch 200b amplifier (Axon Instruments) with a sampling interval of 
0.1ms and filtered at 2 kHz. 
Table 3.4: Table of reagent concentrations (mM) used in solutions for electrophysiological 
experiments, all pH adjusted to 7.35 using NaOH. 
 HEPES bath solution Intracellular 
NaCl 156 - 
KCl 3 26 
MgSO4 2 - 
KH2PO4 1.25 - 
CaCl2 2 - 
Glucose 10 - 
HEPES 10 10 
EGTA - 5 
KG - 115 
MgCl2 - 1 
 
RMPs were adjusted by +3.5mV (Table 3.5) to offset the junction potential created by the use 
of two solutions of different concentrations. 
Table 3.5: Solutions used in each experiment and the junction potentials for these conditions, 
calculated using JPcalc software (Axon Instruments). 
Experiment 
configuration 














 Resting membrane potential (RMP) recording and analysis 
Whole-cell configuration was used to record the RMP, for whole-cell configuration once the 
giga-seal was obtained, increased negative pressure was then applied to perforate the cell 
membrane and create a whole-cell seal. The amplifier settings were then adjusted so that there 
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was no current being applied to the cells to record the cells natural RMP (I=0). RMP was then 
recorded for ~200 seconds. Gain used in recordings was 10x. 
The most stable 100 seconds of recording was (mode) averaged to calculate the RMP for each 
cell. Ten recordings were collected for each cell type and age (dpd) and all recordings are 
plotted alongside median of recordings and standard error of the mean (SEM).  
 Single channel recording and analysis 
Following on from obtaining a giga-seal, recordings were made in the voltage-clamp mode to 
record changes in current, with a high gain of 200x. Holding potential of the cell was then 
changed (between -100mV and 100mV) in increments of 10mV to record any changes in 
amplitude due to channels gating (opening or closing).  
Holding voltage was subtracted from the RMP of cells to calculate the real cell voltage during 
recordings. These were plotted against currents (pA) measured at different holding voltages 
from the raw data traces to create current-voltage (IV) curves from which reversal potential 
(Vrev) (the membrane voltage at which there is no net flow of ions) and slope conductance (pS) 
(rate of ion travel through channels) were calculated from the curve.  
QuB software (QuB, State University of New York) was used to create all-points histograms 
by selecting areas of the trace that represented the channel at ‘open and ‘closed’ gating. These 
provided information on the time in the traces the channels spent at either ‘open’ or ‘closed’ 
states. 
 K-means clustering 
K-means clustering is a form of unsupervised machine learning that groups (“clusters”) 
multi-dimensional data by similarity. Scripts were written in python (Python) by another 
researcher, Dr. Barrett-Jolley, using the open source library sklearn (Scikit-learn package). 
These were used to identify patterns of ion channel phenotype using two dimensions; channel 
reversal potential and single channel conductance. These were first calculated for each patch 
using linear fits to current-voltage relationships.   
 Equilibrium potentials 
The equilibrium potential (Eqx) was calculated from the Nernst equation (Equation 2).   











Where, [X] is the concentration of ion X, R is the universal gas constant (8.314 Joules per 
Kelvin per mole), F is the Faraday’s constant (96485 Coulombs per mole) and z is the valence 
of ion X. Ion channels are often selective for a single ionic species and their equilibrium 
potential value therefore approaches the value for the reversal potential of the channel (Vrev). 
This is useful since the Vrev itself can be measured directly using the IV (current-voltage) 
curve; the point where the line crosses the X axis (current = 0). 
Table 3.6: The theoretical equilibrium potentials, of the major monovalent ions.  
As discussed in the text, the reversal potential of a selective ion will approach the ion’s equilibrium 
potential under normal conditions. Note that for a non-specific ion channel, one would expect a reversal 
potential near to 0mV. Values calculated using Equation 3 for the solutions used in these studies. 
(Values for cellular concentration of ions within muscle obtained from McKenna et al., 2008). 






With the exception of the k-means clustering, all statistics were performed with GraphPad 
Prism (GraphPad Software Inc.). 
Two-way ANOVAs (analysis of variance) were conducted for qRT-PCR data and represented 
as mean values with error bars indicating standard error of the mean (SEM). Student’s t-tests 
were performed to analyse any significance between control and Hacd1-kd RMPs. For k-
means clustering, statistical differences between numbers of clusters and between cell 
populations were determined by F-tests computed within the Python code (Scipy package). 
Significance was annotated on graphs as follows: * indicates p≤0.05, ** indicates p≤0.01, *** 










 Control and Hacd1-kd C2C12 cell morphology over differentiation is 
comparable 
Figure 3.3 shows the morphology of both control and Hacd1-kd cells over eight days of 
differentiation, which was comparable between both cell types. At Day 0 single myoblasts 
were present for both cell types and by 4dpd (days post differentiation) the myoblasts had 
begun to fuse and elongate. At 4dpd the control cells covered more of the dish compared to 
the Hacd1-kd cells – this was likely due to the control cells observably proliferating at a faster 
rate, reported also by Blondelle et al., (2015). By 8dpd both control and Hacd1-kd cells had 







Figure 3.3: Morphology of both control and Hacd1-kd C2C12 cells over differentiation.  
Both control and Hacd1-kd cells were single myoblasts at 0dpd (days post differentiation), by 4dpd 
both control and Hacd1-kd cells began to elongate as they started to fuse with nearby cells and by 8dpd 
there were distinct myotubes with multiple nuclei. Scale bar represents 200µm. 
 
Both control and Hacd1-kd cells expressed the tGFP (Figure 3.4) due to the pGIPZ plasmid 





Figure 3.4: tGFP expression in pGIPZ transfected cells.  
Myoblasts of wildtype cells did not express tGFP and both control and Hacd1-kd cells transfected with 
pGIPZ plasmid did express the tGFP. Scale bar represents 500µm. 
 
 Hacd1 expression was significantly knocked down in the later stages of 
differentiation in this Hacd1-kd cell line 
Cells were collected for qRT-PCR analysis to evaluate levels of all four Hacd genes in the 
context of Hacd1 knockdown and to independently validate the cell lines used. Previous work 
had demonstrated consistent knockdown of Hacd1 of at least 80% at all time points in this 
particular clonal cell line (Walmsley, 2013).   
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In control cells, expression levels of Hacd1-total (which detects all Hacd1 isoforms), 
increased significantly from 4 days post differentiation (dpd) by ~1.5-fold and after - up till 
10dpd where the increase was 3.5-fold (Two-way ANOVA, p<0.01). In the Hacd1-kd cell line 
the Hacd1-total expression did not increase up until 8dpd where there was a small, 
insignificant, increase. By 10dpd the knockdown was a 3.5-fold knockdown (35%, Sidak’s 
multiple comparisons, p<0.01). 
Expression of the Hacd1-fl isoform increased by 5-fold between 2 and 4dpd and then by 10dpd 
had increased by 20-fold (Two-way ANOVA, p<0.0001). In comparison, the Hacd1-kd cell 
line did not have this increase and the knockdown was significant from 4dpd onwards. At 













Figure 3.5: Expression levels of Hacd1-total and Hacd1-fl over 10 days of differentiation in C2C12 
cells presented as fold change from control cells at 0dpd (days post differentiation) (n=3).  
(a) Two-way ANOVA reported Hacd1-total expression increased significantly by 3.5-fold (p<0.01) in 
control cells over differentiation and was significantly lower in Hacd1-kd cells over the time course 
(p<0.001). (b) Hacd1-fl expression levels were unchanged in control cells up until 2dpd when it began 
to be upregulated 20-fold (p<0.0001). This upregulation after 2dpd was not present within the Hacd1-
kd cells and the difference between Hacd1-fl expression within control and Hacd1-kd cells was 
significant (p<0.0001). Sidak’s post-hoc tests assessing significance between control and Hacd1-kd 
cells at each timepoint are annotated on the graphs as follows: * indicates p≤0.05, ** indicates p≤0.01, 





 Reduction in Hacd1 expression is not associated with a compensatory change 
in Hacd2-4 expression in C2C12 myotubes 
Expression levels of Hacd2 were significantly affected (Two-way ANOVA) by differentiation 
(p<0.05) in control cells where they increased by 2-fold over differentiation. Expression levels 
of Hacd2 in Hacd1-kd cells decreased by 2-fold over differentiation (p<0.05). Despite these 
changes over differentiation, there was no significant difference in Hacd2 expression at any 
time point between control and Hacd1-kd cells. Hacd3 expression in control cells was 
unchanged over differentiation yet in Hacd1-kd cells Hacd3 expression was 3.5-fold 
upregulated at 0dpd (days post differentiation) (p<0.0001) but by 4dpd onwards expression 
was not significantly different between control and Hacd1-kd cells. Overall two-way ANOVA 
analysis found the Hacd1 knockdown to have a significant effect upon Hacd3 expression. 
Hacd4 expression was also unchanged over differentiation in control cells, but significantly 
affected in Hacd1-kd myoblasts (p<0.0001). At 0dpd there was 5-fold more Hacd4 expression 
in Hacd1-kd cells than in control (p<0.0001) and at 1dpd there was 4 times more expression 
(p≤0.01). From 2dpd onwards there was no significant difference between control and 





Figure 3.6: Expression levels of Hacd2, Hacd3 and Hacd4 over 10 days of differentiation in C2C12 
cells presented as fold change from control cells at 0dpd (days post differentiation) (n=3).  
Hacd2 expression increased 2-fold over differentiation in control cells, and this was seen to decrease in 
Hacd1-kd cells by 1.5-fold. Two-way ANOVA results reported differentiation to have a significant 
effect on Hacd2 expression (p<0.05) and that there was no significant difference overall between 
control and Hacd1-kd group (p=0.5020). Hacd3 expression levels were significantly different over 
differentiation in Hacd1-kd cells (p<0.0001) and there was a significant difference between expression 
in control and Hacd1-kd cells (p<0.0001). Hacd4 expression was significantly different over 
differentiation (p<0.0001) and also between control and Hacd1-kd cells (p<0.001). Sidak’s post-hoc 
tests to test for significance between control and Hacd1-kd cells at different time points are annotated 
on the graphs as follows: * indicates p≤0.05, ** indicates p≤0.01, *** indicates p≤0.001 and **** 
indicates p≤0.0001 and error bars represent the standard error of the mean (SEM). 
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 Myogenic differentiation analysis 
To quantify aspects of myogenic differentiation, both control and Hacd1-kd myotubes aged 
8dpd were used to perform immunocytochemistry (ICC) for MF20 (a marker of myogenic 
differentiation). MF20 antibody was first validated as seen in Figure 3.7, where it was not 
present in 0dpd but was present in differentiated myotubes at 8dpd. Both cell lines expressed 
sarcomeric myosin confirming myogenic differentiation at 8dpd. Figure 3.8 shows fairly 
uniformed myotubes formed by control cells and myotube formed by Hacd1-kd cells that 




Figure 3.7: Validation of MF20 immunocytochemistry within control day 8 myotubes.  
Left column shows MF20 stain, the middle column shows the DAPI stain and a merged image of both 
stains in shown in the right column. Only the DAPI stain was present at 0dpd (days post differentiation) 





Figure 3.8: MF20 (sarcomeric myosin) stained C2C12 myotubes at 8dpd (days post differentiation).  
Analysis of myogenic differentiation was performed as an n=6, and representative images are shown above. 
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Abnormal nuclei clusters were counted in both control and Hacd1-kd myotubes to assess the 
frequency of these in both cell lines. There were twice as many myotubes with these abnormal 
clusters in the Hacd1-kd populations (10% in control and 20% in Hacd1-kd cells) although 
this was not a significant result (t-test, p=0.26). 
 
Figure 3.9: Quantification of abnormal nuclei clustering in control and Hacd1-kd myotubes at 8 
days post differentiation (dpd).  
Clustering of nuclei was considered abnormal if there were four or more nuclei in contact that was not 
linear. There was no significant difference between the amount of control and Hacd1-kd myotubes with 
abnormal clusters (10% control myotubes, 20% Hacd1-kd myotubes) (p=0.26, n=6). Coloured bars 
represent the mean and error bars represent the standard error of the mean (SEM). 
 
The MF20 ICC images were also used to quantify myogenic differentiation. Figure 3.10a 
displays the quantified differentiation index results, which were not significantly different 
between control and Hacd1-kd cells (28.5% and 26.9% of nuclei within myotubes 
respectively, p=0.812). Figure 3.10b shows results from the fusion index, which was also not 
significantly different between control and Hacd1-kd cells (6.9 and 6.8 nuclei per myotube 
respectively, p=0.926). Figure 3.10c shows results from the myotube density quantification -  
no significant difference was found between myotube density in control and Hacd1-kd cells 




Figure 3.10: Assessment of myotube differentiation in both control and Hacd1-kd myotubes at 
8dpd (days post differentiation).  
(a) Differentiation index in control and Hacd1-kd cells was reported to be 28.5% and 26.9% 
respectively (% of nuclei within MF20 positive cells). Unpaired t-test reported no significant difference 
between the two groups, p=0.812. (b) Fusion index (average nuclei per MF20 positive myotube) of 
control cells was reported to be 6.9, and 6.8 in Hacd1-kd cells. Unpaired t-test reported no significant 
difference between the two groups, p=0.926. (c) Control cells had a myotube density of 10.1% 
compared to 8.4% in Hacd1-kd cells, this was not significantly different (t-test, p=0.566). All 
experiments were n=6. Coloured bars represent the mean and error bars represent the standard error of 
the mean (SEM). 
 
 RYR1 & DHPR calcium channels are both present in myotubes at 8dpd 
Immunocytochemistry was performed to confirm the presence of both DHPR and RYR1 
channels in mature myotubes. Figure 3.11 shows the validation of the co-staining of RYR1 
and DHPR which was confirmed to be specific due to the absence of either red or green 






Figure 3.11: Validation of RYR1 and DHPR co-stain within control day 8 myotubes.  
Far left image shows DHPR channel, then next along the RYR1 channel, the DAPI channel and finally on the far left a merge of all 3. Only the DAPI stain was present when 
no primary controls were tested, confirmed specificity of stain visualised. 
121 
 
Figure 3.12 shows the co-staining of both DHPR and RYR1 calcium channels. Whereas RYR1 
was only present within the myotubes, DHPR was also present within the myoblasts that had 
not differentiated in the dishes. RYR1 staining was stronger with consistent imaging technique 
within the control than the Hacd1-kd myotubes and the Hacd1-kd myotube annotated by a red 
arrow indicates an area of intense RYR1 stain alongside an abnormal nuclear cluster. Some of 
the areas of high staining appear to be extracellular therefore this was thought to be non-
specific staining of debris. Importantly, the ICC confirmed the presence of the two channels 





Figure 3.12: Immunocytochemistry of both RYR1 and DHPR calcium channels in myotubes aged 8 days post differentiation (dpd).  
DHPR staining is shown in the far left column, followed by RYR1 in the second left hand column, DAPI staining in the third and a merge of all 3 channels in the far-right 




 Electrophysiological analysis of a Hacd1 deficient myogenic cell line 
 Resting membrane potential of control and Hacd1-kd myoblasts was not 
significantly different 
For accurate single ion channel analysis, the resting membrane potential (RMP) of cells was 
required to calculate the true cell voltage from the holding voltage used during recordings. 
RMPs were therefore recorded for both myoblasts and myotubes in both control and Hacd1-kd 
cells: this also allowed assessment of any differences in RMP as a result of Hacd1 knockdown. 
After recording RMP for both control and Hacd1-kd myoblasts, and using a student t-test, 
there was no significant difference (p=0.88, n=10) in the RMP for control cells (-7mV ± 
2.1mV) and for Hacd1-kd cells (-4mV ± 4.8mV). An F test of variance found there to be 
significantly more variance within the Hacd1-kd myoblast RMPs (F= 5.6, p=0.01). 
 
Figure 3.13: Resting membrane potential (RMP) of control and Hacd1-kd C2C12 myoblasts. 
There was no significant difference (p=0.89) between the RMP of control (-7mV) and of Hacd1-kd 
(-4mV) cells by unpaired t-test analysis, n=10. F test of variance found Hacd1-kd RMPs to be 
significantly more varied (F=5.6, p=0.01). 
 
 K-mean clustering reveals differences in ion channel profile between control 
and Hacd1-kd myoblasts 
Patch-clamp recordings of control and Hacd1-kd myoblasts provided data on a number of 
different ion channels. It was observed that the Hacd1-kd cells were easier to achieve a seal 
with and for that reason there were a higher number of recordings achieved for the Hacd1-kd 
cells. After all ion channel openings seen in recordings had been analysed (conductance in pS, 
and reversal potential in mV), channels from both control and Hacd1-kd myoblasts were run 
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through a k-means clustering script in Python. Clustering analysis was carried out to evaluate 
which myoblast channels were similar in regards to the conductance and reversal potential. 
Six clusters were determined to be appropriate for cluster analysis after running the analysis 
on control cells as six clusters were a significantly better fit for grouping similar channels than 
using five clusters to group the channels (p<0.0001). This was also the case for Hacd1-kd 
myoblasts with six clusters providing a significantly better fit (p<0.0001). Further analysis 
reported clusters seen in control and Hacd1-kd myoblasts were significantly different 
(p<0.0001). If calcium-activated potassium channels were present within these recordings we 
would have expected them to reverse at approximately -93mV (Lee & Cui, 2010): a few 





Figure 3.14: Clustering of ion channels seen during patch-clamp single channel analysis of control 
(a, n=14) and Hacd1-kd (b, n=29) myoblasts.  
For both control and Hacd1-kd myoblasts, clustering channels into six clusters provided a significantly 
better fit than five clusters (p<0.0001 for both). Comparison of clusters between the two groups reported 




 Non-selective channels were predominantly seen in both control and 
Hacd1-kd myoblasts 
The predominant channels for both control and Hacd1-kd myoblasts did not appear to be 
calcium-activated potassium channels and were analysed in more depth in order to 
characterise their properties.  In control myoblasts, this unknown channel in Figure 3.15 was 
seen in 28% of channel recordings (4/14). Figure 3.15a shows raw data from a representative 
trace at three different holding voltages, dashed lines represent channel gating (O=open, 
C=closed) and this channel opened at a negative amplitude with clear openings. Figure 3.15b 
shows the all-points amplitude histogram from a holding voltage of -80mV displaying the 
channel as closed (0pA) and open (~1.4pA). Current-voltage (IV) analysis on the data were 
plotted (Figure 3.15c); this channel was found to have a slope conductance of 18pS ± 1.3pS 
and the current reversed at a reversal potential of -1mV ± 8mV. This channel was therefore 










Figure 3.15: Patch-clamp recordings of control myoblasts revealed the predominant channel was 
a non-selective channel. 
(a) Raw traces of cell-attached patch single channel activity at -50mV, -60mV and -80mV from a 
representative recording. (b) All-points amplitude histogram at -80mV from the same recording in (a). 
(c) Single channel current-voltage (IV) curve for the channel from all recordings of the channel 
reporting the channel to have a conductance of 18pS and a reversal potential of -1mV. IV curve plotted 
with the calculated cell membrane potential using the cells RMP (resting membrane potential) minus 
the holding potential (n=4). 
 
The predominant channel seen in Hacd1-kd myoblasts was also one that could be a non-
selective channel. This unknown channel, as shown in Figure 3.15, was seen in 28% of 
channel recordings (8/29). Figure 3.16 shows raw data from a representative trace at three 
different holding voltages, dashed lines represent channel gating (O=open, C=closed) and this 
channel opened clearly at a negative amplitude. Figure 3.16b shows the all-points amplitude 
histogram from a holding voltage of -60mV displaying two peaks, the closed peak at 0pA and 
then the open at around -1.5pA indicating this was the amplitude of the channel at -60mV. IV 
analysis on the data were plotted (Figure 3.16c) and the channel was found to have a slope 
conductance of 22pS ± 12.9pS and the current reversed at a reversal potential of 0mV ± 6mV. 
Figure 3.16c for this channel shows a plateau of currents with very positive and negative 
potentials, which indicates that has both inwardly and outwardly rectifying properties at 
positive and negative potentials respectively. Rectification in channels is often seen due to 




Figure 3.16: Patch-clamp recordings of Hacd1-kd myoblasts revealed the presence of a non-
selective channel.  
(a) Raw traces of cell-attached patch single channel activity at holding voltages of -40mV, -50mV and 
-60mV from a representative recording. (b) All-points amplitude histogram at -60mV from the same 
recording in (a). (c) Single channel current-voltage (IV) curve for the channel from all recordings of 
the channel reporting the channel to have a conductance of 22pS ±12.9pS and a reversal potential of 
0mV ± 6mV.  IV curve plotted with the calculated cell membrane potential using the cells RMP (resting 
membrane potential) minus the holding potential. This channel has been fitted with a Boltzmann 
sigmoidal line due to the nature of the data points (n=8). 
 
 Resting membrane potential of control and Hacd1-kd myotubes was not 
significantly different 
Resting membrane potentials for the myotubes at 8dpd were more negative than those for the 
myoblasts (p<0.0001 for both control and Hacd1-kd cells). There was no significant difference 
in the RMP when Hacd1-kd was knocked down (p=0.13, n=10). The RMP for control cells 
(-33mV ± 3.9mV) and for Hacd1-kd cells (-41mV ± 4.7mV). An F test for variance did not 




Figure 3.17: Resting membrane potential (RMP) of control and Hacd1-kd C2C12 myotubes at 8 
days post differentiation (dpd).  
There was no significant difference (p=0.13) between the RMP of control (-33 mV) and of Hacd1-kd 
(-41 mV) cells by unpaired t-test analysis, n=10. Variance in cell populations was not significantly 
different (F=1,45, p=0.58). 
 
 K-mean clustering found no differences in channels seen between control and 
Hacd1-kd myotubes 
Patch-clamp recordings of control and Hacd1-kd myotubes were performed and analysed in 
an identical manner to the myoblasts. The myotubes were harder to work with and so recording 
numbers were fewer. For this reason, four clusters were used for myotubes to evaluate which 
channels might be similar. Four clusters was determined to be a significantly better fit for 
clustering data, when comparing to three clusters; this was determined by running the analysis 
on control cell channels (p<0.0001). This was also the case for Hacd1-kd myoblasts with four 
clusters providing significantly better grouping than three clusters (p<0.01). When analysing 
the difference in clustering between the control and Hacd1-kd myotubes this was not found to 
be significantly different (p=0.18). There were a few channels in each cell type that reversed 





Figure 3.18: Clustering of ion channels seen during patch-clamp single channel analysis of control 
(a, n=10) and Hacd1-kd (b, n=11) myotubes at 8 days post differentiation (dpd).  
It was found that for both control and Hacd1-kd myotubes that clustering channels into four clusters 
was a significantly better fit than three clusters (p<0.0001 and p<0.01 respectively). Comparison of 
clusters between the two groups reported that the channels in control and Hacd1-kd were not 




 Predominant channel seen in myotube patch-clamp analysis were likely to be 
either non-selective or Cl- channels 
The predominant channel seen in both control and Hacd1-kd myotubes was then analysed in 
more depth in order to characterise its properties, as done for myoblasts also.  
The unknown channel in Figure 3.19 was seen in 50% of channel recordings (5/10). Figure 
3.19a shows raw data from a representative recording at three different holding voltages. The 
dashed lines represent the channel gating (O=open, C=closed) and this channel opened clearly 
at a positive amplitude at these holding voltages. Figure 3.19b shows the all-points amplitude 
histogram from a holding voltage of -60mV displaying the channel as closed (0pA) and open 
(~3pA). Current-voltage analysis on the data were plotted (Figure 3.19c) the channel was 
found to have a slope conductance of 65pS ± 10.3pS and the current reversed at a reversal 
potential of -44mV ± 14mV. From the Nernst equations in Table 3.6 this channel had a reversal 
potential between that expected for a non-specific channel (which always reverse at 0mV) and 
that of a pure Cl- channel (-66mV) therefore it is possible that this channel was either 








Figure 3.19: Patch-clamp recordings of the predominant channel observed in control myotubes 
at 8 days post differentiation (dpd).  
(a) Raw traces of cell-attached patch single channel activity at holding voltages of -40mV, -50mV and 
-60mV from a representative recording. (b) All-points amplitude histogram at -60mV from the same 
recording in (a). (c) Single channel current-voltage (IV) curve for the channel from all recordings of 
the channel reporting the channel to have a conductance of 65pS ± 10.3pS and have a reversal potential 
of -44mV ± 14mV. IV curve plotted with the calculated cell membrane potential using the cells RMP 
(resting membrane potential) minus the holding potential (n=5). 
 
One of the predominant channels seen in Hacd1-kd myotubes that was similar in properties to 
the one seen in control myotubes is presented in Figure 3.20. This unknown channel, was seen 
in 45% of channel recordings (5/11). Figure 3.20a shows raw data from a representative trace 
at three different holding voltages, dashed lines represent channel gating (O=open, C=closed) 
and this channel like that seen in control myotubes opened clearly at positive amplitudes at 
holding voltages shown. Figure 3.20b shows the all-points amplitude histogram from a 
holding voltage of 60mV displaying the channel as open (0pA) and open (~2.5pA). This 
histogram is less clear than previous due to few openings and less consistent channel gating. 
Current-voltage analysis on the data were plotted (Figure 3.20c) and the channel was found to 
have a slope conductance of 39pS ± 10.1pS and the current reversed at a reversal potential of  
-35mV ± 15mV. Similarly, to the channel seen in control myotubes this channels selectivity 
was more difficult to determine as the channel has a reversal potential that fell between Cl- 




Figure 3.20: Patch-clamp recordings of Hacd1-kd myotubes at 8 days post differentiation (dpd) 
revealed the presence of a predominant channel with unknown selectivity.  
(a) Raw traces of cell-attached patch single channel activity at holding potentials of 80mV, 60mV and 
0mV from a representative recording. (b) All-points amplitude histogram at 60mV from the same 
recording in (a). (c) Single channel current-voltage (IV) curve for the channel from all recordings of 
the channel reporting the channel to be 39pS ± 10.1p and have a reversal potential of -35mV ± 15mV. 
IV curve plotted with the calculated cell membrane potential using the cells RMP (resting membrane 













Expression of HACD1 mRNA is reduced to less than 1% in canine HACD1-CNM (Pelé et 
al., 2005) and this has been reported to lead to tubuloreticular membrane abnormalities 
(Walmsley et al., 2017). These membrane disruptions are also a common feature in other 
CNMs (Jungbluth et al., 2018; Nance et al., 2012). Very long chain fatty acids (VLCFAs) are 
thought to promote curvature within membranes (Schneiter et al., 2004) and although little is 
known about the role of VLCFAs and HACD1 that elongates them in muscle, it could be 
hypothesised that HACD1 deficiency causes a disruption in the function as well as the 
structure of muscle membranes, resulting from the lack of VLCFAs, which in turn affects ion 
channel gating and calcium homeostasis (Jungbluth & Gautel, 2014). We have shown this 
particular Hacd1-kd cell line to have significant knockdown of both total and full length hacd1 
transcripts (the latter of which encodes the catalytically active isoform), after cells begin to 
fuse at 4dpd. This chapter reports similar myogenic differentiation seen in both the control 
and Hacd1-kd cell lines. The electrophysiological properties between the Hacd1-kd and 
control cell lines were found to be significantly different in the myoblasts, though this could 
not be demonstrated in myotubes and no significant amount of calcium-activated potassium 
channel activity was recorded in any of the cells. 
 A knockdown of Hacd1 does not associate with a compensatory increase in 
Hacd2-4 expression in myotubes 
Quantitative RT-PCR was used to evaluate expression of all four Hacd genes over C2C12 
differentiation in both control and Hacd1-kd cells: these cells had been previously shown to 
have 80% knockdown of both total Hacd and Hacd1-fl at all time points (Walmsley, 2013). 
Stable transfection with the pGIPz plasmid was assumed based on survival in selective media 
and direct visualisation of tGFP expression. Therefore, the qRT-PCR was not performed as 
an initial assessment to confirm Hacd1 knockdown, but undertaken at a later time to assess 
any compensation via upregulation of genes Hacd2-4. 
The results from control cells here show both total Hacd1 transcripts and Hacd1-fl are 
upregulated from 4dpd, which differs slightly from all previous studies of Hacd1 expression 
in C2C12 which saw earlier upregulation (Blondelle et al., 2015; Lin et al., 2012; Walmsley, 
2013). Specifically, Lin et al., (2012) found Hacd1-fl expression upregulated after 1dpd and 
was upregulated by approximately 6-fold when expression peaked at 3dpd. Expression then 
decreased to a 3-fold upregulation by 7dpd (Lin et al., 2012). Blondelle et al., (2015) also 
reported an upregulation of Hacd1-fl in differentiating C2C12 cells that peaked at a 6-fold 
upregulation at 3dpd before decreasing again by 5dpd. Walmsley, (2013) similarly conducted 
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qRT-PCR assays and found Hacd1 total and Hacd1-fl to increase significantly by 2dpd with 
upregulation sustained throughout myogenesis up until 14dpd. 
In the Hacd1-kd cells used in this study, Hacd1-total significantly reduced in comparison with 
controls after 8dpd and Hacd1-fl was significantly knocked down from 4dpd onwards. Lin et 
al., (2012) reported the upregulation of Hacd1 seen in control cells to be completely absent in 
their Hacd1-kd cells. Blondelle et al., (2015) also saw no increase in the Hacd1 expression in 
Hacd1-kd cells and Walmsley, 2013 found an 80% knockdown at all time points studied in 
the Hacd1-kd cells. 
The differences seen between Blondelle et al., (2015), Walmsley, (2013) and Lin et al., (2012) 
and the results here in regards to knockdown may be due to the cell clones used although this 
would not explain the variation seen between this thesis and the results from Walmsley, 
(2013). Knockdowns using transfected plasmids are sensitive to efficiency loss: methylation 
of CMV promoters have been associated with this (Moritz et al., 2015). Differences in cell 
culture are likely to have affected the rate of differentiation and myotube fusion seen within 
the cells (Blondelle et al., 2015; Lin et al., 2012). Since this has been linked with Hacd1 
expression (Blondelle et al., 2015) this could also explain the differences seen in Hacd1 
expression across laboratory groups. Importantly, the knockdown was present after 8dpd in 
the more mature myotubes which this chapter aimed to study. 
Quantitative RT-PCR assays of the other three Hacd genes demonstrated no significant 
difference between control and Hacd1-kd cells from 4dpd onwards, after the upregulation of 
Hacd1. Therefore, we could not detect a significant compensatory upregulation of these genes 
in the Hacd1-kd cells over the time points where they were deficient in Hacd1 vs controls. 
This was particularly important for Hacd2 which has high sequence homology to Hacd1, 
Hacd2 elongates the same classes of lipids and it has been hypothesised that Hacd2 could 
have been responsible for compensating in a Hacd1-knock out mouse model (Sawai et al., 
2017). The results confirmed that this was not the case in these cells and we would suggest 
therefore that expression of other Hacd genes would not have contributed to any differences 
seen between cell types in later stages of differentiation. Surprisingly Hacd3 and Hacd4 
expression were both higher in the Hacd1-kd myoblasts in early myogenesis in comparison 
with controls (cells from 0-2dpd and 0-1dpd respectively).  This may be due to the dynamic 
process of cellular fusion which could be further investigated using membrane fluidity studies 
such as in Blondelle et al., (2015). Nevertheless, these differences are unlikely to affect any 
results seen when looking at later stages of differentiation as there was no significant 
upregulation at those time points.  It is also possible that HACD3 and HACD4 have functional 
differences to HACD1 (Sawai et al., 2017), and so cannot elongate VLCFA in a compensatory 
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manner. Hence the early expression changes seen for Hacd3 and Hacd4 are less important for 
understanding HACD1-deficiency. Blondelle et al., (2015) evaluated Hacd2 and Hacd3 in 
their Hacd1-kd cell model (but not Hacd4) and found no upregulation. The work in this thesis 
confirmed these findings for Hacd2 and Hacd3, obtained expression data for Hacd4 and in 
addition evaluated all hacd enzymes over a much longer time course and at later stages of 
differentiation. Thus, it can be concluded that Hacd2-4 are unlikely to be acting in a 
compensatory manner here. 
 Hacd1-kd cells differentiate comparably to control C2C12 cells 
Cells in this chapter differentiated into mature, multinucleated myotubes independent of 
Hacd1 expression, yet the Hacd1-kd myotubes did appear to have an increase in the aberrant 
cluster of nuclei in the Hacd1-kd myotubes, though this was not found to be significant. We 
would hypothesise that the current dataset lacked power and so if it was increased the number 
of abnormal nuclear clusters in Hacd1-kd cells might become significant. Previous literature 
on abnormal nuclear clustering was performed at 12dpd and found to be significantly 
increased with Hacd1-deficiency (Walmsley, 2013; Walmsley et al., 2017). This suggests that 
the abnormal nuclear clustering could be progressive within the cells, as is seen in the canine 
CNM phenotype (Blot et al., 2002; Tiret et al., 2003). 8dpd was chosen in this thesis due to 
the temperamental nature of cell differentiation once taken past this time point. We speculate 
these abnormal nuclei clusters develop with the cells due to a disruption in internal membrane 
systems that are known to occur in HACD1-CNM (Walmsley et al., 2017) and it is possible 
that these clusters represent the centralised nuclei seen in vivo (Blot et al., 2002; Roman & 
Gomes, 2018; Spiro et al., 1966).  
Myogenic differentiation has been assessed in C2C12 cells and Hacd1-kd C2C12 cells in a 
number of papers. Blondelle et al., (2015) and Lin et al., (2012) reported that in their cell clone 
Hacd1-kd cells did not differentiate well, indicated by a significantly decreased fusion index. 
However, different sera (e.g. canine instead of equine serum) and different growth surfaces 
have been observed to rescue the fusion-defect in Hacd1-deficient myoblasts by this group 
(Tiret, personal communication). This may be the mechanism by which embryonic canine 
myofibres fuse:  via VLCFAs provided to developing canine embryos by the placenta 
(Duttaroy, 2009). 
Using the same cell clone as in this thesis, Walmsley, (2013) reported their Hacd1-kd cells to 
fuse and form myotubes: this was hypothesised due to a partial phenotype rescue by fatty acids 
in the differentiation media or the particular serum used, or the surfaces cells were cultured 
on however objective measures of differentiation were not evaluated. Differentiation of 
control and Hacd1-kd myotubes at 8dpd was quantified by scoring the fusion index, 
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differentiation index and myotube density – of which there was found to be no significant 
difference between control and Hacd1-cells. Thus these cells were capable of differentiation 
independent of Hacd1 expression in these experiments.  The cells appeared to have some areas 
of intense RYR1 staining with an area of high stain surrounded by an abnormal nuclear cluster, 
which indicated a potential inconsistency in sarcoplasmic reticulum development, and that 
this coincided with aberrant clustering of myonuclei. Quantification of RYR1 and DHPR 
within myotubes by western blotting would be the logical next step to confirm any altered 
protein expression. There were a number of stained areas within Figure 3.12 that did not 
appear to be within cells – possibly on a higher focal plane than the cells themselves. The cells 
were temperamental and often hard to differentiate to later time points and so we speculate 
that these areas are most likely cell debris which is increased in kd cultures, for example from 
cells that have apoptosed and peeled away from the surface. Confocal microscopy would 
provide higher resolution images to confirm this.  
 Characterising electrophysiological properties affected by Hacd1 knockdown 
in undifferentiated myoblasts 
Hacd1-kd cells were found to differentiate comparably to the control cells and Hacd1 
deficiency was confirmed in the differentiated myotubes in Hacd1-kd cultures compared with 
controls. Myoblasts and myotubes of 8dpd were used to evaluate the electrophysiological 
properties of the cells with the focus on single ion channel analysis. This part of the study 
aimed to work towards characterising a basic phenotype of ion channels present in the cells 
since there is strong evidence to suggest that the predicted changes in free calcium handling 
would result in changed activity in calcium activated potassium channels.  We therefore 
characterised a number of electrophysiological parameters from C2C12 with and without 
Hacd1 expression.  
Accurate determination of the RMP was essential before undertaking single channel recording 
because the RMP was used in the calculation of channel reversal potentials (Equation 3). 
Furthermore, increase in intracellular calcium would be expected to lead to depolarisation of 
cells, via activation of constituently expressed BK channels (Vergara et al., 1998), and also 
an altered RMP would be expected to, in turn, alter the calcium handling.  The cells RMPs 
were recorded and were found to be significantly more polarised in 8dpd myotubes for both 
control and Hacd1-kd cells, which was expected as by 8dpd C2C12 have differentiated into 
excitable cells (Cárdenas et al., 2004). Membrane potential is an important control mechanism 
for cellular differentiation and maturation (Abdul Kadir et al., 2018). RMP was not 
significantly different when Hacd1 was knocked down in either myoblasts (although it was 
significantly more variable within Hacd1-kd myoblasts) or myotubes. As Hacd1 expression 
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levels are comparable in myoblasts (and Hacd1-fl levels are very low prior to differentiation) 
in both cell types it could be conjectured that there may not yet be any significant changes 
within the cell populations. However, the RMP was also found to be similar within control 
and Hacd1-kd myotubes suggesting that Hacd1-deficiency does not lead to insufficiently 
negative RMP within CNM muscle fibres. This is an important finding as ECC relies upon a 
negative basal RMP within the myofibres prior to the depolarisation of the membranes, which 
in turn triggers ECC through the opening of the DHPR and activates the SR calcium release 
(Robin & Allard, 2012). Therefore, we conclude that an increasingly positive RMP does not 
contribute to altered calcium homeostasis in Hacd1-kd C2C12 cells. 
Previous electrophysiological studies on the C2C12 myoblasts and myotubes, have reported 
similar RMPs to that seen in the control cells in this study. Yet these studies only looked at 
myoblasts or myotubes and not both. Tanaka et al., (2017) found myoblasts to have an average 
RMP of -15mV and Asano et al., (2015) found C2C12 myotubes to have a RMP of -32mV 
which was only 1mV different from our average RMP recordings for control myotubes. These 
values for RMP correspond well with control cells from this study. 
The ideal way to monitor ion channels in large cells such as muscle or myoblasts is 
cell-attached patch. This technique does not require the experimenter to control the membrane 
potential of the entire cell and also keeps the target cell intact (it does not alter intracellular 
calcium for example). During single channel recordings it was noticeably easier to seal 
Hacd1-kd myoblasts than the controls and therefore a larger dataset was collected for Hacd1-
kd myoblasts. A review by Suchyna et al., (2009) discusses five forces involved in biological 
patch-clamp seals: membrane tension, stresses from cytoskeleton, electroosmotic forces, 
membrane viscosity and adhesion energy of the membrane. Differences in any of these 
membrane properties could factor into Hacd1-kd cells forming seals easier: such as membrane 
fluidity, or viscosity, which has been reported to be reduced in Hacd1-kd cells at 3dpd 
(Blondelle et al., 2015) and this could provide a reason as to why the Hacd1-kd cells were 
easier to seal. Analysis through k-means clustering found there to be significantly different 
channels recorded between control and Hacd1-kd cells. This was unexpected as we 
hypothesised there to be no quantifiable differences between the cells; as Hacd1 expression 
levels are the same at this stage in differentiation and Hacd1-fl was not highly expressed at 
this stage in either control or Hacd1-kd cells. Hacd3 and Hacd4 were seen to have a 
significantly increased expression in early time points however so there may well be other 
early differences in the cells, independent of HACD1, leading to this difference in ion channel 
profile seen between control and Hacd1-kd myoblasts. One visible difference in the clusters 
of channels which may have contributed to the significant difference in clustering was the 
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presence of larger channels with conductances of 140pS and 240pS in the control myoblasts. 
Future patch-clamp of these cells could provide enough data to conclude that there is a higher 
frequency of larger channels in these cells but the limited data set means this conclusion cannot 
be made at this time. 
The predominant channels seen in both control and Hacd1-kd myoblasts were apparently not 
the anticipated calcium activated potassium channels, widely expressed in muscle, but non-
selective cation channels according to the IV (current-voltage) curves. Coupled with their 
single channel conductance and their high abundance this makes TRP channels (transient 
receptor potential) the primary candidates. TRP channels are non-selective channels made up 
of six transmembrane segments and are a highly diverse category of ion channel with varying 
levels of permeability towards different ions: often with permeability for calcium (Brinkmeier 
et al., 2011). The TRP channels can be segregated into seven subfamilies: TRPC, TRPV, 
TRPM, TRPN, TRPA, TRPP and TRPML (Venkatachalam et al., 2014). TRP channels have 
been studied in skeletal muscle, and gene expression data from rodent muscle has shown 
TRPC channels to be present, with TRPC1, C4 and C6 protein expression confirmed on the 
sarcolemma (Kruger et al., 2008; Sabourin et al., 2009) and TRPC3 has been reported to have 
a functional interaction with RYR1 (Lee et al., 2006). TRPC1 expression has been reported at 
all time points during muscle cell culture and differentiation whereas TRPC3 was found to 
upregulate with differentiation (Formigli et al., 2009; Louis et al., 2008). A study by Zanou 
et al., (2010) concluded that TRPC1 channels regulate the entry of Ca2+ during repeat 
contractions and is important for muscles to maintain their force throughout these 
contractions. They reported their TRPC1 channels from murine fibres to have a conductance 
of 13pS (Zanou et al., 2010). Whilst blockers of TRP channels do exist and could theoretically 
be used to provide confirmation of phenotype, few of these inhibitors are very selective and 
so further work in this area may require si-RNA knock-down experiments.   
The channels seen in the myoblasts in this study, and hypothesised to be TRP channels, had 
conductance’s of 18 and 22pS (control and Hacd1-kd myoblasts respectively) which are only 
a little bigger than the previously reported conductance of the TRPC1 channel (13pS) (Zanou 
et al., 2010). As TRPC1 has been reported to be localised to the sarcolemma and reported of 
similar size we hypothesise that the TRCP1 is a likely candidate for the channel reported in 
this study. Conversely; a study by Berbey et al., (2009) found opposing results for TRPC1 and 
stated that it is actually localised to the SR where it acts as an SR Ca2+ leak channel as opposed 
to aiding influx of Ca2+ into the cell via the plasma membrane. This study would require 
pharmacological interventions in order to fully establish the channel seen in the myoblasts. 
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As well as TRPC1-like channel, the predominant channel seen in the Hacd1-kd cells appeared 
to have unusual rectifying properties, this can be distinguished by the sigmoidal fit of the line 
and so this channel may be different to the one in the control cells. TRPC5 has been reported 
to have rectifying properties (Obukhov & Nowycky, 2004); but there is little data on TRPC5 
within skeletal muscle suggesting it may not have significant expression there. TRPC3 has 
inward and outward rectification (Alexander et al., 2011) and although it has not been reported 
to be expressed on the sarcolemma, TRPC3 could be the channel seen in the Hacd1-kd 
myoblasts and due to its functional coupling with RYR1 would be an interesting channel to 
study further in this cell line (Lee et al., 2006). Of the TRPV family, an ion channel array on 
C2C12 myoblasts found TRPV2 and TRPV4 to be present in the cells (Morgan et al., 2018). 
TRPV4 channels tend to be larger than the channels seen in these recordings so it was unlikely 
to be a TRPV4 channel – TRPV2 is a possible candidate for this channel (Alexander et al., 
2011). TRPV2 has roles in accelerating membrane depolarisation and therefore triggering 
ECC, this would therefore be an interesting channel to investigate further (Zanou et al., 2015). 
 Characterising electrophysiological properties affected by Hacd1 knockdown 
in differentiated myotubes 
As myotubes were more difficult to get sufficient seals and clear traces from, the number of 
channels recorded in both control and Hacd1-kd was fewer than in myoblasts, and for this 
reason only four clusters were used to cluster data. As with myoblasts one of the visible 
differences between channels in control and Hacd1-kd myotubes was the presence of large 
channels. In control myotubes there was one large channel of just below 400pS, however it 
was only one channel and the number of channels detected in the myotubes was low. This lack 
of channel data could be the reason there was no significant difference seen between control 
and Hacd1-kd channel phenotype clustering. Predominant channels seen in both the control 
and Hacd1-kd myotubes were harder to identify than those seen in myoblasts. The reversal 
potentials for the channels seen in myotubes was -44mV ± 14mV for the control and -35mV 
± 15mV for the Hacd1-kd myotubes. These fall quite close to that of Cl- ions (-66mV). It is 
worth bearing in mind though that there was an error of 14/15mV therefore the reversal 
potential could be higher or lower than calculated.  
Chloride channels are involved in regulating the excitability of myofibres, and a major 
chloride channel of muscle is the voltage-gated C1C-1 channel (Alexander et al., 2001; 
Fahlke, 2011). C1C-1 channels are found along the t-tubule membrane systems and mutations 
cause myotonia, highlighting their importance for skeletal muscle function (DiFranco et al., 
2011; Koch et al., 1992). The channel seen in the cells was unlikely to be a Cl- channel as 
these are not often seen in patch-clamp experiments due to their small conductance (often 
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around 2pS) which means they are often hidden by other larger conductance channels 
(Alexander et al., 2011). Chloride channels are also thought to only activate at high or low 
voltages (±~100mV) (Syeda et al., 2016). Therefore, it is unlikely that the channels seen were 
chloride, and further pharmacological/molecular intervention experiments should be 
conducted to help with identification. 
The other candidate for these unknown channels could also be a TRP channel like those seen 
in the myoblasts. Kruger et al., (2008) reported the most abundant TRP channels in murine 
skeletal muscle to be: TRPC3, TRPC6, TRPV4, TRPM4 and TRPM7. Some of these channels 
are of similar conductance to the channels seen in the myoblasts in this study (65pS in control 
and 39pS in the Hacd1-kd myotubes).TRPM7 has been reported to have a conductance that 
varies from 40-105pS, TRPC6 has a conductance of around 28-37pS and TRPC3 is 
approximately 66pS in conductance (Alexander et al., 2011). Further patch-clamping and the 
use of channel blockers would be the next step in this research to define the channels seen. 
Further work in this cell culture model would involve not only an increased n number of single 
channel recordings in myotubes but measuring calcium responses by using HEPES buffer 
containing high KCl concentration perfusion to depolarise control myotubes and assessing 
changes in gating or channels present – particularly for the calcium-activated potassium 
channels we speculate would be activated during this protocol. Channel inhibitors would be 
advantageous to truly determine which channels were seen to be present in the cells. This was 
not done during this study as the focus was the global ion channel phenotype initially. Ion 
channel qRT-PCR would also allow us to determine changes in channel expression associated 
with Hacd1 knockdown and this would help with identification of channels seen in recordings. 
The rectifying channel seen in Hacd1-kd myoblasts is an uncommon channel phenotype to 
detect and this therefore would be interesting to explore further using the suggested methods. 
 Conclusions 
From the work done in this chapter it can be concluded that Hacd1 is upregulated during 
myogenic differentiation in C2C12; this upregulation was abolished in the Hacd1-kd cells 
where Hacd1 expression remained consistently low and was not associated with a 
compensatory upregulation of Hacd2-4 expression. Differentiation was comparable in both 
control and Hacd1-kd myotubes suggesting that in these cells the HACD1-deficiency did not 
affect differentiation. Hacd1 may still be implicated in cell fusion as previously described 
(Blondelle et al., 2015), we have excluded compensation from Hacd2-3, therefore the cells in 
this study may have partial rescue due to lipids and fatty acids from the serum. Differences 
were apparent between our findings and those of previous studies in these cells and their 
phenotype appears to vary dependent upon culture conditions – perhaps most likely relating 
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to presence of lipids particularly VLCFA in differentiation media. Electrophysiological 
profiles, including the variance of myoblast RMP, were shown to be significantly different 
between control and Hacd1-kd myoblasts however this is unlikely to be related to HACD1 as 
the time point is prior to Hacd1 upregulation and Hacd1-fl and total Hacd1 expression were 
similar between control and kd myoblasts. There was no difference demonstrated in the 
myotubes, however a more extensive study with a larger data set might have been able to 
detect more differences. There was little evidence for differential activity of calcium-activated 
potassium channel activity during these experiments, therefore continuing on from this work 
to depolarise cell membranes would be an appropriate next step. The predominant ion 
channels recorded in both myoblasts and myotubes could instead be TRP channels however 
this is inconclusive since no pharmacological/siRNA interventions were used to confirm it. 
As TRP channels are involved in calcium movement these channels may provide a novel angle 
for studying altered calcium homeostasis, as seen in CNM, research (Alexander et al., 2011; 
Brinkmeier et al., 2011; Jungbluth & Gautel, 2014). Overall this study has provided ground 
work to continue study calcium responses and ECC within this cell model. These cells are far 
less complex in their internal structures than myofibres however and so more complex models 














4 Lipidomic effects of Hacd1 deficiency in a myogenic cell 
line 
 Introduction 
The HACD enzymes (HACD1-4) catalyse the dehydration stage in the four-step cyclical 
process of VLCFA elongation (>20 carbons). The other elongase complex enzymes are: fatty 
acid elongase1-7 (ELOVL1-7), 3-ketoacyl-CoA reductase (KAR) and trans-2-enoyl-CoA 
reductase. The dehydration step catalysed by the HACD enzymes is rate-limiting, as seen by 
the accumulation of 3-hydroxyacyl-CoAs seen in in vitro FA elongation assays (Ikeda et al., 
2008; Sassa & Kihara, 2014). 
The active full-length isoform of HACD1 is specifically expressed in striated muscles where 
fatty acids with longer chain lengths are stored within more complex lipids such as 
sphingolipids and glycerophospholipids (Kihara, 2014; Morales et al., 2017; Watt & Hoy, 
2011). VLCFA-containing molecules are of importance within biological membranes and 
used as ‘structural’ lipids (Baur et al., 1998); in particular, the phospholipids with VLCFA 
constituents provide strength and curvature to membranes (Guillou et al., 2010; Molino et al., 
2014; Schneiter et al., 2004). Glycerophospholipids (GPL), glycerol based phospholipids, are 
the most abundant phospholipid found in cell membranes and the most important mammalian 
GPL’s include phosphatidylcholine (PC) phospholipids incorporating a choline head group 
(Blanco 2017). GPL’s vary in chain length and very long chain GPL’s have been reported at 
lengths of 20-24 and PC has been reported at lengths of up to 36 carbons (Maier et al., 2016; 
Sigruener et al., 2014). In the L6 muscle line GPLs in total membranes represented more than 
50% of total lipids with PC contributing highly (Briolay et al., 2013). 
Lipid membranes are dynamic and within muscle cells are redistributed and recruited during 
myoblast fusion and myotube formation. Membrane composition changes during early 
differentiation to allow fusion to occur in sections of cholesterol free membrane (Mukai et al., 
2009). Cholesterol composition is associated with membrane fluidity and decreases in relation 
to GPL’s over myogenic differentiation (Briolay et al., 2013; Mukai et al., 2009). Relative 
saturation of fatty acids also decreases during differentiation and influences membrane 
fluidity, PUFA (polyunsaturated fatty acid) supplementation has been reported to increase 
myogenic differentiation in L6 cells (Briolay et al., 2013).  
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Membrane abnormalities within skeletal muscle of HACD1-CNM affected dogs are 
progressive, including both sarcolemmal and t-tubule system membrane disorganisation and 
mislocalisation of the triads. The roles of VLCFA in developing and mature muscle are poorly 
understood. Although the pathological changes in CNM-affected dogs, high lipid content 
within cellular membranes and the role of HACD1 in lipid biosynthesis would suggest a 
function in tubuloreticular membrane development and maintenance (Al-Qusairi & Laporte, 
2011; Blanco, 2017). Blondelle et al., (2015) researched the effects of Hacd1 deficiency in 
C2C12 cells using a knockdown which resulted in abnormal early myogenesis – the cells were 
unable to fuse. A decrease in lysophosphatidylcholine (LPC) was observed in differentiating 
controls at 3 days post differentiation (dpd) (Blondelle et al., 2015). Previous work by Leikina 
et al., (2013) showed LPC levels reduced to allow cell membrane fusion and inhibited 
myoblast fusion when added to cell culture media. (Leikina et al., 2013). The decrease in LPC 
did not occur in Hacd1-kd cells but was restored, rescuing the phenotype and allowing 
myoblast fusion to proceed by re-expression of Hacd1-fl. This suggests the drop in LPC during 
differentiation was dependent upon HACD1 activity. At 3 days of differentiation, Hacd1-kd 
cells had higher SFA (saturated fatty acid) and lower MUFA (monounsaturated fatty acid) 
content than control cells at this stage of differentiation and these differences were also 
rescued with Hacd1-fl expression. Higher levels of unsaturated phospholipids are associated 
with an increase in fluidity of lipid bilayers and it is believed that PUFAs provide a less packed 
membrane (Briolay et al., 2013; Maxfield & Tabas, 2005). Blondelle et al., (2015) reported a 
9% decrease in membrane fluidity in Hacd1-kd myotubes which corresponded to previous 
literature as the Hacd1-kd cells had reduced MUFA content (Blondelle et al., 2015). Blondelle 
et al., (2015) also reported that proportions of VLCFA increased within control cells between 
myoblasts and myotubes (3dpd) and that Hacd1-kd did not show this increase and in fact had 
significantly lower levels of VLCFA in both myoblasts and myotubes. This work by Blondelle 
et al., (2015) has provided us with knowledge of lipid changes within early differentiating 
C2C12 cells as evaluated by GC- and LC-MS and the effects of Hacd1-kd on early myogenesis 
and myotube fusion. Their work also correlates with that seen in yeast when knocking down 
levels of the HACD1 homologue, Phs1. When Phs1 levels were decreased, an accumulation 
of long chain bases was reported alongside an accumulation of ceramide and decrease in more 
complex sphingolipids (Kihara et al., 2008). 
Walmsley, (2013) used similar cells to those used by Blondelle et al., (2015) (cells contained 
the same plasmid and shRNA sequence but were a different clonal population in which cells 
retained the ability to fuse and differentiate) and found 80% knock down of Hacd1 expression 
levels throughout differentiation. These cells were used to obtain more detailed information 
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on HACD enzyme expression during development and intracellular membrane structure and 
function. We have concluded from the previous experiments, as described in Chapter 3 that 
both the control and Hacd1-kd cell differentiate in to mature myotubes. In addition, that when 
Hacd1 is knocked down in later stages of differentiation, there is no upregulation of the other 
Hacd genes to compensate for this loss. Differences in ion channel presence between the 
control and Hacd1-kd cells were identified, suggesting sarcolemmal membrane differences. 
In this chapter these cells were used to evaluate changes of the C2C12 lipidome by proton 
nuclear magnetic resonance (1H-NMR) lipidomics in control cells and Hacd1-kd cells for 
comparison.  
1H-NMR provides detailed information on molecular structure through analysis of spectra 
produced via the principal of nuclear spin. Different lipids provide the spectra with unique 
peaks produced by the environment of specific hydrogen atoms within the molecule allowing 
the detection of certain lipids. These can also be quantified due to properties of NMR as signal 
intensity is directly proportional to the number of hydrogens present in that environment. (Li 
et al., 2017). NMR is a cost effective, robust method to analyse lipids and was therefore chosen 
for this study as an initial step in characterising the cells lipidomes (Emwas et al., 2015). 
 
 Chapter aims & hypotheses 
Due to the role of HACD1 in the elongation of VLCFA, we hypothesised there would be a 
significant difference in the lipidome of C2C12 cells once Hacd1 was knocked down. The 
work of this chapter sought to: 
1) Evaluate the lipidome of differentiating C2C12 myoblasts and myotubes up to 12 days 
post differentiation to evaluate early and late changes during differentiation; 
2) Evaluate the lipidome of differentiating Hacd1-kd C2C12 cells to identify and 









 Cell culture and collection 
Control and Hacd1-kd C2C12 myoblasts (0 dpd) and myotubes (1, 2, 4, 6, 8, 10- and 12- dpd) 
were grown and differentiated in T25 flasks (Corning) as described previously (Section 3.2.1) 
and harvested using a cell-scraper and ice-cold Dulbecco’s phosphate buffered saline (DPBS) 
(Sigma Aldrich). Efficient scraping was verified visually before centrifuging at 13,000g for 
one minute. Pellets were then snap frozen before storing at -80°C. 
 Lipid Extraction 
Ice cold solvents were required for this work, and to the frozen cell pellets 500μl chloroform 
(CHCl3) (Sigma Aldrich) was added. Samples were then sonicated in two x 30 second intervals 
including a 30 second pause in between. Samples were vortexed briefly before incubating at 
4°C for 10 minutes.  Then samples were centrifuged for 10 minutes at 21,500g and 4°C. The 
supernatant was snap frozen in liquid nitrogen and lyophilised to remove any solvent and 
solidify samples. 
 Lipid Extract Preparation 
As proton NMR (1H-NMR) detects H+ ions, 200μl of deuterated chloroform (CDCl3, Sigma 
Aldrich) was added to lyophilised material before vortexing briefly and centrifugation at full 
speed for one minute. Supernatant was transferred to a new tube and spun again if high levels 
of debris were present. Clean diluted samples were then transferred to 3mm (outer diameter) 
NMR tubes. 
 NMR spectrophotometer runs  
All samples were run on a Bruker Avance III HD spectrometer with a TCI cryoprobe and 
chilled SampleJet autosampler with a field strength of 700.17MHz. Software for acquisition 
and processing was carried out using Topspin 3.1. Spectra were acquired and pre-processed 
according to standard metabolomics practices (Beckonert et al., 2007) by an NMR 
spectroscopist at the Shared Research Facility for NMR metabolomics. Briefly 1D 1H-NMR 
NOESY standard vendor pulse sequence (all parameters constant between samples) was used 
to acquire with a 25ppm spectral width and 32 scans (four minute experiment) at 15°C to 
offset the volatility of the chloroform. Pre-processing of spectra proceeded using automated 
standard vendor routines (Fourier transform, phasing and window function) and spectra was 
aligned using the residual CHCl3 peak at 7.26ppm due to the impurity of CDCl3 (99.8%). 
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 Peak QC and analysis 
Stringent quality control was performed on all samples.  Any samples failing these limits were 
re-run up to three times, at which point the sample was discarded from analysis. Phasing of 
lines was checked by eye to ensure a straight baseline and manually corrected where required. 
The CHCl3 reference peak was checked to ensure it was a clear single peak, consistent between 
samples and that the half height peak width was < 1.1MHz. 
 Pattern file assembly  
Using a collection of spectra from a variety of samples, all peak positions were noted down in 
a file with their spectral position (parts per million, ppm). Where possible peaks were 
identified and annotated, unfortunately lipid extracts had many unknown peaks due to the 
novel nature of the technology. The pattern file was checked using the Tame NMR Galaxy 
software which overlaid the pattern file with provided spectra to check all peaks within the 
spectra were accounted for and pattern file was amended accordingly (See Figure 4.1). This 
file was then used to ‘bucket’ or ‘bin’ the data into numerous blocks for analysis. 
 
Figure 4.1: Tame NMR outputs.  
Figure shows a selection of spectra run against the final pattern file created (grey boxes), with no peaks 
unaccounted for. Inset displays a previous Tame NMR run with an incomplete pattern file, which when 
run in Tame NMR highlighted missing sections (annotated with asterisks). 
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 Spectra annotation  
To quantify specific hydrogens or head groups of lipids the pattern file and spectra were 
annotated where possible. Figure 4.2 shows the peaks used to quantify proportions of saturated 
fatty acids (SFA) represented by a single carbon bond (HC-CH), poly unsaturated fatty acids 
(PUFAs) represented by the hydrogens between two double bonds (-CH=CH-CH2-CH=CH-) 
and also for unsaturated fatty acids (MUFA/PUFA) represented by hydrogens either side of 
one double bond (HC=CH). These peaks at ~1.3ppm, ~2.8ppm and ~5.4ppm were assigned 
respectively. Figure 4.3 shows lipid head groups annotated on to the same sample spectra. 
Head groups from lipids can be identified by numerous peaks but for quantification only one 
peak was used. The PC peak used for annotation was the characteristic peak for the PC lipid 
class found at ~3.3ppm, representing the hydrogens from the three methyl groups in the 
choline head. The peak used to quantify GPL was found at ~4.1-4.2ppm and was produced 
from the glycerol backbone of the GPLs. 
 
Figure 4.2: C2C12 sample spectra with positional hydrogens annotated.  
Annotations includes hydrogens on either side of a carbon double bond (~5.4ppm), hydrogens between 






Figure 4.3: C2C12 samples with lipid head groups annotated.  
Annotations include: monounsaturated/polyunsaturated fatty acids (MUFA/PUFA), 
glycerophospholipids (GPL) phosphatidylcholines (PC), free cholesterol (FC) and 
lysophosphatidylcholine (LPC). For lipid classes with more than one peak, the respective peak used for 
quantification is shown in bold red font.  
 
 Outlier analysis 
The sensitivity of 1H-NMR detects confounding variables within samples, including those 
down to human error, sample degradation, or experimental conditions (Xia et al., 2011). 
Samples with great variability causing them to lie outside the 95% confidence interval in a 
PCA scores plot, were initially identified as outliers and put through preliminary statistical 
testing. Peak intensities for each biological population were averaged and those that were 
identified by the PCA plots as being outside the confidence intervals, such as ‘ct_d00_r12’ 
and ‘kd_d00_r14’ in Figure 4.4 were tested. If over 30% of a sample’s peaks lay outside one 
standard deviation of the peak mean average then the sample was removed as an outlier. 
The initial sample size for each population was 15, but after peak quality control and outlier 
analysis and removal numbers were as follows: control 0 dpd n = 11, 1 dpd n = 12, 2 dpd = 
13, 4 dpd = 9, 6 dpd = 11, 8 dpd = 11, 10 dpd = 12, 12 dpd = 14. Knockdown 0 dpd = 10, 1 






Figure 4.4: Lipidomic profile for control and Hacd1-kd C2C12 cells at 0 days post differentiation 
(dpd) displaying outlying samples.  
Samples ct_d00_r12 and kd_d00_r14 lay outside the 95% confidence region for their group (red and 
green shaded areas respectively). 
 
 Reproducibility analyses 
Three technical replicates were seeded simultaneously for both control and Hacd1-kd cell 
lines, and  repeated five times to create a total n=15. Days 1 and 12 were chosen to represent 
both early and late stages of the experiment. Metaboanalyst software requires a minimum 
group size of n=3 and so reproducibility analysis was undertaken on spectra that had passed 
quality control before outlier removal, as all 15 samples were required to provide the software 
with five groups of three.  
 Statistical analysis 
Data was normalised by median peak intensity and pareto scaled. Pareto scaling scales larger 
fold changes more heavily than small changes allowing smaller changes to be more easily 
identified. It uses the square root of the standard deviation as a scaling factor (van den Berg et 
al., 2006). Multivariate lipidomic analysis, including heat maps and PCA or PLS-DA (partial 
least squares-discriminant analysis) scores plots were performed using Metaboanalyst (Xia et 
al., 2011), an open source online software. The multivariate analyses were used to show any 
151 
 
clustering between samples: PCA or PLS-DA score plots. PLS-DA test outputs are in the form 
of two values, R2: degree of fit to data, and Q2: predictive power. Q2 values >0.4 were thought 
to be acceptable for a biological model (Worley & Powers, 2013).  
ANOVA and student t-test results were conducted in GraphPad (GraphPad Software Inc) are 
shown as mean results with error bars indicating the standard error of the mean (SEM). 
Significance scores were as follows: * indicates p≤0.05, ** indicates p≤0.01, *** indicates 
p≤0.001 and **** indicates p≤0.0001. Or in the case of graphs with high numbers of 
significant comparisons: black dash line indicates p≤0.05, black solid line indicates p≤0.01, 

















 Lipid extraction and analysis reproducibility 
To provide confidence in the sample sizes chosen and in the consistency of experimental 
procedure, the reproducibility of control and Hacd1-kd samples at 1dpd and 12dpd were 
assessed qualitatively by use of PCA scores plots. Between control myotubes (12dpd) and 
both Hacd1-kd myoblasts (1dpd) and myotubes (12dpd) there was little separation between 
clusters. Control 1dpd samples were the most variable between the cell seeding groups with 
two clusters (“ct_d01_4” and “ct_d01_5”) separated out entirely on their own. Groups in 
control 1dpd may be separated out further due to outliers which were subsequently removed. 
The variation between control 1dpd samples can be seen in the context of all four groups in 
Figure 4.6. Samples within group “ct_d01_4” continued to cluster separately and were 






Figure 4.5: Reproducibility of C2C12 biological replicates.  
Unsupervised PCA scores plots for control and Hacd1-kd C2C12 myoblasts at 1-day post 




Figure 4.6: In-group and between-group variation of control and Hacd1-kd at 1 day post 
differentiation (dpd) and 12dpd.  
PCA scores plot for the 20 groups assessed for reproducibility. Shading represents the 95% confidence 
region. 
 
 Lipidome changes over differentiation C2C12 cells  
Before comparing lipidomic profiles after Hacd1 knock-down in a C2C12 cell line (and 
therefore HACD1 activity reduced), the lipidomic profile in control cells was established. 
Figure 4.7 shows PCA scores plot used to identify major differences in lipids between cells as 
they fused together from single myoblasts, 0dpd, into multinucleated, mature myotubes at 
12dpd. Figure 4.7 shows control cells grouped by time point (days post differentiation, dpd). 
Here there was no distinct clustering with any time point although there was slight variation 
in cluster shapes, represented by the cluster’s shaded areas.  
Figure 4.8 shows a supervised multivariate partial least squares-discriminant analysis 
(PLS-DA) plot of control cells both before and after the upregulation of Hacd1. The clusters 
of both groups overlap and the PLS-DA values: R2 and Q2 show the model of separation 





Figure 4.7: Lipidomic profile for control C2C12 cells over 12 days of differentiation. 
Unsupervised PCA scores plot showing no distinct clustering with samples grouped into individual time 
points (days post differentiation, dpd). All data was normalised by median peak intensity and shading 






Figure 4.8: Lipidomic profile for control C2C12 cells over differentiation; before and after 
upregulation of Hacd1.  
Supervised multivariate analysis by a two component PLS-DA (partial least squares-discriminant 
analysis) plot of samples grouped into those before (0, 1 and 2 dpd) and those after (4, 6, 8, 10 and 12 
dpd) the upregulation of Hacd1. No distinct clustering was seen and the R2 and Q2 values (0.17 and 
0.044 respectively) indicated a poor ability in the model to distinguish between the two sets of samples. 
All data was normalised by median peak intensity and shading represents the 95% confidence regions. 
 
After examining the control cells lipidomes, we examined individual lipid phenotypes to 
quantify changes over differentiation namely, the structure of the lipid hydrocarbon chains. It 
had been documented previously that the ratio of saturated: unsaturated fatty acids decreases 
over earlier C2C12 differentiation (up to 3dpd). Therefore, peaks were tested that represented 
this to assess if our cells were conforming to this ratio change over a longer time scale than 
previously reported (Blondelle et al., 2015). The peaks chosen for this represented the double 
carbon bond (HC=CH) seen in MUFAs and PUFAs and the peak that was produced by 
hydrogens in a single carbon bond (HC-CH). The peak from a hydrogen between two double 
bonds was also quantified to represent PUFAs. Figure 4.9a shows raw values for these peaks 
and shows how the C-C peaks were more abundant due to their presence within all 
hydrocarbon chains, whether they were saturated or not. As it was incomparable as such (b) 
shows the normalised data and displays the relative saturation levels (C-C) decreasing over 
differentiation whilst the unsaturation (C=C) increases in relation. The decrease in relative 




Figure 4.9: Relative saturation levels of hydrocarbon chains in differentiating control C2C12 
cells. 
Measured by peak intensity of single bonds (C-C) double bonds (C=C) carbon bonds and PUFA as 
measured by the PUFA peak annotated in Figure 4.2 from 1H-NMR spectra. (a) Displays raw peak 
intensities showing the larger abundance of C-C bonds due to their presence in unsaturated fats also. 
All saturation levels increased over differentiation. (b) shows median normalised values in which 
saturation levels (C-C bonds) decreases relative to the double bonds (C=C and PUFA) over 
differentiation. Student t-tests between C-C and C=C bonds indicate the relative levels of hydrocarbon 
saturation were significantly decreased in 6dpd, 1-dpd and 12dpd (p<0.0001 for all significant results). 
Significance scores were as follows: * indicates p≤0.05, ** indicates p≤0.01, *** indicates p≤0.001 and 
**** indicates p≤0.0001 All data was normalised by median peak intensity. 
 
Lipid classes, by analysis of peaks produced by characteristics of lipid head groups were also 
analysed (Figure 4.10). A significant decrease in LPC was observed over myotube 
differentiation (ANOVA, p=0.0087) with post-hoc Tukey multiple comparisons indicating 
significance between 0-4dpd and 0-8dpd. GPL abundance were found to significantly decrease 
over differentiation (ANOVA, p<0.0001). Post-hoc tests indicated the most significance was 
between early and late time points. PC abundance significantly increased over differentiation 
(ANOVA, p<0.0001) with post-hoc analysis showing most significant increases were between 
early-late and middle-late differentiation, with little significant changes occurring between the 
early-middle time points. FC abundance also decreased over differentiation (ANOVA, 




Figure 4.10: Relative abundance of lipid head groups during C2C12 myotube differentiation.  
LPC = Lysophosphatidylcholine, PC = phosphatidylcholine, GPL - glycerophospholipids, FC = free 
cholesterol. Statistical testing done via one way ANOVA with Tukey post-hoc testing annotated on 
graph via lines. LPC, GPL & FC relative abundances decreased significantly over C2C12 differentiation 
(p=0.0087, p<0.0001 and p=0.0224 respectively). PC relative abundance significantly increased over 
differentiation (p<0.0001). All data was normalised by median peak intensity. Black dash line indicates 
p≤0.05, black solid line indicates p≤0.01, the red dash line indicates p≤0.001 and red solid line indicates 
p≤0.0001. 
 
 Lipidome comparisons between control vs Hacd1-kd C2C12 cells 
After gaining insight into the lipidomic profile of control C2C12 cells over differentiation, 
analysis was then performed between control and Hacd1-kd samples to identify any 
differences seen by 1H-NMR. As an initial look, all control and all Hacd1-kd samples over 
differentiation were grouped in order to perform a supervised PLS-DA. Figure 4.11 shows, 
overlap between the populations, yet there appeared to be a clear difference in population 





Figure 4.11: Lipidomic profile of Hacd1-kd C2C12 cells was moderately different to that of 
control cells.  
Multivariate supervised PLS-DA shows overlap between control and Hacd1-kd clusters but was 
moderately predictive of which samples belong in which group, R2=0.51 and Q2=0.36. All data was 
normalised by median peak intensity, shading represents the 95% confidence regions and for clarity 
only first two components of a five-component model are shown. 
 
 Lipidome changes between control and Hacd1-kd at time points 
To separate out differences between the control and Hacd1-kd cell population’s PLS-DA were 
performed at each time point. Figure 4.12 shows these plots along with Table 4.1 displaying 
PLS-DA scores. All time points had R2 values over 0.7 which indicates substantial model 
structure and Q2 over 0.4 suggesting predictive power within the model; with the exception of 




Figure 4.12: Control vs Hacd1-kd C2C12 cells at different time points during myotube 
differentiation.  
Panel of figures shows supervised, multivariate PLS-DA plots of control and Hacd1-kd cells at different 
days during differentiation (scores from tests shown in Table 4.1). Comparison at 1dpd has no predictive 
power, comparisons of 0, 2 and 12dpd shows weak predictive power between the day-wise 
comparisons, 4dpd and 8dpd show moderate predictive power and comparisons between 6dpd and 
10dpd show strong predictive power of the models. All data was normalised by median peak intensity, 










Table 4.1: PLS-DA scores for analysis shown in Figure 4.12.  
Days post 
differentiation (dpd) 
R2 Q2 Number of components 
0 0.72 0.23 3 
1 0.76 0.0203 5 
2 0.86 0.31 4 
4 0.95 0.58 5 
6 0.91 0.75 5 
8 0.88 0.51 5 
10 0.92 0.75 5 
12 0.88 0.43 5 
 
 Specific lipid phenotypes compared in control and Hacd1-kd cells throughout 
differentiation 
The same analysis to quantify saturation levels within control samples was then performed on 
the Hacd1-kd samples (Figure 4.13) and compared to the data from the control cells (Figure 
4.14). The saturation levels in Hacd1-kd cells followed the same trend as in the control cells. 
 
Figure 4.13: Relative saturation levels of hydrocarbon chains in differentiating Hacd1-kd C2C12 
cells.  
Measured by peak intensity of single bonds (C-C) double bonds (C=C) carbon bonds and PUFA as 
measured by the PUFA peak annotated in Figure 4.2 from 1H-NMR spectra. (a) Displays raw peak 
intensities showing slightly larger abundance of C-C bonds due to their presence in unsaturated fats 
also. All saturation levels increased over differentiation. (b) shows median normalised values in which 
saturation levels (C-C bonds) decreased relative to the double bonds (C=C and PUFA) over 
differentiation. Student t-tests between C-C and C=C bonds indicated the relative levels of hydrocarbon 
saturation were significantly decreased in 6dpd, 1-dpd and 12dpd (p<0.0001 for all significant results). 
Significance scores were as follows: * indicates p≤0.05, ** indicates p≤0.01, *** indicates p≤0.001 and 




Figure 4.14: Saturation levels of control and Hacd1-kd C2C12 cells over differentiation 
represented by relative abundance of C-C bonds in hydrocarbon chains.  
Both cell types followed an identical trend over differentiation and two-way ANOVA reported that the 
decrease in saturation levels over differentiation for both cell types was significant (p<0.0001) but there 
was no significant difference between control and Hacd1-kd saturation levels (p=0.8). All data was 
normalised by median peak intensity. 
 
Figure 4.15 shows lipid class abundance in both control and Hacd1-kd cells over 
differentiation. Relative abundances of LPC and FC were significantly different between 
control and Hacd1-kd samples by a two-way ANOVA (p=0.02 and p=0.04 respectively) over 
differentiation whereas PC and GPL were not significantly changed in Hacd1-kd cells (p=0.9 




Figure 4.15: Relative abundance of lipid classes in both control and Hacd1-kd C2C12 cells over 
differentiation.  
LPC = lysophosphatidylcholine, PC = phosphatidylcholine, GPL = glycerophospholipid, FC = free 
cholesterol. Two-way ANOVAs were performed and found that Hacd1-kd cells had significantly 
different LPC and FC abundances compared with control cells (p=0.0210 and p=0.0480 respectively). 
PC and GPL abundances were not significantly changed in the Hacd1-kd cells. Sidak’s multiple 
comparison tests were performed on control vs Hacd1-kd at each time point and there was no 












HACD1 is required for elongating very long chain fatty acids (VLCFAs) within striated 
muscle (Ikeda et al., 2008). When the HACD1 gene is mutated, such as in the canine 
neuromuscular disorder CNM, the enzyme activity is severely reduced (Blondelle et al., 2015; 
Muhammed et al., 2013; Pelé et al., 2005). Utilising a cell culture model with shRNA 
knockdown of Hacd1, this work describes changes seen in lipid phenotype through myogenic 
differentiation and the effect of Hacd1 deficiency. By understanding the effect that Hacd1 
deficiency has upon lipid content in cells it provides us with a deeper understanding of 
HACD1 function and which lipids are likely to be most affected in HACD1-CNM.  
 Establishing the lipid phenotype for control C2C12 cells over differentiation  
Work by Blondelle et al., (2015) provided initial insight into the lipid profile of C2C12 
myotubes as they began to differentiate over early time points within myotube fusion and 
differentiation up to 3 days post differentiation (dpd). We aimed to expand this further in the 
C2C12 cell line and identify later lipidomic changes associated with Hacd1-deficiency that 
might be related with abnormalities in intracellular membranes that occur later after fusion 
(Walmsley et al., 2017). When differentiating control C2C12 cells up to 12 days subtle 
changes were observed within the lipidome of the differentiating sample set using 1H-NMR. 
Samples were initially separated out by time point (dpd) and there was high overlap of group 
clusters within the PCA scores plot. Cluster size appeared reduced in later time points over 
the course of differentiation (Figure 4.7) which indicated that differentiation was associated 
with reduced variability in the lipidome. When samples were grouped into time points pre- 
and post Hacd1-upregulation (0-2 dpd and 4-12 dpd based on qRT-PCR, Chapter 3 Figure 
3.5) there were only subtle changes between the two groups, as with differentiating cells the 
cluster size was reduced after Hacd1 upregulation. This could suggest that inducing cells to 
differentiate leads to upregulation of Hacd1 and stimulates synthesis of specific lipids which 
increases the uniformity in the myotubes lipidome. Although this is a possible explanation, it 
has been reported that cultured cells have lipid profiles similar to the media in which they 
were cultivated (Briolay et al., 2013). In this study serum starvation was used to stimulate 
differentiation and the same batch of horse serum was used throughout the project for 
consistency (Bajaj et al., 2011; Jing, 2012; Walmsley, 2013). As proliferating C2C12 are 
easier to culture than differentiating C2C12 cells, FBS was not controlled as strictly. Therefore 
possible differences between batches of serum in proliferation media may have accounted for 
the increased variability seen in myoblasts and early stages of differentiation. Future work on 
lipid phenotype in these cells should ensure to use the same proliferation and differentiation 
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media throughout the project to assess whether the variability seen was due to culture 
differences or the biology involved in myotube fusion and differentiation. A study by Lee et 
al., (2009) reported fatty acid content of differentiation media for culturing C2C12 cells to be 
important modulators of proliferation and differentiation, providing further suggestion that 
FBS used in proliferating media should be consistent across lipidomic studies (Lee et al., 
2009). 
Considering more specific lipid changes during C2C12 differentiation, we looked at fatty acid 
chain saturation and abundance of LPC due to previous reporting in a Hacd1-deficient cell 
line (Blondelle et al., 2015). Ratios of fatty acid chain lengths within phospholipids in early 
differentiation have also been reported to favour chain lengths of 10-16 carbons over those of 
18-26 carbons in length when Hacd1 was knocked down (Blondelle et al., 2015). 
Unfortunately, this was not possible to detect by 1D 1H-NMR in this study. Blondelle et al., 
(2015) who described saturation levels of fatty acid chains within phospholipids within 
proliferating myoblasts and differentiating cells at day three of differentiation; found saturated 
fatty acids (SFA) were most abundant in control myotubes, followed by monounsaturated fatty 
acids (MUFAs) and least of all polyunsaturated fatty acids (PUFAs). Proportions of these fatty 
acids were comparable in the Hacd1-kd cells, and MUFA was significantly decreased when 
Hacd1 was knocked down. The work in this chapter demonstrates that relative amounts of 
fatty acid saturation decreased over differentiation with significantly lower saturation levels 
at 6, 10 and 12dpd after the upregulation of Hacd1. Our findings correspond to work by 
Briolay et al., (2013) in which they also reported a decrease in the saturated: unsaturated fatty 
acid ratio in differentiating L6 muscle cells from proliferation to 4-5 days differentiated. This 
decrease in fatty acid saturation leads to an increase in plasma membrane fluidity which has 
been reported to be a primary event in the fusion of myoblast membranes, before the rigidity 
is restored in the membranes post myoblast fusion (Prives & Shinitzky, 1977).  
Lysophosphatidylcholine relative abundance was significantly reduced over differentiation 
with significant changes occurring from 0-4 and 0-8dpd suggesting the LPC levels decrease 
in early-mid differentiation which coincides with cellular fusion (Blondelle et al., 2015; 
Leikna et al., 2013). The addition of LPC to cell culture medium has been reported to inhibit 
myoblast fusion and LPC content reduced in the C2C12 cell line between proliferating 
myoblasts and 3dpd cells (Blondelle et al., 2015; Leikna et al., 2013). Blondelle et al., (2015) 
determined that the drop in LPC seen up to 3dpd was dependent upon Hacd1 upregulation 
because it occurred in parallel with upregulation of Hacd1, was diminished by Hacd1-kd and 
the re-expression of Hacd1-fl normalised LPC levels and fusion. 
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Phosphatidylcholine, GPL and FC were also quantified due to their presence within muscle 
(Ladbrooke & Chapman, 1969; Mukai et al., 2009). PC relative abundance was significantly 
increased over differentiation and is reported to be an important plasma membrane 
phospholipid and one of the major phospholipids within skeletal muscle (Stefanyk et al., 
2010). Therefore, as myoblasts begin to differentiate and membranes fuse and reorganise 
themselves into more complex membrane systems the increased level of PC was expected. 
Significant changes were documented at 2 and 4dpd (Figure 4.10) coinciding with fusion and 
the onset of more complex membranes developing as the myotubes differentiate. 
Phosphatidylcholine rich membranes are relatively fluid and this corresponds with the 
decrease seen in saturation levels, also linked to membrane fluidity (Ladbrooke & 
Chapman, 1969). GPL abundance decreased over differentiation; Briolay et al., (2013) 
reported a decrease in the concentration of long chain PUFAs as cells differentiated into 
myotubes and this study reported a significant decrease in LPC, a class of GPLs. We 
hypothesise therefore that a decrease in certain GPL’s accounts for the decrease reported 
however it cannot be concluded which GPLs were decreasing apart from LPC.  
FC abundance also decreased over differentiation, and the only significant change was 
between 0-6dpd. This significant decrease in cholesterol happens in time with cells beginning 
to fuse as LPC levels drop off. Membrane cholesterol composition is organised into discrete 
and dynamic areas of the cell membrane, called lipid rafts (Brown et al., 2000). Cholesterol 
has been reported to reduce along areas of the membranes that are about to fuse (Mukai et al., 
2009) and so in my opinion this suggests the levels of cholesterol are likely to decrease in the 
cells during early differentiation to allow the fusion of membranes. 1dpd cells had the lowest 
mean relative abundance of FC, which could be explained by the membrane lipid composition 
shifting and preparing the membranes for fusion - however this was not found to be 
significantly lower any other timepoint. Briolay et al., (2013) described a reduction in 
cholesterol: phospholipid ratios that occurred alongside changes in the saturation levels 
associated with cell fusion. Membrane fluidity was not evaluated in this study although 
increased fluidity has been associated with changes in cholesterol, FA saturation and PC levels 
during myogenic differentiation as reported here (Blondelle et al., 2015; Mukai et al., 2009).  
 Evaluating lipidomic differences when Hacd1 was knocked down in the 
C2C12 cell line 
Moderate differences were observed within the overall lipidome of Hacd1-kd cells when 
compared with controls when entire data sets were grouped together (R2=0.51 and Q2=0.36). 
These differences were clearer still when control and Hacd1-kd groups were analysed by each 
time point separately. Early time points 0, 1 and 2dpd had the least difference between groups, 
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then after Hacd1 upregulation at 4dpd the differences between control and Hacd1-kd were 
exaggerated with 6, 8 and 10dpd having substantial separation in clustering of groups. 12dpd 
had less separation and predictive power in the PLS-DA model and we hypothesise this may 
be due to either a developmental delay in Hacd1 deficiency that was overcome at this later 
stage or the onset of senescence as the cultures become more temperamental at later 
differentiation stages. 
In the study conducted by Blondelle et al., (2015) they found that Hacd1-kd myoblasts, prior 
to differentiation, had a higher proportion of saturated fatty acids and a lower proportion of 
MUFAs. Here no significant difference was seen between saturation levels in control and 
Hacd1-kd cells and both followed a very similar pattern of saturation decrease over 
differentiation. Cells exhibited a cyclical pattern of saturation levels with an overall decreasing 
trend; we hypothesise this may be due to culturing limitations as media was changed 
approximately every other day and media changes were performed at room temperature, 
potentially causing cells stress due to movement in and out of incubators. Therefore, both of 
these factors may be confounding results. The cell culture and lipidomic methods used in this 
study were different to that of Blondelle et al., (2015) as well as a different Hacd1-kd clone 
and so differences in findings were not unexpected. 
Blondelle et al., (2015) reported that, instead of the decrease in LPC content seen in 
differentiating control C2C12 cells, when Hacd1 was knocked down LPC content increased 
and MUFA content decreased. In this study, Hacd1-kd myoblasts and myotubes in early 
differentiation (0-6dpd) had higher levels of LPC (insignificant) compared with controls but 
a similar decrease in LPC was observed on differentiation. As previously discussed, a cell 
clone was selected for this study that differentiated under the culture conditions presented and 
there was no observable difference in myogenesis between this Hacd1-kd cell line and the 
control (Figure 3.10). Contrastingly Hacd1-kd C2C12 used by Blondelle et al., (2015) had 
reduced fusion and differentiation. This likely explains the differences between LPC levels 
here and in comparison with Blondelle’s results as these Hacd1-kd cells did fuse, LPC levels 
should decrease, as seen in Figure 4.15. This is, however, contradictory to their conclusion 
that the LPC decrease was dependent on Hacd1 - as this decrease was present in our study 
without Hacd1 expression being upregulated. The difference seen here could be due to a 
number of factors including differences in cell culture protocols as previously mentioned. The 
phenotype may be somewhat rescued by the higher concentration of horse serum used in 
differentiation media in this study: 4% compared to 2% used by Blondelle et al., (2015). 
Levels of Hacd1 knockdown also vary between the Blondelle study and this one: Blondelle et 
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al., (2015) observed knockdown at all time points, and undifferentiating cells, suggesting a 
more severe phenotype than the cells in this study. 
Phosphatidylcholine and GPL levels in Hacd1-kd cells followed the patterns seen in control 
cells suggesting Hacd1 does not act upon these lipid classes. Although as the cells in this study 
also did not present with increased LPC levels in Hacd1-kd cells compared to control it is 
possible the Hacd1-deficient phenotype was being rescued by the serum within the media and 
therefore alleviating potential lipidomic changes caused by Hacd1-deficiency. The importance 
of media can be seen in Figure 4.14 in which both the control and Hacd1-kd exhibit the same 
saturation pattern across differentiation: which we hypothesise as due to media changes. 
Significant differences between FC levels between control and Hacd1-kd were identified but 
inconsistent with FC having higher mean abundance in 1, 2, 4, 10 & 12dpd but lower in the 
other time points (all multiple comparisons insignificant).  
 Limitations and future work 
Lipidomics can provide a great deal of information but it has limitations. Analysis produced 
by NMR can be directed down two main routes: a nontargeted method which was conducted 
for global investigation into lipid profiles within our cells and a quantitative method which 
was performed for saturation levels and to evaluate a selection of different lipid classes within 
the cells. NMR lipidomics is a developing discipline which meant we were unable to fully 
annotate the spectra due to a lack of validated reference data. Quantitative evaluation to 
determine all lipids detectable by the spectrometer and all molecules and pathways affected 
by Hacd1-deficiency was therefore incomplete and this limitation in spectra annotation 
created a bottleneck in the number of lipids that were quantifiable. This study therefore began 
by focusing on lipids associated with plasma membranes and changes previously documented 
in myoblast fusion, early myogenesis and Hacd1-deficiency (Blondelle et al., 2015, Walmsley 
et al., 2017). Lipids associated with intracellular organelles, membrane trafficking and 
involved in signalling, for example ceramides and diacylglycerol (van Meer & de Kroon, 
2011), have not been deeply explored in this data set and this may be a future avenue for 
analysis once lipid annotation is more accessible.  
Experimental design created difficulties with normalising spectral data post 1H-NMR runs. 
Cells were counted before seeding into flasks however as cells proliferated before beginning 
to differentiate this may have caused some differences in cell mass when pelleted. It was 
observed, that the knockdown cells appeared to proliferate slower; this had also documented 
by Blondelle et al., (2015). In future weighing these pellets would be considered, although 
this would have to be done wet and it is technically difficult to remove all the PBS thereby 
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creating another potential source of inaccuracies in measurements. We chose to normalise the 
data by median peak intensity per bucket for a robust normalisation method, in future 
experiments introducing a non-native lipid peak to each sample would be an appropriate 
method by which to normalise samples. These could include a lipophilic compound such as 
trimethyl silane which is well documented within metabolomics studies as a reference peak, 
due to its strong signal which falls out of the range of most lipid peaks (Tiers et al., 1958). 
The in-group variation was high which masked lipidomic differences in cluster analysis (PCA 
and PLS-DA analyses), this was due to the inherent uniqueness in samples, even in immortal 
cell lines (Rubakhin et al., 2011). The variation seen in early time points could be due to serum 
differences as previously discussed due to the sensitivity of NMR. Samples were collected 
and lipids extracted over a long period of time throughout the project so as experimental 
technique improved this will have created variation between samples.  
Compared to the mass spectrometry (MS) methods, NMR-based lipidomics are less sensitive 
and limited by overlap of signals and poor separation of peaks that can make identification of 
individual peaks difficult (Yang et al., 2016). NMR does however offer a number of 
advantages including cost, sample preservation and reproducibility and so was chosen for this 
study as a preliminary exploratory technique. Samples are not destroyed during the NMR 
protocol and so can be stored for further analysis by MS in future. The high level of potential 
reproducibility, lipid identification and quantification make NMR an appealing technique (Li 
et al., 2017). 1H-NMR cannot provide information on chain length though which is important 
for the study of HACD1. As determined by Blondelle et al., (2015) previously, we would 
anticipate that VLCFA in phospholipids would increase corresponding to the upregulation of 
Hacd1 and that in the Hacd1-kd cells this would be attenuated with proportional shift and 
increase in less complex lipids with shorter fatty acid chain lengths. Ultimately, other methods 
will need to be employed as well such as MS which would provide accurate masses for lipids 
and fatty acids and allow any changes in chain length would be detected. 
Future work should also evaluate which lipids are affected by HACD deficiency within the 
context of the entire elongation cycle as the ELOVL condensation step has also been reported 
to be a rate-limiting step (Ikeda et al., 2008; Sassa & Kihara, 2014). Rescue experiments would 
also confirm changes seen were due to Hacd1-deficiency - the lipidome of cells once rescued 




This study evaluated the lipidome of C2C12 cells and their changes over myogenic 
differentiation and with Hacd1-deficiency. This study describes the lipid phenotype seen in 
C2C12 cells as they form mature myotubes and conclude that Hacd1-deficiency has an impact 
on the lipidome at all time points studied particularly after upregulation of Hacd1-fl. In this 
evaluation we found significant differences in LPC and FC abundances when Hacd1 was 
knocked down. As these are broad lipid classes, further work could be conducted to specify 
which individual lipid species are affected. To fully evaluate the lipids affected by Hacd1 
deficiency – rescue experiements could be conducted to determine if lipid levels can be 
restored by re-expression. This will be important to expand our knowledge of HACD1 
function, in particular which lipids are altered in Hacd1-deficient membranes to help 
understand the high levels of tubuloreticular membrane disorganisation in HACD1-CNM 
affected dogs (Pelé et al., 2005; Walmsley et al., 2017). To conclude, when comparing the 
lipidome between control and Hacd1-kd cells at each time point, there were clear differences 
between the two lines, however these were not accounted for by the specific lipids evaluated 
so far. Differences seen within the cell types was prominent at later stages of differentiation, 
which are more representative of myofibres than the early myoblasts are and so the findings 
in this chapter have provided a first look in to the lipidome of the cells this late into 
differentiation. Despite the cells providing an initial insight into the effect of 
Hacd1-deficiency on the lipidome, cells were found to be highly influenced by their 
environment suggesting this model may not be the most appropriate for studying the effects 











5 Hacd1-mutations in zebrafish embryos as a novel congenital 
myopathy model 
 Introduction 
The embryonic zebrafish is well-established as a model for studying embryonic development 
(Veldman & Lin, 2008), and more recently it has found to be a good model of mammalian 
genetic diseases. Sequencing of the zebrafish genome first started in 2001 by the Sanger 
Institute (UK) and it has since been revealed that 70% of human genes have functional 
homologues in zebrafish (Howe et al., 2013). In the 1990s large-scale random mutagenic 
screens began and numerous mutants were created modelling a variety of genetic conditions 
affecting various body systems and demonstrating the capabilities zebrafish have as a model 
of disease (Driever et al., 1996; Lieschke & Currie, 2007). Zebrafish have a number of 
characteristics that make them a highly desirable model for genetic study and manipulation. 
Zebrafish reach sexual maturity quickly at around three months: this allows mutant 
heterozygous lines to be established rapidly (Guyon et al., 2007). Embryos are fertilised 
externally and so can be harvested, observed and manipulated throughout development 
without needing to sacrifice the mother (Guyon et al., 2007).  
Genetic manipulation is typically carried out by microinjection of nucleases or RNA, for 
example, into the nucleus or yolk of early (ideally single cell stage) embryos, resulting in 
over- or under expression of genes (Hogan et al., 2008). Morpholinos are widely used to knock 
down gene expression or interfere with splicing (Heasman, 2002), though genome editing is 
becoming more common utilising ZFN, TALENs and more recently CRISPR/Cas9 (Carroll, 
2011; Clarke, 2011; Liu et al., 2017). The embryo’s development from outside the body of 
the mother also allows direct observations and manipulation of embryos to be made before the 
onset of external confounding variables such as diet, up until 5 days post fertilisation (dpf) 
when they begin to feed. (Liu et al., 2017). Other benefits include their small size and shoaling 
behaviour of adults which allows for efficient housing relative to mammals and they are 
optically transparent in early embryonic stages allowing for high quality imaging (Guyon et 
al., 2007). The development of the central nervous system (CNS) with zebrafish begins during 
the first few days of fertilisation, although higher CNS function is not present until after 5dpf 
whereby A(SP)A protection of the zebrafish begins (Schmidt et al., 2013). 
Muscle disorder models using genome editing technology are becoming increasingly common 
in zebrafish. Some of the genes involved in human centronuclear myopathies (CNM) are 
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currently being investigated using zebrafish models, often using morpholinos to edit the 
genomes of the embryos. CNM target genes currently being studied include: mtm1, mtmr14, 
bin1 and dnm2 (Dowling et al., 2009; Dowling et al., 2010; Gibbs et al., 2013a; Sabha et al., 
2016; Smith et al., 2014). Dowling et al., (2009 & 2010) reported that mtm1 and mtmr14 
morphant zebrafish presented with early muscle phenotype using morpholino technology. 
Sabha et al., (2016) used ZFN genome editing to mutate the mtm1 gene within zebrafish. 
Gibbs et al., (2013a) investigated dmn2 within zebrafish embryos through the overexpression 
of a mutated version dnm2 gene via plasmid transfection. Smith et al., (2014) used 
morpholinos to knockdown bin1 in zebrafish: here they found a dose dependent reduction in 
gene expression for one of the morpholinos tested. These models were possible due to the fast-
developing muscle that is readily available for experiments (Guyon et al., 2007) and the 
phenotypes seen in the models are transferable to mammalian CNM as they reflect the 
mammalian disorders and so represent CNM pathology (Dowling et al., 2009; Dowling et al., 
2010; Gibbs et al., 2013a; Sabha et al., 2016; Smith et al., 2014). 
Models of HACD1 deficiency are currently limited to cell line (Blondelle et al., 2015; Lin et 
al., 2012; Walmsley et al., 2017) or mammalian models: mice and Labrador models 
specifically (Blondelle et al., 2015; Sawai et al., 2017). Mammalian models, particularly large 
animals such as dogs, have limitations including: size, cost, speed of reproduction and ethical 
and moral implications. A mammalian muscle cell culture model was established, as used in 
Chapters 3 & 4, however there are also limitations here not least with the degree of 
differentiation that can be achieved in these cultures. A novel zebrafish embryo model would 
allow investigators to study HACD1-deficiency in a complex vertebrate system and bridge the 
gap between these existing models. 
HACD1 functions alongside other proteins including the elongases (ELOVLs) to elongate the 
chain length of very long chain fatty acids (VLCFA). Hence, we first aimed to characterise 
the lipidomic changes occurring during development of normal zebrafish embryos and 
correlate this with changes in hacd1 expression using 1H-NMR, with the future aim of 
comparing results with hacd1-mutant embryos once the model had been developed. Previous 
work has shown that the yolk sac in zebrafish embryos has a highly dynamic lipid composition 
and the most abundant lipids within whole embryos up to 5dpf are phosphatidylcholine (PC), 
cholesteryl ester (CE) and triacylglyceride (TAG) (Fraher et al., 2016). Fraher et al., (2016) 
reported that at 1dpf embryos had little lipid content other than within the yolks sac and by 
3dpf the embryos had an increased lipid content in the forebrain, around eye and the optic 
vesicle and also the pharyngeal areas that form the gills. Cholesteryl ester (CE) was the most 
abundant lipid at 0dpf/1 cell stage, accounting for 40% lipid content, and so they concluded 
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that CE was the most abundant lipid class within the yolk sac. PC was the next abundant at 
17% in yolk sac and Fraher et al., (2016) reported TAG and PC increase in the yolk sac from 
0-1dpf and then decrease during rest of embryogenesis and CE levels within the embryo body 
increased after 1dpf. 
Previous work on the elongation of fatty acids, specifically in the context of the ELOVL 
proteins, has shown that there are similarities between mammalian and zebrafish mechanisms 
and expression. Two isoforms of elovl1: elovl1a and elovl1b were shown to be highly 
expressed in the swim bladder and the kidney (elovl1b only) and when knocked down in 
embryonic zebrafish long chain fatty acids (LCFA) were increased alongside a reduction in 
yolk lipid consumption (Bhandari et al., 2016). Work conducted by Monroig et al., (2010) 
also found the zebrafish orthologue of ELOVL4, elovl4b had comparable expression to 
mammals within the pineal gland of embryonic zebrafish and expressed in the eye and gonads 
of adult fish. They also reported an alternative elongase within zebrafish elovl4a which was 
expressed neuronally in embryonic zebrafish and then expressed ubiquitously within adult 
fish. Both elovl4a and 4b functioned to elongate fatty acids when expressed in yeast (Monroig 
et al., 2010). ELOVL2 has also been studied within zebrafish and an increase in C22 
docosahexaenoic acid (DHA) was seen alongside the upregulation of elovl2 from 
approximately 12 hours post fertilisation (hpf) (Monroig et al., 2009). 
These models have furthered our understanding of CNM mechanisms and pathogenesis. The 
effects of hacd1 mutation have yet to be studied within zebrafish and currently no CRISPR 
knockdowns or mutants have been created either for any of the CNM genes. 
 Chapter aims & hypotheses 
Due to the success of previous embryonic zebrafish CNM models we hypothesised that the 
newly generated CRISPR/Cas9 hacd1-mutant zebrafish embryos would be also be a good 
model for HACD1-CNM. Specifically, the work in this chapter sought to: 
1) Evaluate the lipidome of wildtype AB zebrafish embryos from 1-3 days post 
fertilisation (dpf) and optimise 1H-NMR lipidomics within this model organism; 







 Sample preparation and 1H-NMR experiments  
AB wildtype zebrafish (Danio rerio) embryos were collected at either 1dpf, 2dpf or 3dpf. 
Embryos were collected in groups of 10 unless otherwise stated and placed into 
microcentrifuge tubes, as much water was removed as possible before snap freezing in liquid 
nitrogen and storing at -80oC. For sample size experiments, embryos aged 3dpf were used as 
it was thought these would contain the most material to extract lipids from and therefore 
produce good quality, reproducible peaks. For experiments with dechorionated embryos 
(section 5.3.2.1), chorions were removed manually from live embryos using a pair of fine 
watchmaker forceps (Dumont Laboratories) and discarded before freezing embryos. 
Experiments were all performed in triplicate. 
Lipid extraction and extract preparation was carried out as described in Sections 4.2.2 and 
4.2.3, with the addition of an extra sonication step in order to fully disrupt and break apart 
samples. 1H-NMR spectrometer experiments and quality controls were set up and run as 
described in 4.2.4. 
 Lipidomic analysis of developing wildtype embryos 
Pattern files and spectra annotation for spectra ‘bucketing’ was undertaken as described in 
Sections 4.2.6 and 4.2.7. Lipid abundance was measured using both Metaboanalyst, an open 
source online software (Xia et al., 2011) and analysed in GraphPad Prism (GraphPad Software 
Inc.). Data was normalised to the methyl peak (CH3) as this was considered to be the most 
stable reference peak (Appendix Figure A3.1): this method assumes most molecules only have 
one methyl group and a small proportion of lipids may be branched, so this must be considered 
when analysing data (Jakobsson et al., 2006). Data was pareto scaled to avoid large peak 
changes masking smaller changes within the data set (van den Berg et al., 2006). Multivariate 
analyses were used to identify clustering between samples using PCA (principal component 
analysis) or PLS-DA (partial least squares-discriminant analysis) score plots. PLS-DA test 
outputs are provided in the form of two values: R2 which describes degree of fit to data; and 
Q2 denotes predictive power. Q2 values >0.4 are thought to be acceptable for a biological 
model (Worley & Powers, 2013).  ANOVA tests (analysis of variance) were also used to 
identify any specific lipid changes between samples. ANOVA results are shown as mean with 
error bars indicating the standard error of the mean (SEM). Significance scores were as 




 Phenotypic evaluation of injected embryos 
 Embryos were injected with Cas9 protein and a previously validated guide RNA targeting 
exon 1 of hacd1 (data not shown). Validation was performed by another researcher and 
confirmed that the guide and Cas9 together was the only combination to cut the hacd1 
sequence within the plasmid and that the guide was specific to hacd1 (plasmid containing 
hacd2 transcript was not cut). Injection mixes contained: 1µl (20µM) Cas9 protein (NEB), 2µl 
(350ng/µl) guide RNA (in vitro synthesis), 0.5µl (0.5%) phenol red solution in PBS (Sigma) 
and 1.5µl H2O. The guide specifically targeted an area within exon 1 adjacent to the hacd1 
start codon (see Figure 5.1).  
 
Figure 5.1: hacd1 guide directed cut site.  
hacd1 sequence for a section of exon 1 with the start codon, PAM sequence and the designed, the 
validated guide RNA and the expected cut site (red dashed line) annotated. 
 
Around 75% of embryos screened by high resolution melt curve analysis (not presented in this 
thesis) at 72hpf had an abnormal peak in comparison with wild type and control embryos and 
subsequent cloning from these embryos demonstrated a 25-100% somatic lesion frequency. 
An abnormal live phenotype had been observed in 10-25% of F0 Cas9/guide injected embryos 
at 72hpf, this correlates with the presence of mutations and are not seen in control embryos 
injected with Cas9 alone. Embryos were evaluated throughout development and 
phenotypically abnormal embryos at 72hpf selected for this work. Morphology was evaluated 
at 72hpf and a grading system devised for scoring. To assess swimming behaviour in embryos 
at 72hpf: embryos were touched on the tail by an external stimulus and their response was 
observed and recorded using a 5MP digital camera (Microtech) and Touplite software 
(ToupTek photonics). This assessed muscle function - following the tactile stimulus a rapid, 
strong response was seen in wild type embryos and they swam out of the view of the camera 
(Smith et al., 2013). 
 gDNA mutation screening in F0 embryos  
Mutation analysis was performed on single embryos selected based upon morphological 
abnormalities and frozen prior to evaluation or following immunohistochemistry (IHC). 72hpf 
single embryos were digested using a lysis buffer (50µl per embryo) containing: 10mM 
Tris-HCl pH8 (Gibco), 1mM EDTA (Ethylenediaminetetraacetic acid, Invitrogen), 80mM 
KCl (Sigma Aldrich), 0.3% NP40 (Sigma Aldrich), 0.3% Tween (Sigma Aldrich) and 
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0.5mg/ml proteinase K (Qiagen). Embryos were incubated at 55oC with intermittent vortexing 
until samples were disrupted. Typically this occurred within 90 minutes in embryos already 
processed for IHC or up to three hours otherwise. Digestion was followed by 15 minutes at 
95oC to inactivate the reaction and digests were then stored at -20oC. 
A PCR to amplify a 440bp region around the target sequence was performed on these digests 
using Amplitaq Gold DNA polymerase (Applied Biosciences). The forward primer sequence 
targeted a sequence upstream from the hacd1 gene: GCATAACTTAATGTGGGGGA and the 
reverse primer sequence targeted intron 1: AAAAGCTTCAGTACAAGCCA. 
 
Figure 5.2: Primer binding sites around exon 1 of the zebrafish hacd1 gene.  
Forward primer bound to a section of sequence upstream from the hacd1 gene and this section is 
denoted by lower case letters and the end of exon 1 is indicated by a black line: the reverse primer 
bound to a section within intron 1. Guide RNA sequence, start codon and PAM sequence are also 
annotated for context. 
 
Each 50μl reaction contained: 2% DNA, 0.25μM forward and reverse primers (Invitrogen 
Custom Oligonucleotides), 0.25mM dNTPs (Fisher Scientific), 1 x PCR buffer II, 2.5mM 
MgCl2 and 0.025U/μl Taq DNA polymerase (Applied Biosciences). Reactions were run for 
35 cycles of: 95oC for five minutes (initial denaturing) followed by 35 cycles of 94oC for 30s 
(denaturing), 55oC for 30s annealing and 72oC for 30s extension and a final extension step of 
72oC for 7 minutes. Products were divided and 10µl with 1X BlueJuice loading dye 
(Invitrogen) was run on a 1.5% agarose gels with GelRed nucleic stain (Cambridge 






Figure 5.3: Example agarose gel from PCR on Cas9 guide injected embryos, digested using lysis 
buffer.  
Left hand lane shows the 100bp ladder with the 500bp band annotated by a black arrow. All bands in 
other lanes represent hacd1 DNA that has been successfully amplified by the PCR – with some lanes 
representing more successful PCRs than others. 
 
The remainder of the PCR product was purified for cloning using a QIAquick PCR 
purification kit (Qiagen, catalogue number 28104) according to the datasheet. PCR product 
was then cloned into the pCR2.1-TOPO vector using a TOPO TA kit (Thermo Fisher) in 
accordance with the datasheet. Briefly, 4µl of the purified product was incubated with 1µl 
vector and 1µl salt solution for 20 minutes at room temperature before transferring to ice. 
Competent E.coli cells (TOP10, Invitrogen) were then thawed and ligation mixture was added 
before incubating again on ice for 20-30 minutes. Competent cells were then heat shocked for 
30 seconds at 42°C in order to take up ligated vector then transferred back to ice before 250μl 
pre-warmed SOC medium (Sigma Aldrich) was added and cells were shaken for one hour at 
37°C. Cell mixture was plated up on LB agar (Sigma Aldrich) plates containing 100μg/ml 
ampicillin (Sigma Aldrich) overnight to allow colonies to grow. Colonies formed were then 
selected and grown in LB broth (Sigma Aldrich) containing 100μg/ml ampicillin before 
plasmids were extracted via minipreparation (QIAprep Miniprep kit, Qiagen, catalogue 
number 27104) and submitted for external sequencing (GATC). Sequencing was analysed 
using CLC workbench software (Qiagen). 
 Immunohistochemistry 
Phenotypically abnormal F0 and wildtype embryos were fixed with 4% paraformaldehyde 
(PFA) and then dehydrated with graded methanols and stored at -20oC. Embryos for staining 
were thawed to room temperature and rehydrated with PBS (Sigma Aldrich) and 0.1% Tween-
20 (Sigma Aldrich) (PBTw) before de-pigmentation using a bleach solution (0.5x SSC (Sigma 
Aldrich), 1% H2O2 (Sigma Aldrich), 5% formamide (Sigma Aldrich) and 0.1% Tween-20 in 
PBS). Bleaching was performed for 10-25 minutes until pigment was removed from the tails 
to avoid damaging the muscle and then embryos were transferred into PBTw before washing 
with PBS with 0.8% Triton X (Sigma Aldrich) (PBT), a detergent.  
Following the bleaching protocol, embryos were then trypsinised on ice with 0.25% trypsin 
in PBT for four minutes. While still incubated on ice, embryos were washed twice for five 
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minutes with PBT before incubating in block solution (PBT with 1% DMSO and 10% goat 
serum) for one hour at room temperature. Embryos were then incubated with the primary 
antibody in block solution overnight at 4oC (see Table 5.1 for concentrations). Embryos were 
then rinsed twice in PBT and washed for four x 30 minutes with PBT, blocked for an hour in 
PBT with a block solution containing a lower concentration of goat serum: 1% DMSO and 
1% goat serum. Samples were then incubated again at 4oC overnight with secondary antibody 
in this secondary block solution (1:200 concentration, Alexafluor 488). Following secondary 
antibody incubation embryos were rinsed twice in PBT before four x 15-minute PBT washes 
and incubated with Hoechst (Thermo Fisher) at a concentration of 1mg/ml for one hour. They 
were then rinsed twice and washed for two x 10 minutes in PBS before being mounted in soft 
set fluorescent mountant (Vectashield, Vector Laboratories) for imaging to allow embryos to 
then be retrieved for digestion.  
Whole embryos were imaged in wide-field view using a Nikon TE2000 microscope. For 
fluorescent confocal microscopy a Nikon Eclipse Ti (Nikon) was used along with the Nikon 
EZ-CI software (Nikon). Levels for the offset and gain were chosen after imaging wild type 
embryos. 
Table 5.1: Table of antibodies used for immunohistochemistry in this chapter.  
Primary 
Antibody 
Type Concentration Source & 
Catalogue 
Number 























 Evaluating the developing lipidome in wildtype embryonic zebrafish  
Studies were performed to determine the optimal sample size and technique for 1H-NMR 
lipidomic analysis of embryonic zebrafish and to establish the normal lipidomic changes in 
developing zebrafish. 
 Increasing sample size increases signal: noise ratio for lipidomic analysis of 
72hpf zebrafish embryos by 1H-NMR  
To optimise the technique of extraction and lipidomic analysis from zebrafish embryos sample 
sizes of 1, 2, 5 and 10 embryos were evaluated at 3dpf. Figure 5.4a shows raw spectra of all 
experimental samples (n=3 per group) which clearly show an increase in peak intensity in the 
larger sized samples. Figure 5b shows signal: noise analysis from these spectra and the R2 
value (0.998) shows a highly positive correlation between this and increasing number of 









Figure 5.4: Signal intensity in samples of increasing embryo number (n=3).  
(a) Output from Topspin 3.1. software displaying all signals from varying sample sizes analysed. (b) 
Signal: noise ratio analysis reported a positive correlation between the two variables (R2=0.998). 
Samples were not normalised here in order to determine effects of sample size.  
 
Multivariate analysis (Figure 5.5) showed that groups of different numbers of embryos per 
sample cluster separately almost completely from each other. Correlation using heat map 
analysis in Figure 5.5b shows samples from 10x embryo group clustered together whereas for 
smaller sizes there was more variability and they did not cluster together. These analyses 
determined that a sample size of 10 embryos provides more intense and therefore more 





Figure 5.5: Multivariate analysis of increasing the number of embryos analysed per sample size. 
1x embryo is represented by a red colour, 2x by dark blue, 5x by light blue and the 10x group by a green 
colour (a & b). (a) PCA scores plot of all four groups which all cluster separately, shaded region 
indicates 95% confidence region. (b) Heat map also showing clustering in which samples from the 10x 
group segregate together and samples in other groups also partially cluster. Samples were not 
normalised to determine effects of sample size. 
 
 Chorions do not affect the lipidome of zebrafish embryos 
Embryos hatch from their chorions between 2-3 days post fertilisation (dpf) and this can be 
delayed in mutants with poor motility. Over the developmental time course studied chorions 
would have been variably present: on all embryos at 1dpf, most at 2dpf and a few at 3dpf. 
Therefore, to determine if chorions should be removed prior to analysis (a time consuming 
task manually), we conducted preliminary analyses to determine what effect the presence of 
chorions had upon the lipidome. Cluster analysis (Figure 5.6) of 1dpf embryos both with and 
without the chorions showed there was little separation between the two groups and a greater 
variation was seen in-between samples with chorions removed (Figure 5.6a). The heat map 
shown in Figure 5.6b displayed no clustering of groups and was unable to distinguish between 
groups. It was therefore concluded that removal of chorions was not required for this study 




Figure 5.6: 1H-NMR lipidomic profiles of 1 day post fertilisation (dpf) embryos with (red samples) 
and without chorions (green samples) present (n=3).  
(a) Unsupervised PCA scores plot of 1dpf embryos with and without chorions present shows overlaps 
between groups. Shaded areas represent 95% confidence region (b) Heat map analysis of samples 
showed that samples within groups do not cluster together. Samples were normalised to the methyl peak 
(CH3). 
 
 Lipidomic changes during embryo development 
These conditions (groups of ten embryos and not dechorionated) were then applied to analyse 
the lipidome in zebrafish embryos from 1-3dpf. These time point were selected based on onset 
of HACD1 expression and myogenic differentiation from myoblasts present at 1dpf to mature 
myotubes seen in 3dpf embryos. 
Initially the entire data set was analysed in a multivariate approach to determine, at the global 
level, what effect the development of the embryos had on the lipidome. Figure 5.7a displays 
a PCA scores plot of all three ages with 1 and 2dpf overlapping and 3dpf clustering almost 
separately from the earlier ages. When using a more supervised analysis; PLS-DA (Figure 
5.7b) that allows for greater discrimination between groups, the groups separated out 
completely reporting three discrete groups. This analysis is normally used for analysis of two 
groups however the PLS-DA scores were very acceptable: R2=0.98 and Q2=0.72 suggesting 
this analysis appropriate and that samples dependent upon age are discrete from one another 
in regards to their lipidome. Figure 5.7c shows heat map analysis of all samples with the three 
3dpf samples grouped together and samples from 1 and 2dpf were unable to be separated out 
by dpf. Blue colours within the heat map indicate relatively low intensities for peaks compared 
to the peak average and red indicates higher relative intensities and overall there were more 
blue boxes representing peaks within the samples for 3dpf suggesting lower lipid content in 
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these samples. There were some lipids that appeared to be more abundant in the 3dpf samples. 
 
Figure 5.7: Cluster analysis of embryonic zebrafish lipidome over the developmental time course 
at ages 1, 2 and 3 days post fertilisation (dpf), red colours represent 1dpf. 
Blue represent 2dpf and green represents 3dpf. (a) Unsupervised PCA scores plot displaying some 
overlap between groups. (b) Supervised multivariate PLS-DA plot displaying clear discrete groups 
dependent upon age of embryo (R2=0.98 and Q2=0.72) and for clarity only 2 components from a three 
component model are shown. Shaded areas represent 95% confidence regions (a & b). (c) Heat map of 
developing embryos; 3dpf embryos cluster together in heat map whereas the clustering was less discrete 
with 1 and 2dpf embryos. Samples were normalised to the methyl (CH3) peak. 
 
As the literature (Blondelle et al., 2015; Briolay et al., 2013) and previous work in Chapter 4 
show the level of saturation within fatty acids should decrease during muscle cell 
differentiation it was hypothesised that the same change would occur in zebrafish myoblasts 
as they developed. Whole embryos from 1-3dpf were evaluated and saturation analysis (Figure 
5.8) showed the relative abundance of different hydrocarbon saturation levels: saturated bonds 
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(HC-CH), unsaturated bonds (HC=CH) found in both mono- and polyunsaturated fatty acids 
and levels of PUFA (HC=CH-CH2-CH=CH). At 1dpf the levels of saturated bonds were 
higher than unsaturated bonds in both MUFA and PUFA. At 2dpf the proportions of all carbon 
bond saturations were similar and then by 3dpf the relative abundance of saturated bonds 
decreased and became lower than the relative abundance of unsaturated bonds. Two-way 
ANOVA analysis reported the effect of age of embryos on levels of saturation was significant 




Figure 5.8: Relative abundances of hydrocarbon saturation over developing embryos from 1-3 
days post fertilisation (dpf).  
C-C represents single carbon bonds and therefore a saturated bond, C=C represents double bonds found 
in all unsaturated fatty acids and poly unsaturated fatty acids (PUFA) are those with more than one C=C 
double bond. All levels of saturation decrease over development with relative levels of saturated bonds 
being the most abundant at 1dpf and dropping to the least abundant by 3dpf. Two-way ANOVA results 
signify the age of embryos has a significant effect on saturation levels (p<0.0001) and the interaction 
between age and groups was also significant (p=0.0056). Samples were normalised to the methyl (CH3) 
peak. 
 
Lipid class head groups were then quantified over the course of embryonic development from 
1-3dpf as previously investigated in muscle cells (Chapter 4). 
Figure 5.9 shows the relative abundance of LPC, PC, FC, TAG, GPLs and CE. LPC decreases 
over myotube differentiation in murine cells (Blondelle et al., 2015; Briolay et al., 2013; and 
Chapter 4); the relative abundance of LPC in whole embryos had a reducing trend over 
development and there was no significant difference. PC levels significantly decreased 
(ANOVA, p=0.0230) over embryonic development. FC levels are relatively unchanged over 
development, levels of which were seen to decrease in C2C12 cells. TAG was not studied in 
C2C12 cells due to undefined roles within muscle however as they have been previously 
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reported to be highly abundant with embryonic zebrafish yolk sacs (Fraher et al., 2016) and 
to decrease over embryogenesis, TAG was therefore analysed within our samples and also 
saw its abundance decrease significantly over development (ANOVA, p=0.0406). GPL levels 
changed in an opposite manner and levels of GPL had a trending increase in abundance over 
development. CE levels were also not studied in muscle cells as cholesterol is only present in 
muscle as free cholesterol and not the esterified molecule (CE). CE has been reported to be 
the most abundant lipid within zebrafish embryo yolk sacs (Fraher et al., 2016) and CE was 





Figure 5.9: Relative abundance of lipid classes over developing embryos from the age of 1 day 
post fertilisation (dpf) to 3dpf.  
LPC = lysophosphatidylcholine, PC = phosphatidylcholine, FC = free cholesterol, TAG = 
triacylglyceride, GPL = glycerophospholipids and CE = cholesteryl ester. ANOVA tests performed to 
assess significance of findings. LPC abundance increases at 2dpf before decreasing at 3dpf. PC 
abundance significantly decreases over development (p=0.0230). FC increases at 2dpf before 
decreasing between 2dpf and 3dpf embryos. TAG significantly decreases over development 
(p=0.0406). GPL abundance increases over development and CE decreases significantly overall 
between 1 and 3dpf (p=0.0362). Post-hoc Tukey multiple comparison tests are annotated on graphs by 




 Phenotypic evaluation of CRISPR/Cas9 injected zebrafish embryos 
Embryos were observed during development following injection with guide RNA and Cas9 
protein and evaluated at 72hpf. Injected embryos presented with a spectrum of phenotypes 
due to the mosaic nature of the CRISPR editing in F0 embryos and so the classification system 
was created as a guide for the severity of the embryos phenotype and not a definitive 
classification. Phenotypic classification was evaluated as in Figure 5.10 and Figure 5.11. 
Embryos were categorised as phenotypically normal, mild, moderate or severe based on their 
live phenotype and abnormal embryos were selected for further analysis.  
 
Figure 5.10: Phenotype of Cas9/guide injected embryos at 72hpf.  
(a) Example embryos for wildtype, mild, moderate and severe phenotypes, ‘E1’ indicates the first set 
of embryos assessed. Mild embryos may present with either normal phenotypes as seen above, but they 
have no motility when assessed. Moderate embryos might exhibit a curved and bent tail/spine as seen 
above. Severe embryo in figure exhibits malformed head, enlarged heart sac, enlarged yolk sac and a 
bent tail which was visibly thinner. (b) A proportion of embryos exhibited very severe generalised 
defects and developmental abnormalities, including absence of normal body structure – for example the 
eyes, and severely underdeveloped tails. These phenotypes are unexpected and may be due to the 
injection toxicity or manual process damaging the yolk sac and were therefore not analysed in this 
thesis. Scale bars represent 0.5cm. 
 
To assess skeletal muscle function in injected embryos a touch-evoked swim test was 
performed. Wild type embryos swim quickly away when they are touched by an external 
stimulus as they have ‘normal’ muscle contraction and function. Figure 5.11 shows the 
responses of a wild type embryo along with two injected embryos of moderate phenotype that 
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exhibited reduced and absent motility. The embryos with reduced motility had weak twitches 
of the tail and showed some movement in response to the stimulus yet they never moved out 
the field of view in the 10 second recording. The embryos with absent motility simply do not 
















Figure 5.11: Cas9/guide injected embryos (72 hours post fertilisation, hpf) had different levels of motor function as tested by touch evoked swim responses.  
(a) row shows the response from wild type embryos that immediately swam away in response to touch. (b) row shows an embryo classified as moderate CRISPR injected 




Two batches of injections provided 82 Cas9/guide injected embryos of which 45 (55%) were 
of normal phenotype, 27 (33%) were mild and moderate and 10 (12%) were severe. The mild 
and moderate embryos were split into two batches and fixed for IHC to examine finer muscle 
structure, and sequencing of the hacd1 gene. 




Mild • Slight/no abnormality in tail morphology 
• Touch evoked swim response poor/no swim response 
Moderate • Abnormal tail morphology, truncated somites, curvature 
• May/may not have abnormal heart or pericardial sac 
• May/may not have mild abnormalities of the eyes 
• Touch evoked swim response poor/no swim response 
Severe • Very abnormal tail morphology 
• Abnormal heart or pericardial sac 
• May/may not have mild abnormalities of the eyes 
• Abnormalities of other organs including eyes, head 
• Touch evoked swim response poor/no swim response 
 Muscle evaluation within phenotypically abnormal embryos  
Immunohistochemistry was first trialled on wildtype embryonic zebrafish at 72hpf to evaluate 
efficiency and specificity of primary and secondary antibodies. Antibodies (all represented in 
green due to the secondary 488-Alexafluor bound) for MF20 (myosin), RYR1 and Pax7 (the 
transcription factor found in satellite cells) were tested alongside DAPI (seen in blue) (Figure 
5.12). Pax7 was present within the nuclei of eye, brain and the myotome boundaries, with a 
number of Pax7 positive nuclei present within the myotomes. MF20 staining was present with 
the developing muscles of the head and the myofibres of the tail. RYR1 staining was also 
present with the tail myofibres. Green stain was absent in embryos incubated without primary 






Figure 5.12: Test immunohistochemistry on 72 hours post fertilisation (hpf) wildtype embryos to 
assess muscle structure.  
Images were taken using the same settings for all stains. (a and b) Pax7 staining within the developing 
eye, brain and within the satellite cells of the tail muscle and between myotome boundaries. (c) MF20 
can be seen within the muscles in the head including mandibular and hyoid muscle. (d) MF20 also seen 
within the myofibres of the tail. (e and f) RYR1 staining was located to the myofibres within the muscle 
tail. (g and h) represent the no primary control for these stains showing no non-specific staining of the 




Wild type embryos have a long straight tail and clear myotome definition and sarcomeric 
striations visible on phase contrast imaging. MF20 staining in the wild type embryos clear and 
even myotome definition and striations are visible (Figure 5.13). The Cas9/guide injected 
embryos presented with uneven myotomes, myofibre disorganisation, shortened and irregular 
somites either side of the neural tube (Figure 5.13).  
 
Figure 5.13: Cas9/guide injected embryos at 3 days post fertilisation (dpf) have different muscle 
phenotype.  
Left images are phase contrast at 4x magnification and images in the middle are at 40x. Images on the 
right correspond to embryos to images in the same row and display sections of the tail from MF20 and 
dapi stained whole embryos. Top panel (a) shows a wild type embryo with normal phenotype with the 
three embryos below (b-d, E2.4, E2.5 and E2.6) displaying differing affected phenotypes. Scale bars 




Staining of RYR1 was performed in the phenotypically abnormal zebrafish embryos to 
evaluate triadic SR within the embryo muscle and assess if RYR1 staining was altered (Figure 
5.14).  Myofibre disorganisation was also evident from RYR1 staining and embryos presented 
varying levels of abnormalities in RYR1 staining particularly loss of the normal regular 
staining pattern. RYR1 was patchy and disorganised within all injected embryos and the 
normal striated pattern was lost or unclear in Cas9/guide injected embryos. Also, the gain had 
to be increased to image the RYR1 staining within injected embryos suggesting RYR1 protein 
might be also be reduced.  
 
Figure 5.14: Cas9/guide injected embryos at 3 days post fertilisation (dpf) have altered phenotype 
and muscle structure.  
Left images are phase contrast at 4x magnification with 40x images in the middle. Right images are 
corresponding embryos in their row and display the tail section of RYR1 stained whole embryos. Top 
panel shows a wild type embryo with normal phenotype with the three embryos below displaying 
affected phenotypes (E3.4-6). Microscope gain was turned up higher to image injected embryos and, 
scale bars represent 100µm. 
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 Mutation analysis of F0 embryos 
10 phenotypically abnormal embryos (five mild, three moderate and two severe) were digested 
for amplification and cloning of the hacd1 exon 1 for mutation analysis with 4 clones from 
each embryo sequenced. Mutations that were out of frame or affected the start codon were 
considered likely to affect functional transcripts and therefore designated disease causing. Of 
the mildly affected embryos: two had 1/4 clones, one had 3/4 and the other two had 4/4 clones 
with likely disease-causing mutations. For the moderate embryos one had 2/4 clones and two 
4/4 clones with likely disease-causing mutations. Both severely affected embryos had 4/4 
clones with likely disease-causing mutations. Most mutations were small deletions of which 
a 7bp deletion was the most common seen in 16 clones.  
Stained embryos were digested following RYR1-IHC and it was determined as possible to 
perform PCR and cloning of hacd1 after fixation and processing. After imaging, 
RYR1-stained phenotypically abnormal embryos were analysed to confirm the presence of 
hacd1 mutations. Embryo E3.5 with markedly abnormal RYR1 staining was evaluated in more 
detail. All sequenced clones were abnormal and 11/12 mutations affected the reading frame 




Figure 5.15: PCR of RYR1 stained Cas9/guide injected embryos from Figure 5.14.  
Agarose gel displays bands for each embryo indicating successful amplification of the hacd1 gDNA 
via PCR and that sequencing previously stained embryos would be possible. Samples were run against 









Figure 5.16: Mutations seen within the hacd1 gene from Cas9/guide injected zebrafish embryos. 
Line 1 shows the hacd1 exon 1 sequence with the start codon and PAM sequence annotated. Line 2 
shows a clone with a 12bp deletion which would not affect the reading frame and so it represented by 
a green coloured sequence. Line 3 shows a clone in which the common 7bp deletion has occurred which 
would cause a frameshift and therefore shown in red – it would likely be a disease causing mutation. 
Lines 4-5 show larger deletions within the sequence that has led to a removal of the start codon, the 
hacd1 sequence, likely disease causing, and is therefore represented in red here also, with pre-hacd1 





















Zebrafish models targeting other CNM-associated genes have contributed immensely to our 
understanding of CNM pathogenesis (Dowling et al., 2009; Dowling et al., 2010; Gibbs et al., 
2013a; Sabha et al., 2016; Smith et al., 2014). The work in this chapter has begun 
characterising a novel model for hacd1-deficiency in zebrafish embryos which could 
ultimately pave the way for similar advances for HACD1-CNM. Our previous work (Chapter 
2) demonstrated that hacd1 has an expression pattern in zebrafish embryos that corresponds 
with that of its mammalian homologue: namely that it is the major hacd gene expressed in the 
muscle of developing zebrafish embryos and is strongly upregulated during myogenesis. 1H-
NMR lipidomics was performed in differentiating murine myoblasts which documented 
changes in hydrocarbon chain saturation levels over differentiation and differences in a 
number of lipid classes that occurred following the onset of hacd1 expression: there were also 
lipidomic differences between control and Hacd1-kd myoblasts (Chapters 3 and 4). Here 
lipidomic changes in wildtype embryos were evaluated and a protocol was optimised for future 
use in hacd1-mutant embryos.  The phenotype was evaluated in F0 Cas9/guide injected 
zebrafish embryos and those with abnormal phenotype were also found to have disrupted and 
disorganised muscle structure when examined via IHC. Sequencing found a variety of 
mutations present as a result of the CRISPR/Cas9 genome editing of which a 7bp deletion 
affecting the reading frame was the most common. 
 Embryonic zebrafish lipidome can be studied via 1H-NMR, however the 
presence of the yolk sac may hide changes occurring elsewhere within the 
embryo 
The first stage of optimisation was to determine the number of embryos required to obtain 
informative spectra. The signal: noise ratio improved linearly with increased embryo numbers 
within samples up to 10 (R2=0.998) therefore further samples with larger numbers should be 
evaluated to see when the increase in number of embryos ceases to add value to the results. 
Multivariate analyses showed groups of different embryos to be discrete from one another 
suggesting spectra were different dependent on sample size. These results indicate that 
including more embryos per sample to be extracted give improved spectra from which more 
information can be obtained. Wild type embryos are produced in large quantities therefore 
larger sample sizes can be included (Guyon et al., 2007). Our current hacd1-mutant model in 
F0 embryos produces a heterogeneous population with variable phenotypes and mutations 
therefore it may be difficult to obtain sufficient sample sizes of embryos grouped by phenotype 
for optimal spectra. Our ultimate aim is to generate a line of zebrafish with a germline mutation 
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in hacd1 and in this case it would be feasible to collect the required numbers of embryos that 
are homozygous for a specific mutation and, hopefully, a more consistent phenotype. To 
analyse lipids from a single embryo or even specifically the muscle of the tail, a different 
technique such as matrix-assisted laser desorption/ionisation (MALDI) could be used (Duneas 
et al., 2017).  
Wildtype embryonic zebrafish were then optimised for 1H-NMR lipidomics through analysing 
the lipidome of 1dpf embryos with and without their protective chorions. The chorion is an 
extraembryonic structure, in that it will not contribute to the developing embryo (Bonsignorio 
et al., 1996). It is proteinaceous (Kim et al., 2004) and therefore was thought unlikely to 
contribute to the lipidome. Nevertheless, as embryos hatch from their chorions between 2 and 
3dpf so would therefore be present in younger embryos and not older embryos, and mutations 
that affect development or motility can delay hatching and so it was necessary to rule the 
chorions out as a confounding variable. The results suggested that the chorions do not affect 
the lipidome as multivariate analysis could not separate out the two groups. Variation was 
actually greater in the sample set that had been dechorionated and this may reflect the 
additional handling these embryos received, more residual water leftover or the presence of 
leftover chorion could have contributed to the variation seen. Manual dechorionation is time 
consuming and the process is performed on live embryos at 1dpf which are fragile and injuries 
to the embryo or yolk sac could greatly affect results. Therefore, it was concluded that 
removing chorions from embryos would not improve lipidomic analyses and in fact contribute 
to more variation and potential error and so was not performed on subsequent embryos. 
Chorions can also be removed enzymatically using a combination of proteases (Pronase, 
Sigma Aldrich) (Mandrell et al., 2012); this was not evaluated as adding an additional 
treatment step to the chorionated embryos could introduce additional sources of error and 
variability to the highly sensitive 1H-NMR technique. One lab group has developed an 
automatic system of chorion removal using Pronase and robotic equipment, allowing the 
dechorionation of 1,600 embryos simultaneously – this is a great development for studying 
embryonic zebrafish (Mandrell et al., 2012). 
Through analysing the lipidome of embryos aged 1, 2 and 3dpf we were able to conclude that 
there were distinct differences between ages and demonstrating that the lipid content within 
the embryos is dynamic over the course of development. Heat map analysis showed that there 
was relatively less lipid content within the 3dpf embryos and we hypothesised this to be due 
to decrease in yolk sac size/volume over this time course. The yolk sac is high in lipids and 
fatty acids which are incorporated into the developing embryos and used as an energy source 
up to 5dpf when the embryos start to feed (Avdesh et al., 2012). As the contents of the yolk 
sac are absorbed by the embryos and lipids are hydrolysed for energy this may have 
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contributed to the lipid content decrease seen in this study (Quinlivan & Farber, 2017). The 
observed decrease in lipid content over 1-3dpf may also be due to extraction technique aswe 
expect lipids within membranes would be more difficult to extract than those within the yolk 
sac. Therefore, further work to optimise the extraction protocols for lipids in intracellular 
organelles may be warranted. A combination of both of these factors is plausible, as lipids 
incorporate into complex systems such as membranes they may be harder to attain for 
lipidomic analyses, therefore resulting in what appears to be a decrease in lipid content.  
Further optimisation of the sonication technique might be required to ensure the full break 
down of samples. 
Saturation levels of fatty acids decreased in differentiating muscle cells (Blondelle et al., 2015; 
Briolay et al., 2013) and this was also evident in this thesis in Chapter 4. Therefore, we 
evaluated this in developing embryos and saw a decrease in both saturated and unsaturated 
bonds, likely due to the overall decrease in lipid content. The decrease in the saturated bonds 
was in fact greater, with a higher abundance of saturated bonds relative to unsaturated bonds 
at 1dpf and lower at 3dpf. These follow the results from this thesis seen in C2C12 cells cannot 
be attributed solely to muscle as lipids were extracted from whole embryos. 
Lipid classes were also analysed and although LPC abundance decreased in differentiating 
C2C12 cells this was not seen in the zebrafish embryos. The decrease in LPC within cells was 
seen along with the upregulation of Hacd1 at the onset of myogenesis (myoblast fusion) 
(Blondelle et al., 2015) and our previous results showed that hacd1-fl starts to be expressed in 
embryos from 18 hpf and by 1dpf myoblasts fuse and hacd1-fl was found to be present within 
the muscle from ~18hpf therefore it would have been interesting to include a time point at 0 
and/or 12 hpf before hacd1-fl expression. It is also possible LPC was decreasing in muscle but 
by analysing the whole embryos we were unable to detect this as changing levels of LPC 
elsewhere in the embryo are confounding results from muscle. LPC is low within the yolk sac 
(Fraher et al., 2016) and so the potential confounding LPC would be unlikely due to the yolk 
sac unlike other lipid classes: LPC may be high within other regions of the embryo.  
Abundances of PC, TAG and CE were reported to be high within the embryo yolk sac (Fraher 
et al., 2016). Lipidomic results from this study show a significant decrease in PC and TAG 
which is in line with the study conducted by Fraher et al., (2016) and we suggest that since 
the results match up with their work on yolk sacs that this is indeed due to the yolk sac lipid 
dynamics and therefore not muscle related. CE is the most abundant lipid class within the yolk 
sac (Fraher et al., 2016) and they reported that CE levels increase within the embryo body 
after 24hpf. There was a significant decrease in CE between 2 and 3dpf embryos - which could 
be due to the effect of the yolk sac decreasing in size and lipid content. FC was relatively 
unchanged over development. FC is essential for normal functioning in cells as it plays an 
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important role in the biophysics of lipid membranes (Maxfield & van Meer, 2010) and 
therefore we hypothesise its relative abundance was unchanged over development due to its 
necessity for cellular functions. The GPL peak, which represents this entire class, was seen to 
increase within developing embryos between 1 and 3dpf. This overall increase suggests the 
class is increasing in abundance however of the specific members evaluated LPC was stable 
and PC decreases. GPLs are a major component of plasma membranes (Blanco, 2017) and as 
cells divide and differentiate to produce the embryo an increase in GPL would make biological 
sense. Overall, the results seem to be highly affected by the yolk sac and likely also other areas 
of the developing embryo body. Therefore for further work to compare control and mutant 
embryos at 72hpf their tails should be isolated from the rest of the embryo before extracting 
lipids for 1H-NMR.  
A limitation to significant results within the study was the sample size used. This work was 
undertaken as a pilot study to explore if lipid content in embryos could be studied and so n 
numbers were small (n=3). Therefore the study likely lacked power and in the case of LPC no 
significance was found despite the literature (Blondelle et al., 2015; Briolay et al., 2013), and 
our findings in Chapter 4 suggesting LPC should significantly decrease in the developing 
embryos. Another limitation to the developmental lipidomic study were the time points used 
(1-3dpf). These were selected because over this period myoblasts develop into mature muscle 
(Kimmel et al., 1995), though this provided us with no information on the lipidome of embryos 
prior to hacd1 upregulation (~1dpf) and so further work would need to be done to examine 
the lipid profiles of earlier embryos. 
A significant limitation of 1H-NMR in this study was the inability to determine chain length 
of lipids which is important to evaluate as we would expect the proportion of VLCFA should 
increase in comparison with shorter FA over embryonic muscle development and that this will 
be disrupted with hacd1-mutants, due to results from Blondelle et al., (2015) in which this 
was seen in the Hacd1-kd C2C12 cell line. Because of this, other methods should be employed 
such as LC-MS or MALDI (Blondelle et al., 2015; Yang et al., 2016) to gain insight into 
lengths of fatty acids present over embryogenesis. As whole embryo lipidomics seems to be 
highly affected by the yolk sac and other anatomy, we hypothesise that the directed MALDI 
technique on embryo tails will be a possible approach to take forward. LC-MS on pooled 
embryos or embryo tails would also provide more information regarding chain length and has 
high sensitivity for low abundant VLCFA (Monroig et al., 2010; Yang et al., 2016). 
Further work could also involve studying HACD1 in the context of the other elongation 
enzymes, such as ELOVL proteins which have comparable orthologues in zebrafish to that of 
mammals that have similar expression patterns and functions (Bhandari et al., 2016; Monroig 
et al., 2009; Monroig et al., 2010). As there is a lack of literature on any ELOVL orthologue 
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specific to zebrafish embryos, fatty acid assays such as those conducted by Ikeda et al., (2008), 
and utilising yeast (Monroig et al., 2009; Monroig et al., 2010) to express zebrafish Hacd and 
Elovl proteins may provide a greater understanding into the functional relationship between 
the zebrafish Hacd1 and the Elovl enzymes within zebrafish. 
 CRISPR/Cas9 genome editing produces hacd1-mutant F0 zebrafish embryos 
with myopathic phenotype 
A guide RNA targeting exon 1 had previously been generated and validated by another 
researcher. My work aimed to evaluate the phenotypically abnormal F0 embryos in order to 
characterise their muscle abnormalities in more detail and correlate these with the presence of 
hacd1 mutations.  
When assessing the muscle structure though IHC, this was found to be affected within the set 
of Cas9/guide embryos stained for MF20 (sarcomeric myosin) as a spectrum of phenotypes. 
The fluorescence intensity was subjectively consistent between wildtype and Cas9/guide 
injected embryos. These embryos presented with myofibres that were disorganised, variable 
and uneven myotome shape and size and often the striated pattern of the fibres was indistinct. 
RYR1 stained Cas9/guide embryos as previously discussed, including: loss of visible 
striations, myofibre disorganisation, shortened somites, irregular myotomes and a decrease in 
RYR1 fluorescence (gain was increased in order to obtain informative images of muscle 
structure within the phenotypically abnormal embryos). This decrease in fluorescence could 
be due to a reduction in RYR1 from a lack of triad membrane development. Molecular 
quantification through qPCR and western blot could allow quantification of RYR1 in wildtype 
and mutant embryos to differentiate between disorganisation/mislocalisation and reduced 
expression and protein levels. Staining embryos with antibodies specific to the DHPR channel 
(Smith et al., 2014) may also be interesting, in that it may provide more information regarding 
triad formation: a co-stain of both channels would be a good way to look visually at the triad 
structure and development. Electron microscopy has been previously used on zebrafish 
embryos to visualise triads (Walmsley, 2013) and so this would also be a useful tool going 
forward. 
Similar myofibre phenotypes were seen in the other CNM zebrafish models. The BIN1-CNM 
model was reported to have disorganised myofibres, along with mislocalised nuclei (Smith et 
al., 2014). The MTM1-CNM model using morpholinos was documented to have thin 
myofibres, also with abnormally localised myonuclei; interestingly the MTMR14-CNM 
zebrafish did not have altered muscle structure (Dowling et al., 2009; Dowling et al., 2010). 
ZFNs have also been used to generate mtm1-mutants (Sabha et al., 2016). This model was 
found to have triad abnormalities comparable to those seen in human XLMTM as well as 
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being used to perform drug screens and rescue experiments allowing for the identification of 
a potential therapeutic agent (Sabha et al., 2016). The DNM2-CNM model was documented 
to have severe myofibre disorganisation (Gibbs et al., 2013a) and so this is a common feature 
of all CNM models: which correlate to the disease phenotype seen in human and canine CNM 
(Blot et al., 2002; Cassandrini et al., 2017). 
As F0 embryos generated by CRISPR/Cas9 gene editing are mosaic this provided a spectrum 
of phenotypes in embryos injected (Mehravar et al., 2019). 45% of Cas9/guide injected 
embryos presented with an abnormal phenotype – categorised on the basis of both morphology 
and functional muscle testing. Of the current zebrafish CNM models differing levels of 
abnormal phenotypes were produced (Dowling et al., 2009; Dowling et al., 2010; Gibbs et al., 
2013a; Smith et al., 2014). Gibbs et al., (2013a) used morpholino technology to create two 
morphants for the two dynamin isoforms discovered within zebrafish (dnm2 and dnm2-like). 
The morphants for these isoforms produced 93 and 75% morphologically abnormal embryos 
respectively. Gibbs et al., (2013a) tested and quantified function separately using both a 
touch-evoked method like this study but also by assessing spontaneous twitching in 1dpf 
embryos; this was seen in embryos from 17-26hpf (Saint-Amant & Drapeua, 1998). They 
reported only the dnm2 morphant to have significantly less coiling activity than control 
embryos and this morphants also presented with the most severe lack of touch-evoked swim 
response (Gibbs et al., 2013a). The XLMTM model by Dowling et al., 2009 found the most 
common phenotype in the mtm1-morphants was a thinning of the tail – this was also seen in 
our HACD1-CNM model. They also reported the spontaneous coiling to be significantly 
reduced in these morphants (Dowling et al., 2009). The mtm1-morphants were reported to 
have a delayed development which stopped them hatching from their chorions (35% hatched) 
by 60hpf, a time point by which 90% of the control embryos had hatched (Dowling et al., 
2009). Dowling et al., (2010) then looked again at mtm1 morphants, and also 
mtmr14-morphants. Here they found ~50% of mtmr14-morphants were phenotypically 
abnormal, which was a similar percentage to our findings with hacd1-mutants. Dowling et al., 
(2010) also assessed coiling and found the reduction in coiling was dependent upon the area 
of the gene targeted by the morpholino. The BIN1-CNM model generated by Smith et al., 
(2014) using morpholinos exhibited varying degrees of spine curvature and when measuring 
chorion hatching found that the amount of embryos hatched by 60hpf was halved in 
bin1-morphants and by 3dpf the morphants also had impaired motility, as tested for by 
touch-evoked swim response tests.  
The studies mentioned quantified the gross morphology and the muscle function tests 
separately providing the models with clear statistics regarding abnormality of embryos. This 
was not done in this study as the aim was to identify broadly abnormal embryos to further 
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investigate with regards to muscle structure and mutations introduced. The separation of these 
phenotypes could be implemented in this work in the future. These models also measured the 
hatching of embryos and spontaneous coiling which was not done in this study but could 
provide a more in-depth analysis of muscle function within the HACD1-CNM model: in 
particular, the coiling which provides information on function at an earlier stage of 
development. 
Other techniques used within these studies included measuring the birefringence of the 
embryonic muscle (Smith et al., 2014): whereby the ordered muscle of wildtype embryos 
appears bright (through passing polarised light thorough the embryo) and when muscle 
becomes disorganised this creates patterns specific to the disorder, in myopathies the high 
disorganisation is seen by a reduction in this birefringence (Smith et al., 2013). Myofibre 
length was measured (Gibbs et al., 2013a), electron microscopy was used to study muscle 
ultrastructure (Dowling et al., 2009; Dowling et al., 2010; Smith et al., 2014). These models 
have also been used to functionally assess ECC: Dowling et al., (2010) used electrophysiology 
patch-clamp methods to study the embryos ECC in response to electrical stimulation and 
Smith et al., (2014) used calcium imaging to assess if ECC was disrupted as a secondary 
pathology of the disrupted triads. 
 Future work 
Further work in evaluating this HACD1-CNM model would include the phenotype chorion 
hatching to be evaluated, as having mentioned previously in this chapter the presence of the 
chorion is something to keep in mind with the lipidomic analysis. Calcium imaging and 
electrophysiological experiments would provide great functional insight. There is also 
potential to isolate myofibres from zebrafish embryos (Horstick et al., 2013) which could then 
also be used in ECC experiments as well as being used for IHC to assess fibre structure. 
The mosaicism within genomes of Cas9/guide embryos reported within our embryos can have 
both advantages and disadvantages to the model. One potential pitfall of the mosaicism within 
the embryos is the chance of false-positive genotyping (Mehravar et al., 2019). In future 
studies the head could be removed from the tail section of the embryo to allow genetic analysis 
of the head and other analysis such as 1H-NMR lipidomics of the tail portion. It must be 
considered though that these sections of the embryo are likely to have different hacd1 
genetics/mutations due to the mosaic nature of CRISPR/Cas9. Once a line has been generated 
this would not be of concern however as embryos would no longer no mosaic.  
Future work on this study could involve continuing the evaluation of phenotypically abnormal 
embryos including: expression analysis by qRT-PCR and in situ hybridisation and also 
lipidomic analysis as discussed previously in this chapter. The embryos that do not present as 
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phenotypically abnormal can be utilised in the creation of a hacd1-transgenic zebrafish line: 
during the study no Home Office licence was in place to do this. Breeding from the 
phenotypically normal Cas9/guide fish will produce more consistent F1 progeny than seen in 
the F0 embryos with a varied spectrum of phenotypes. Another avenue of research could be to 
design and direct sgRNA towards the essential amino acids in exon 6 of the hacd1 gene 
(Kihara et al., 2008; Toscano et al., 2017). By mutating these amino acids, the function of 
these enzymes, and importance of these conserved amino acids could be verified within 
zebrafish. Rescue experiments should be implemented within the future of this work: 
including the re-expression of hacd1 and the addition of VLCFA to look at both genetic and 
functional rescues. 
 Conclusions 
To conclude, work from this chapter has both optimised a lipidomic method in zebrafish 
embryos that can be implemented in future studies and evaluated the effects of hacd1 
deficiency in embryonic zebrafish. The 1H-NMR method has proved informative as a first 
assessment of embryonic zebrafish lipidomics, unfortunately using whole embryos as 
undertaken in this chapter does not appear the optimal method to take forward and so isolating 
tails to assess alongside whole embryos, and the implementation of additional techniques 
including mass spectrometry should be undertaken in the future. 
The hacd1-mutant model is highly promising as a relevant model of canine CNM and 
reproduces many of the disease features including disorganisation of triad markers (Blot et al., 












The essential role of HACD1 in mammalian muscle is becoming increasingly apparent through 
the characterisation of HACD1 mutations in dogs and humans that cause HACD1 deficiency 
and lead to congenital myopathies (Maurer et al., 2012; Muhammed et al., 2013; Pelé et al., 
2005; Toscano et al., 2017). These mutations have since been modelled in mice and cell 
culture models paving the way for HACD1 research (Blondelle et al., 2015; Sawai et al., 2017; 
Walmsley, 2013; Walmsley et al., 2017) and it is known now that HACD1 functions in very 
long chain fatty acids (VLCFA) elongation (Ikeda et al., 2008). The essential roles of VLCFA 
for functions including barrier formation and inflammation in tissues such as the skin, eye, 
CNS and testis have been well documented (Monroig et al., 2010; Sassa & Kihara, 2014; 
Schneiter et al., 1996), yet little is known regarding their specific role in muscle. 
The work described here in Chapters 2 and 5 presents evidence that embryonic zebrafish are 
a novel and appropriate model for the study of HACD1-CNM. The hacd1 gene in zebrafish 
appears to be a true homologue of mammalian HACD1. The embryos expressed hacd1 within 
their skeletal muscle, and importantly, the other three genes encoding HACD enzymes were 
not highly expressed in developing or mature muscle. Furthermore, when hacd1 was mutated 
in embryos, the phenotype was comparable to the pathology of CNM (Blot et al., 2002; Tiret 
et al., 2003) and to the previously studied embryonic zebrafish CNM models (Dowling et al., 
2009; Dowling et al., 2010; Gibbs et al., 2013a; Smith et al., 2014). Chapters 3 and 4 further 
characterised a Hacd1-kd cell model which allowed initial studies to be conducted regarding 
the cell membrane function and the effects of hacd1 expression and deficiency on the 
lipidome, both of which are critical to improve the understanding of CNM.  
 
 Major findings 
 Zebrafish embryos as a model for the study of HACD1-CNM  
 hacd1 is the major HACD enzyme within zebrafish muscle 
Mammalian expression of the HACD enzymes has a specific tissue distribution: HACD1 is 
expressed in skeletal and cardiac muscle, HACD2 is expressed ubiquitously, HACD3 is also 
expressed ubiquitously excluding the leukocytes and HACD4 is uniquely expressed within 
leukocytes (Ikeda et al., 2008). Investigations into the expression pattern of the zebrafish 
HACD paralogues was necessary and fundamental work in order to validate embryonic 
zebrafish as a potential HACD1-CNM model. For embryonic zebrafish to be an appropriate 
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model it was essential to determine if the putative HACD1 orthologue (hacd1) was strongly 
expressed in muscle, was upregulated during myogenesis as seen in mammals and that none 
of hacd2, hacd3 or hacd4 were. Quantitative RT-PCR reactions found the hacd1 gene 
expression to be significantly upregulated in line with the development of myofibres which 
begins in developing somites before embryos are 1dpf (Devoto et al., 1996; Kimmel et al., 
1995). Results from ISH documented that hacd1 was expressed most strongly within the 
myotomes of the developing tail and that hacd2 and hacd3 were mostly localised to the head 
and developing abdominal cavity. Expression of hacd4 was not detectable grossly within 
whole embryos and only one section found areas within the brain which appeared to express 
hacd4. These results for hacd4 were thus inconclusive, and future work to comprehensively 
characterise HACD enzyme expression in zebrafish should address this – including by further 
ISH in embryos and adults to evaluate for presence in other areas of the CNS and leukocytes. 
For the purposes of this study, full length hacd4 could be amplified from a number of adult 
tissues and this was cloned, expression in embryos was at a low levels and did not change over 
the time course of muscle development, furthermore, mammalian HACD4 cannot rescue loss 
of Phs1 in yeast as HACD1 and HACD2 can, and only HACD1 and HACD2 share high 
homology in sequence and function (Ikeda et al., 2008; Sawai et al., 2017). Therefore, there 
is unlikely to be any compensatory mechanisms involving hacd4 upon the knockdown of 
hacd1 however, qRT-PCR assay for hacd4 is validated and can be performed to evaluate for 
this in mutants. Ensuring no compensation from any of the other hacd genes should be 
investigated thoroughly in vertebrate models including the zebrafish. Work presented in this 
thesis expanded on previous preliminary data reported by Walmsley, (2013) to further 
recognise when the hacd1 expression first begins within the embryos and to pinpoint the onset 
of hacd1-fl upregulation in line with myogenesis. Where previous results in zebrafish were 
available for comparison, agreement was found with Walmsley, (2013). This is in contrast 
with the cell model also evaluated, in which Hacd1 expression in control cells and the 
knockdown of this expression in Hacd1-kd cells was seen from single cell myoblasts in 
Walmsley, (2013) but only evident after 4dpd in this thesis. Therefore, this highlights the 
variability evident in cell culture between laboratories. 
HACD1 is prone to multiple splicing in humans (Valdés de Hoyos et al., 2011; Tondeur et al., 
2010) and dogs (Maurer et al., 2010; Pelé et al., 2005), most of which do not code for the 
amino acids essential for HACD activity (Kihara et al., 2008). Work by Walmsley, (2013) 
then documented was true of the zebrafish hacd1 including the presence of a splice variant, 
hacd1-d5 (Walmsley, 2013). Chapter 2 characterised two novel transcripts for the zebrafish 
hacd2, both of which do not code for the essential amino acids (Kihara et al., 2008), like the 
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HACD1 splice variants (Valdés de Hoyos et al., 2011; Ikeda et al., 2008; Maurer et al., 2010; 
Pelé et al., 2005; Tondeur et al., 2010; Walmsley, 2013). 
These results on zebrafish embryos confirm that the zebrafish hacd1 gene is the major gene 
expressed within developing muscle of zebrafish embryos and that they exhibit a tissue 
expression pattern of all four hacd genes in a manner that is similar to mammalian expression, 
with the exception, as mentioned above, of hacd4 (Ikeda et al., 2008). It also provided the 
fundamental knowledge regarding HACD expression within developing zebrafish embryos, 
as well as validated assays for evaluation ahead of using them as a model of HACD1-deficient 
myopathies.  
 Use of zebrafish embryos for lipidomic studies 
It was important to first evaluate the lipidome of wildtype embryos, to confirm that the 
protocol was achievable and to establish a lipidomic profile for wildtype embryos ahead of 
the generation of the hacd1-mutant zebrafish embryo model. 1H-NMR was employed to 
characterise the lipidome of the wildtype embryos from 1-3dpf. Work in Chapter 5 was 
undertaken to first validate this technique in which it was found that an increase in sample size 
had a strong positive correlation with signal: noise indicating where possible, pooled embryo 
sets would be the most informative. The chorion did not have a significant effect upon the 
lipidome and therefore it was not removed in further experiments. This was expected as the 
chorion membranes are made up mostly of polypeptides (Bonsignorio et al., 1996). After the 
technique was validated, the experimental data provided evidence that the lipidome of the 
embryos changed during development. The data on abundance of lipid classes within the 
embryos over development corresponded to a previous report on the lipid content of the 
embryo yolk sac (Fraher et al., 2016). Therefore, it is likely that the yolk sac was contributing 
to the results seen here and potentially confounding changes in lipid abundances from the rest 
of the embryo, including the tail muscle. Therefore, in future whole embryos and the tails 
alone can be used for lipidomic studies. We suggest that by using both the whole embryos and 
just the tails, this will be an informative model for examining lipids affected by HACD1-
deficiency than the Hacd1-kd cell model, as the embryos are an isolated system and thus 
variability due to serum and media changes, as shown in Chapter 4, would not be present in 
this model. 
 Validation of an embryonic zebrafish HACD1-CNM model 
A zebrafish embryo model with mutations in hacd1, generated by another researcher using 
CRISPR/Cas9 genome editing, was available for study. Up to 25% of F0 injected embryos 
developed abnormal live phenotypes. The embryos presented with poor motility suggesting 
muscle dysfunction and possible impairment of ECC (Gibbs et al., 2013a), and morphological 
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defects predominantly affecting striated muscles including bent tails and malformed hearts. 
These abnormal phenotypes were comparable to the other zebrafish CNM models in the 
literature (Dowling et al., 2009; Dowling et al., 2010; Gibbs et al., 2013a; Smith et al., 2014). 
Work in Chapter 5 presented evidence that hacd1-mutant embryos had phenotypes that 
corresponded to the disease and will therefore provide a good model to use in the future to 
study both HACD1 and VLCFA in CNM (Blot et al., 2002; Tiret et al., 2003).  
Zebrafish embryos provide an isolated system for the first 5 days after fertilisation due to their 
development external to the mother (Guyon et al., 2007). Mature functioning myotubes have 
developed by 3dpf and can be studied without confounding variables such as the addition of 
media onto cells, which our results strongly suggest impacts the phenotype of cell culture 
models of HACD1 deficiency. C2C12 cells comparatively do not develop mature internal 
structures as zebrafish embryos do and require longer in culture to develop primitive forms of 
internal membranes (Asano et al., 2015). C2C12 have to be cultured for 8 days before the cells 
start to express RYR1, an indicator of SR development (Walmsley, 2013), unlike the zebrafish 
embryo which shows strong RYR1 expression and sarcomeric organisation by 48hpf and 
displays motor function through tail twitches by 17hpf (Saint-Amant & Drapeua, 1998). 
C2C12 cells have been reported to contract (Manabe et al., 2012) however this requires 
stimulation and this is inconsistent with the literature as it has also been reported that robust 
contraction is rare (Asano et al., 2015). 
To summarise this section on the use of zebrafish embryos as a model for CNM, work 
presented here has confirmed the initial hypotheses that the embryonic zebrafish would have 
comparable HACD expression to mammals and that they make a good model of 
HACD1-CNM which may provide certain benefits over a cell culture model. By validating 
the model, this work will allow HACD1, VLCFA and CNM research to advance considerably 
in coming years because of the ready accessibility of zebrafish embryos as a disease model. 
 Further characterisation of HACD1-deficiency in a cell culture model 
The C2C12 cell model allowed us to gain insight into membrane function and membrane lipid 
profiles in HACD1-deficiency and the work done in this thesis has laid down the groundwork 
for future electrophysiological and lipidomic studies. We have conducted novel work into 
C2C12 sarcolemmal ion channels and resting membrane potentials (RMPs) in the context of 
HACD1-CNM and found here was no significant difference in the RMP of the Hacd1-kd cells 
which suggests weakness of HACD1-CNM, thought to be a result of disrupted ECC 
(Walmsley et al., 2017), is not caused by an increasingly positive basal RMP of cells. We 
concluded that it was likely that non-selective channels were commonly recorded in the 
C2C12 cells regardless of HACD1 activity. There were other channels present within 
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recordings, including possible chloride channels and calcium-activated potassium channels, 
further work is required to further characterise and identify channels. As discussed in Chapter 
3 a larger sample size, pharmacological interventions such as channel blockers and looking 
into the effects of depolarisation would be needed to truly understand how the ion channels 
are affected by HACD1-deficiency. Nevertheless, this was the first study to patch clamp 
HACD1-deficicient cells and further work on the cells would provide insight into cellular 
calcium and ionic homeostasis.  
This work in this thesis also furthered previous work undertaken by Blondelle et al., (2015) 
to assess lipid profiles within cells, with the aim of understanding which membrane lipids 
might be affected by HACD1-deficiency. We documented changes within the lipidome when 
cellular Hacd1 was knocked down, in particular the later stages of differentiation when the 
internal membrane systems begin to develop. Unfortunately, it was not possible to determine 
which lipids were causing these differences in the lipidomes due to limitations in the novelty 
of 1H-NMR lipidomics. Lysophosphatidylcholine (LPC) levels were shown to significantly 
decrease in the cells irrespective of Hacd1 expression and this decrease has been reported to 
be necessary for cells to fuse and differentiate (Blondelle et al., 2015; Leikina et al., 2013). 
This finding contrasted with that of earlier work in which the Hacd1-kd were unable to fuse 
together (Blondelle et al., 2015; Lin et al., 2012) and that LPC levels did not decrease in these 
non-fusing cells (Blondelle et al., 2015). It was concluded that these differences are likely 
down to diverse cell clones being used, and that cell media may also have affected lipid results 
due to the 4% serum used in this study. 
LPC has also been linked to the stimulation of the non-selective TRPC5 channel, thought to 
either results from a phospholipid binding site on the channel or the sensitivity of the TRPC5 
channel to bilayer changes by certain lipids (Flemming et al., 2005). The regulation of ion 
channels by membrane lipids has been documented previously and could therefore be a novel 
and interesting avenue for future research (Rosenhouse-Dantsker et al., 2012). 
A novel and important finding was the absence of any compensatory upregulation of the 
Hacd2-4 genes in response to the knockdown of Hacd1 at later stages of differentiation. Hacd2 
and Hacd3 and been previously reported to show no compensatory upregulation in early 
differentiation (5dpd) and also in the Hacd1-null mouse model (Blondelle et al., 2015). The 
work presented in this thesis takes the cell work from Blondelle et al., (2015) further in 
concluding at later stages of differentiation in Hacd1-kd cells that Hacd2, Hacd3 and Hacd4 
do not upregulate and therefore it can be concluded that they are unlikely to compensate for 
the HACD1-deficiency in this model. This should be evaluated in other species – including 
the zebrafish hacd1-mutant model. 
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 Directions for further work and potential applications 
To advance our understanding of HACD1-CNM and the role(s) of HACD1 and VLCFA in 
muscle we must first answer a number of questions. Which VLCFA(s) does HACD1 elongate 
and which molecules are these incorporated into? What are the roles of these VLCFA-
containing lipids in muscle during development, maintenance and disease? A structural role 
has been proposed in highly curved membranes therefore do these localise at the triad in 
muscle and is this also where HACD1 localises within the SR? Can VLCFA in muscle be 
manipulated, for example in the diet, and targeted for therapy?  
I will discuss further work using the two models from this thesis however it is important to 
remember that a larger variety of biological models have been essential in forming our current 
understanding of HACD1-CNM. Yeast was the model in which the function of HACD1 was 
determined (Ikeda et al., 2018), and has since been used to understand more about which 
VLCFA HACD1 may elongate, including the overlap seen in VLCFA elongation between 
both HACD1 and HACD2 (Sawai et al., 2017). Yeast have also been used to study the 
elongase proteins, ELOVLs, whereby zebrafish Elovl proteins were expressed within yeast to 
identify the VLCFAs synthesised (Monroig et al., 2010). Hacd1 null mice have also been used 
to report on the clinical pathology of HACD1-deficiency (Blondelle et al., 2015; Sawai et al., 
2017) which was reported to be comparable to that seen in HACD1-CNM dogs (Blot et al., 
2002; Tiret et al., 2003). The C2C12 cell line used in this thesis and other cell clones also 
discussed have reported on lipidomics and membrane properties (Blondelle et al., 2015; Lin 
et al., 2012), briefly on the calcium homeostasis of the cells (Walmsley, 2013) and the general 
morphology of the cells including staining of triad proteins (Walmsley et al., 2017). 
 Further work using the Hacd1-kd C2C12 cell line 
A preliminary ion channel phenotype for the control and Hacd1-kd cells was identified in this 
thesis, however the aim of measuring calcium responses through ion channel patch-clamping 
was not completed due to time constraints. For that reason this work should be continued to 
recorded single ion channel activity whilst depolarising cells to record calcium responses in 
cells. This can be undertaken using high potassium solutions to trigger the DHPR channels 
via membrane depolarisation or caffeine to stimulate the RYR1 channels. Large-conductance 
calcium-activated K+ channels (BK) (Alexander et al., 2011) would be informative of calcium 
responses and therefore should be the focus of this work. Cell morphology was briefly 
examined in this thesis, showing nuclear clusters to be more common (insignificant) in 
Hacd1-kd cells which had been previously reported along with high levels of RYR1 
(Walmsley, 2013; Walmsley et al., 2017). Internal membrane structures and nuclei 
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ultrastructure could be examined further using electron microscopy to visualise triads formed 
in the cells and compare the morphology of the triads in Hacd1-kd myotubes.  
The lipidomic analysis performed in this thesis found there to be a global difference in the 
lipid profile of Hacd1-kd cells compared to control, particularly at later stages of 
differentiation. Employing different lipidomic techniques will help identify which lipids are 
changing between cell types. Mass spectrometry (Blondelle et al., 2015), and 2D NMR (with 
the inclusion of 13C-NMR) would provide information on chain length (Yang et al., 2016). 
Lipid rescue studies are another avenue for this cell work, by adding different VLCFAs into 
the media and examining membrane properties of the cells. The addition of fluorescently 
labelled VLCFAs (Schultz et al., 2010) would help to understand where these VLCFA are 
localising within the cells.  
 Further work using the novel HACD1-CNM zebrafish model 
As previously discussed, the characteristics of zebrafish embryos make them an excellent 
model for further study of HACD1 and VLCFA. Initially techniques such as 3’ RACE could 
be implemented to fully characterise the unconfirmed isoforms in HACD2 and potentially 
discover any other HACD isoforms that may, as of yet, be unidentified (Deng et al., 2009). 
This would provide a clear picture of the splicing of zebrafish hacd genes. To further validate 
the model, experiments like those described in Chapter 2 to characterise hacd expression in 
wildtype embryos should now be conducted in hacd1-mutant embryos. It will be important to 
evaluate the effect of different mutations on hacd1 expression particularly when selecting a 
mutation to establishing a line of zebrafish. Mutations may trigger the aberrant splicing seen 
in the canine CNM and so expression analysis and 3’ RACE on the embryos would be required 
(Maurer et al., 2010; Pelé et al., 2005). This work will also provide insight into compensatory 
mechanisms which may occur within this model and will allow us to quantify the hacd1 
expression levels in mutant embryos. 
The expression work done in this thesis concentrated on the mRNA level and ultimately it will 
be important to evaluate the protein expression and localisation. At the time of this thesis no 
antibodies were available for the HACD proteins and so going forward self-design of 
antibodies (Tiller & Tessier, 2015) for both zebrafish and mouse species would be appropriate. 
The current guide targets exon 1 and will affect all major isoforms. An additional model 
targeting hacd1-fl only via the essential amino acids would allow us to isolate the specific 
roles of HACD1-fl in muscle (Kihara et al., 2008).  The human mutation reported by Toscano 
et al., (2017) is a point mutation affecting the active site therefore we anticipate that this will 
result in a similar myopathic phenotype. Either of these hacd1-mutant models have the 
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potential to be grown past development and create hacd1-mutant zebrafish lines, which would 
provide consistent genotype and phenotype within embryos. This is turn would tighten up 
results from a highly reproducible model. 
Lipidomic analysis in the hacd1-mutant embryos will provide some functional information on 
HACD1-deficiency.  This can be further optimised from the work in this thesis by using 
isolated tails as this without doing this the lipids from the yolk sac confound the results 
considerably. As with the cell culture model, using more in-depth NMR to look at 13C would 
provide more detail on chain length by separating out spectra further, however MS would 
possibly be the best option to take this work further and fully identify changes in chain length 
when hacd1 is mutated in the embryos (Blondelle et al., 2015; Yang et al., 2016). Also 
similarly to future work with the cell culture model, injecting labelled lipids or VLCFA into 
the yolk sac of embryos (Zeituni & Farber, 2016) will help in the understanding of their role 
within muscle. By using zebrafish embryos this work will benefit from the knowledge of 
VLCFA function within working muscle (Saint-Amant & Drapeua, 1998).  
Another direction to take this work in would involve using the HACD1-CNM embryonic 
zebrafish model currently being validated to study the electrophysiology of 
HACD1-deficiency. C2C12 only develop a basic internal membrane system whereas by 1dpf 
embryonic zebrafish have developed quantifiable motor phenotypes allowing for a more 
in-depth functional study into ECC (Gibbs et al., 2013a). Calcium homeostasis and response 
to contractions has been previously studied in whole zebrafish embryos through injection of 
ratiometric calcium dyes and stimulating contraction in embryos (Smith et al., 2014). 
Experiments to study ECC could also be done via the isolation of whole myofibres from the 
embryos (Horstick et al., 2013). These fibres should then be subjected to calcium imaging 
studies, patch-clamping and immunohistochemistry. Calcium imaging would allow for the 
selection of areas within the myofibres to assess calcium responses when ECC is triggered 
through membrane depolarisation, providing functional information on the workings of the 
calcium channels and associated membranes.  
Immunohistochemistry will provide confirmation of the tubuloreticular membrane 
disorganisation and staining for the other CNM related proteins would provide further detail 
on this disorganisation: DNM2, BIN1 and MTM1 (Jungbluth et al., 2018). Birefringence is a 
common microscopy technique that is utilised to assess the uniformity of skeletal muscle, and 
this could be done within the embryos (Smith et al., 2013). Finally, electron microscopy of 
the embryonic muscle would provide high resolution images of the muscle ultrastructure and 
allow the triad structure to be compared between control and affected embryos.  
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 Potential applications 
By studying the rescue of the HACD1-CNM phenotype, translation from laboratory to clinical 
application can progress. The effects of cell media changes upon fatty acid bond saturation 
(Chapter 4) would suggest there is potential in the manipulation of lipid profiles via external 
factors. To further examine this, rescue studies on the novel HACD1-CNM zebrafish embryo 
model will be conducted; firstly by injecting hacd1 mRNA into zebrafish embryos to assess 
effects of replacing the hacd1 lost via genome editing. Injecting hacd2 mRNA will provide 
further clarity regarding the redundancy of the two enzymes and provide evidence as to 
whether Hacd2 can act to elongate VLCFA in muscle. A lipid based rescue experiment should 
also be performed involving the injection of different VLCFA into the yolk sac of embryos in 
order to determine which VLFCA may ameliorate the effect of hacd1 mutation. This would 
allow us to determine the interplay between diet and genetics on VLCFA in muscle and could 
ultimately lead to the development of a diet-based therapy for dogs with HACD1-CNM or 
humans with HACD1 congenital myopathies. The use of diet therapy for muscle lipid 
metabolic disorders has been discussed by Laforêt & Vianey-Saban, (2010) in the context of 
lipid storage myopathies and humans with muscle lipid metabolism disorders have shown 
marked improvement of symptoms after diet therapy (Roe et al., 2002). Gaining increased 
insight into the role of HACD1 and VLCFA is critical for the understanding of how the 
tubuloreticular membrane disorganisation seen in the canine disorder (Walmsley et al., 2017) 
comes about and how potential therapies could be implemented in the future. With knowledge 
of which lipids and fatty acids are decreased in CNM and can successfully rescue phenotype 
once reintroduced into a biological system: this can have potential medical and veterinary 
translation.  
 
 Final conclusions 
In conclusion the embryonic zebrafish is a promising model to utilise for further research into 
HACD1-CNM and this studypresents work that details their suitability. The zebrafish have a 
comparable hacd expression pattern to that of mammals, embryos can be utilised for 
lipidomics analysis and when hacd1 is mutated embryos present with a phenotype similar to 
that of previous CNM models (Dowling et al., 2009; Dowling et al., 2010; Gibbs et al., 2013a; 
Sabha et al., 2016; Smith et al., 2014) and the disease phenotype in mammals (Blot et al., 
2002; Tiret et al., 2003). Work undertaken in this thesis has allowed for functional 
characterisation of HACD1 within C2C12 cells and has shown the lipidome of the C2C12 
Hacd1-kd cell line to be affected by Hacd1 deficiency. Complementing the use of the 
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zebrafish model with the Hacd1-kd cell line has aided in the characterisation of HACD 
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Appendix 1: Alignment of zebrafish hacd sequences 
 
Figure A1.1: Amino acid sequence alignment for zebrafish transcripts:  hacd1 
(ENSDART00000157873), hacd2 (ENSDART00000133998), hacd3 (ENSDART00000006300) and 
hacd4 (ENSDART00000157618) generated in CLC Workbench (Qiagen). Transmembrane region is 
annotated by the grey bar, the PTPL domain by a pink bar and essential amino acids (tyrosine and 
glutamate) have been annotated in blue. Conservation of residues indicated by pink bars along the 





Figure A1.2: Annotated zebrafish hacd1 sequence. Primers for both whole-mount in situ hybridisation 
and qRT-PCR (both hacd1-total and hacd1-fl) are annotated in green start and stop codon in blue and 
essential amino acids in grey. 
 
Figure A1.3: Annotated zebrafish hacd2 sequence. Primers for both whole-mount in situ hybridisation 
and qRT-PCR (both hacd2-total and hacd2-fl) are annotated in green start and stop codon in blue and 




Figure A1.4: Annotated zebrafish hacd3 sequence. Primers for both whole-mount in situ hybridisation 
and qRT-PCR are annotated in green start and stop codon in blue and essential amino acids in grey. 
 
Figure A1.5: Annotated zebrafish hacd4 sequence. Primers for both whole-mount in situ hybridisation 















Appendix 2: Alignment of mouse (C2C12) Hacd sequences 
 
Figure A2.1: Amino acid sequence alignment for murine transcripts:  Hacd1 
(ENSMUST00000114753.7), Hacd2 (ENSMUST00000061156.9), Hacd3 
(ENSMUST00000036615.6) and Hacd4 (ENSMUST00000030221.2) generated in CLC Workbench 
(Qiagen). The PTPL domain is annotated by a pink bar the transmembrane region is annotated by a 
grey bar and essential amino acids (tyrosine and glutamate) have been annotated in blue. Conservation 
of residues indicated by pink bars along the bottom of alignment rows, with gaps within the sequence 
indicated with (-). 
 
Figure A2.2: Annotated mouse Hacd1 sequence. Primers for both whole-mount in situ hybridisation 
and qRT-PCR (both Hacd1-total and Hacd1-fl) are annotated in green start and stop codon in blue and 





Figure A2.3: Annotated mouse Hacd2 sequence. Primers for both whole-mount in situ hybridisation 





Figure A2.4: Annotated mouse Hacd3 sequence. Primers for both whole-mount in situ hybridisation 
and qRT-PCR are annotated in green start and stop codon in blue and essential amino acids in grey. 
 
Figure A2.5: Annotated mouse Hacd4 sequence. Primers for both whole-mount in situ hybridisation 





Appendix 3: Normalisation methods for 1H-NMR lipidomics of zebrafish 
samples 
 
Figure A3.1: Comparison of normalisation methods for zebrafish samples using heat map analysis. (a) 
non-normalised heat map, (b) PQN normalised and (c) samples normalised to CH3. Normalisation to 
CH3 was chosen in the end after examining heat maps as PQN normalisation skewed the data. 
 
